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Abstract 
The field of enabling techniques for poorly water-soluble drugs has been growing over the last decades. 
Therefore, different formulation strategies and processes have gained relevance within the development 
of solid pharmaceutical dosage forms for oral drug delivery. A prominent example to manufacture such 
dosage forms is the process of hot melt extrusion, where mostly combinations of polymers and drugs 
are melted together and processed to result in an amorphous solid dispersion as a biopharmaceutically 
enhanced drug delivery system. The final extrudate needs to be further processed downstream for 
example in a mill or a pelletizer. Processing a drug in an extruded form comes with the advantage of 
increased apparent solubility and therefore increased amount of dissolved drug available for absorption 
in the gastrointestinal tract. A crucial quality attribute for this formulation approach is selecting the most 
suitable polymer in combination with a given drug. To identify the most suitable polymer, a variety of 
screening approaches can be applied. Some approaches make use of the Flory-Huggins interaction 
parameter or a comparison of Hansen solubility parameters, while an important experimental alternative 
is the screening of polymers for amorphous drug stabilization (SPADS) approach. However, a suitable 
polymer cannot always be found so that a compromise may lead to unbeneficial formulation 
characteristics. There is current research focusing on the development of new synthetic polymers based 
on chemical monomer engineering as well as the combination of polymers. Another approach is the 
addition of a small molecular additive for the stabilization of a drug without the necessary use of a 
polymer, i.e. so-called co-amorphous systems. 
In this work, the interaction of an additive and the modification of the polymer are combined in 
molecularly designed polymeric matrices consisting of interacting small molecular additives and a 
polymeric excipient. The key aspect of this development is the specifically targeted molecular 
interaction between polymer and additive, which alters matrix characteristics thereby leading to possible 
benefits on the level of processing, amorphous stability and/or aqueous dispersion and drug release. 
 
The first study consisted of establishing a concept of combining acidic co-formers with a basic polymer 
to improve processablity as well as drug release. In the beginning of this study, the co-former malic acid 
was identified to be most beneficial for the formulation with the polymer Eudragit E PO 
(dimethylaminoethyl methacrylate copolymer). 
Interactions between the additive and the polymer were confirmed by Fourier transform infrared 
spectroscopy (FTIR) and 13C-nuclear magnetic resonance spectroscopy (NMR). These interactions were 
also present after the addition of the drug fenofibrate. In the next step, the amorphous stability of the 
additive-containing formulation was compared with the corresponding non-additive formulation via 
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atomic force and scanning electron microscopy (SEM). By using energy dispersive X-ray spectroscopy 
during the SEM measurement, the drug was found to be dispersed homogenously in the malic acid 
formulation, whereas in the control formulation without additive, drug-rich domains were visible. This 
finding was supported by an observed phase separation in phasing images of atomic force microscopy 
using the control formulation. 
In addition to the improved stability, the additive formulation showed improved drug release compared 
to the control formulation and the corresponding physical mixture. Since an extruded formulation 
requires further downstream processes, such as milling or grinding in a mortar, the powderized extrudate 
should have sufficient flowability to enable any subsequent processing such as tableting. The modified 
matrix formulation showed also in this technical aspect better flowability than the control formulation 
or the pure polymer. 
To conclude in this case study on Eudragit E PO, the addition of malic acid to the polymer showed a 
specific molecular interaction and resulted in different formulation improvements with regards to 
amorphous stability, downstream processability as well as drug release. 
 
In the second study, a polymer, which is not extrudable in its neat form, was modified in a way to make 
it applicable for extrusion. Different small molecular additives were investigated each as interacting 
partner with the polyelectrolyte sodium carboxymethyl cellulose (NaCMC). Studied additives were 
trometamol, urea, meglumine, and the amino acids lysine, histidine, arginine. These additives were 
intended to exert strong specific interactions with the macromolecular polyelectrolyte via acid-base-
interactions. As manufacturing technique, a combination of solvent evaporation (with and without 
additive) and subsequent hot melt extrusion was conducted as a two-step process. Such processing 
served as a model of what an excipient supplier would do to make the modified NaCMC matrix available 
for a pharmaceutical company to process it together with a drug by hot melt extrusion. Initially, the 
maximum amount of additive in combination with NaCMC was determined for which an amorphous 
solid dispersion was still feasible as produced by extrusion. As a result, an excess molar amount of 
interacting additive was generally needed because amounts of additives below 15 % were shown not to 
be applicable for improving the extrusion behavior of the polymer. There was on the other hand also a 
maximum suitable additive concentration given with higher concentrations leading to residual 
crystallinity after extrusion. 
The suitable polyelectrolyte matrices, which showed no indication of crystallinity in the laboratory X-
ray diffraction analysis, were further investigated for homogeneity and crystallinity by synchrotron X-
ray diffraction. Moreover, possible interactions and melting behavior were studied by hot stage 
microscopy and heat-assisted FTIR. It was shown that the polyelectrolyte matrices containing either 
meglumine, lysine, or urea resulted in an amorphous homogenous formulation. This finding was in line 
with the extrusion performance as well as the heat-assisted FTIR spectroscopy. Therefore, the promising 
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meglumine and lysine excipient matrices were analyzed further in a subsequent study using a model 
drug. 
 
In line with the assessment of glass forming ability, the third study was designed for the practical 
comparison of two crucial enabling techniques i.e. hot melt extrusion and mesoporous silica. 
Therefore, two drugs, which are instable glass formers, were selected for a stability-based comparison 
under ICH Q1 accelerated stability conditions. For an increase in measurement sensitivity, the extruded 
samples were examined at the start of the study and the end using 13C solid-state NMR. This comparison 
was complemented by drug dissolution studies in biorelevant media at defined time points. In line with 
theoretical expectations about drugs that are challenging to stabilize in amorphous form, this study 
confirmed the superior stabilization capabilities of mesoporous silica formulations for which drug was 
successfully loaded and confined in mesopores. In contrast, the extruded formulations were not able to 
stabilize the challenging model drugs in their amorphous form over the duration of a three months 
stability study. These findings were underlined by results of the non-sink dissolution profiles at the 
defined time points, which showed a comparative decrease in supersaturation for the extruded 
formulations. The silica formulations, which were lacking the necessary precipitation inhibitor, showed 
just a “spring-effect” of high supersaturation but they could not sustain it without further excipients to 
act as a “parachute”. There was no decrease in the initial drug supersaturation visible over the duration 
of the study, which was in line with the solid-state evaluation. In conclusion, this study shows the 
advantage of mesoporous silica to formulate drugs that have a high tendency to recrystallize so that 
classical polymeric solid dispersions exhibit a substantial risk of physical instability. 
 
The knowledge gained from the second study formed the basis of the fourth study. The two most 
promising candidates from the synchrotron study of the modified matrices, which were the lysine and 
the meglumine formulations, were further investigated regarding their biopharmaceutical properties. 
Thus, the model drug fenofibrate was selected as quantitative marker for in vitro and in vivo 
performance. During the pre-evaluation of the solid state, the amorphous form of both formulations was 
confirmed via powder X-ray diffraction as well as differential scanning calorimetry. Moreover, a 
possible interaction was investigated via FTIR. 
The in vitro non-sink experiments in Fasted Simulated Intestinal Fluid (FaSSIF) showed a higher 
supersaturation and parachute effect for both formulations compared to the corresponding non-modified 
matrix without additive. The physical mixture only showed a slight drug release in the beginning, which 
decreased even more over time. Due to high viscosity, which was measured in separate rheological 
measurements, there was a 30 min delay in drug release observed in the extruded formulations. These 
findings agreed with results of the subsequent in vivo rat study, which showed a significant difference 
between the AUCs of the meglumine formulation and the corresponding physical mixture as well as 
differences in the Cmax values between both formulations and their physical mixtures. Therefore, this 
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study showed the beneficial impact of the selected additives on the biopharmaceutical performance of 
the model drug fenofibrate. 
 
In conclusion, this thesis focused on designing modified polymeric matrices based on targeted molecular 
interactions of additives and drug carriers. Small molecular additives were used in amorphous solid 
dispersions with a special emphasis on hot melt extrusion. It could be demonstrated that the careful 
selection of small molecular additives, which interact with a polymer, could have a beneficial impact on 
the manufacturing process, the physical stability, and/or biopharmaceutical release properties of a drug 
from its amorphous form. Different analytical methods supported the view of the intended molecular 
interactions in the modified matrices but the various technical and biopharmaceutical benefits are 
currently hard to predict theoretically. While we used molecular simulations occasionally to visualize 
candidate mixtures for experimental evaluation, a next step would be a more intensive use of in silico 
tools to predict formulation performance and to screen mixtures in the computer. 
 
In line with current research and practice in the pharmaceutical industry, the selection of excipients 
during the early formulation development is crucial for the successful design of an amorphous drug 
delivery system on the market. This work showed that the addition of interacting small molecular 
additives could have a positive impact on the resulting matrix properties and therefore this would 
broaden the variety of suitable polymer matrices not by any covalent bonds in the synthesis of novel 
polymers but by virtue of a physical modification of the polymer through the given additive. The 
presented approach of a modified polymeric matrix therefore holds much promise in future 
pharmaceutical development of amorphous drug products. 
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Introduction  
 Background 
In the recent years, the poor water solubility of newly developed compounds has presented a major 
challenge for formulation scientists in the field of pharmaceutical development. There is a great need of 
exactly identifying the solubility limiting factors as well as techniques to cope with them. 
The introduction of a biopharmaceutics classification system (BCS) by Amidon and colleagues [1] 
provided guidance to point out oral biopharmaceutical performance challenges of such components. The 
classification was particularly useful to design bioequivalence studies but appeared to address less the 
needs of scientists in early formulation development. The classification was therefore developed further 
by Butler and Dressmann, who provided differentiation in the so-called developability classification 
system (DCS) [2]. In the DCS, the class 2 of the BCS system is further divided in 2a and 2b to highlight 
the drugs for which solubility enhancement would be favorable to improve oral bioavailability [2]. 
Substances in class 2a profit mostly from an increased dissolution rate, which can be achieved for 
example by particle size reduction. In contrast, an increase in solubility would lead to higher 
bioavailability of class 2b substances [2,3]. The DCS was advanced to the refined DCS or rDCS, which 
consisted of better integration of weak bases and their salts [4] 
 
 
Figure 1.1. Developability classification system according to Butler and Dressman 
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Limiting factors of the previously mentioned solubility of DCS class 2b substances can be described as 
solvation and/or solid-state limiting factors [5–7]. Such factors are expressed for example in the general 
solution equation (GSE) for non-electrolytes (Equation 1) [8]. 
 
log 𝑆𝑤 = 0.5 − 0.01 (𝑇𝑚 − 25) − log 𝑃 (1) 
 
The GSE presents the aqueous solubility (logSw) as a function of a compound's crystal lattice energy and 
lipophilicity expressed as the melting point (Tm, in K) and the octanol/water partition coefficient (logP) 
and allows an estimation of the solubility based on the before mentioned parameters. High Tm values 
and moderate or low logP values are often associated with "brick-dust" characteristics, whereas a 
substance with low Tm and high logP values can be referred to as "grease ball". Brick-dust molecules 
with structural features like aromaticity and rigidity exhibit a solid-state limited solubility as a result of 
a stable crystal structure with breakdown of the crystal lattice as the most difficult step for the drug 
release [9]. For grease-ball substances, the molecular features that lead to high partitioning into an apolar 
phase e.g. as inferred from the Abraham solvation predictors [10,11], have the solvation step in water 
as the main hurdle for drug dissolution [12,13]. The use of Abraham solvation predictors was recently 
reported to gain a better understanding of the molecular drug characteristics that drive solubilisation in 
biorelevant media [14].  
 
It is clear that an improved molecular understanding of solubility limitations would be of great help in 
the drug discovery phase when designing and selecting drug candidates. General developability criteria 
other than the DCS, such as Lipinski’s rule of 5 [15], could be further refined so there is clearly more 
research to be done in this field. Novel compounds from drug discovery present frequent issues for 
formulation development as they often have high Tm and high logP [16–19]. While Tm is a characteristic 
of the above mentioned crystal lattice energy, logP, as a partition coefficient, denotes a solvation 
tendency or a lack of the same. Most importantly, high values of Tm and logP limit aqueous solubility 
and consequently often bioavailability when administered orally in conventional dosage forms 
[5,20,21].  
Therefore, such compounds require a bio-enabling formulation approach [22]. A broad variety of 
formulation approaches exist in the field of pharmaceutical research. Such an approach is a lipid based 
formulation, where the drug is dissolved or suspended in a lipid and ideally maintained in the 
solubilised/supersaturated state in the course of lipid dispersion and digestion [20]. This formulation 
approach comes with the advantage of increasing the gastrointestinal (GI) solvation capacity of 
drugs [23] as well as leading to drug supersaturation in the intestine by fast digestion and absorption of 
the lipid [24]. Therefore, lipolysis is an essential part of the in vivo performance of lipid based systems 
[25]. 
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A further approach is the formulation of a nanosuspension, which can be formed by breaking down 
larger micron-sized particles down (i.e. top-down approach). These broken down particles are then 
stabilized by a mixture of polymer and surfactant, as in a wet milling technique [26]. Such an approach 
is of particular interest when high lattice energy decreases the solubility in any solvent tremendously so 
that any direct solution formulation as final dosage form becomes hard to achieve [27]. 
Cyclodextrin formulations can form an inclusion complex with the drug as a result of their hydrophilic 
outside and hydrophobic cavity [28,29]. Such a complex is an ideal combination, because it can 
incorporate the hydrophobic drug on the inside, while it can be solubilized upon dispersion in the GI 
fluids after oral administration, which leads to an increase in apparent drug solubility [30]. 
Another bio-enabling formulation approach is the transformation of the drug into its amorphous form. 
This drug form leads to an increase in the apparent solubility of the drug [31], which may lead to 
different extents of supersaturation upon aqueous dispersion. Different types of amorphous drug 
formulations and solid solutions were named together under the umbrella term “solid dispersion” by 
Chiou and Riegelmann [32,33]. Any amorphous solid dispersion (ASD) also comes with the downside 
of possible recrystallization in the solid state, which means the drug changes to the energetically more 
favorable crystalline form (Section 2.1.2.1), which has the typical consequence of losing some of the 
increased apparent solubility. 
 
The variety of formulation strategies reflects the fact that there is not a “one size fits all” approach. It is 
critical to more rationally select a bio-enabling formulation type based on the given drug properties. 
Therefore, we developed a decision tree with a focus on amorphous formulation and at what point other 
formulation techniques should be applied. There are critical drug properties [13,34,35], which greatly 
affect the successful amorphization as well as determine the process used. Based on the above-
mentioned considerations Figure 1.2 describes how the glass forming ability (GFA) (Section 2.1.2.3) 
and other drug properties can be applied in the process of formulation technique selection.  
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Figure 1.2. Decision tree for the manufacturing technique of an enabling formulation 
 
The developed decision tree starts with the applicability of a specific GFA class for the compound [36], 
which is commonly determined by scanning differential calorimetry. If such measurement results are 
not available, GFA can be estimated based on molecular properties by Mahlin and Bergström [34] or 
Wyttenbach and Kuentz [37]. GFA is about differentiation of non-glass forming compounds (or poor 
glass formers) vs. glass-formers where the latter can be further differentiated according to the stability 
of the glass [36,38]. Since poor glass formers tend to show a reduced amount of drug supersaturation 
[36,38,39], the supersaturation potential needs to be evaluated. The combination of poor glass formation 
and low supersaturation potential discourages the selection of a solid dispersion and would then lead to 
a preferable formulation in a lipid system or nanosuspension. For increased stabilization of a 
supersaturating instable glass former in dependence of high melting point and ionizable groups either 
micro-precipitated bulk powder (MPB) or mesoporous systems (with a precipitation inhibitor) should 
be selected. The MPB technology is also an option in case that a stable glass former has a very high Tm. 
For stable glass formers, which are heat stable and have a moderate Tm, extrusion is a feasible 
amorphization method. In case that such a substance is not heat stable but soluble in volatile solvents, it 
can be alternatively processed in a spray dryer or if the solubility in volatile solvents is not sufficient, 
ball milling could be performed in combination with a small molecular co-former [40]. 
 
Figure 1.2 highlights the necessity of a polymer for the majority of formulation approaches. Therefore, 
such a selection can be crucial for the performance of a bio-enabling drug delivery system. A review of 
the polymers used in amorphous formulations showed that a small number of polymers is used in 
marketed amorphous drug products [41], which underlines the need for more polymers. The 
development of new polymers would come on one side with more options to choose a polymer for a 
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given drug. On the other side, the implementation of such a newly developed polymer would result in 
regulatory hurdles to approve the novel excipient, which is particularly demanding when it is a new 
chemical entity. A possible solution to this challenge is the combination of approved polymers and 
additives to develop new polymeric matrices. Such an approach of a modified polymeric matrix is based 
on specifically targeted molecular interactions that are comparatively strong, which is different to an 
ordinary formulation strategy. The intelligent choice of an additive with the potential to interact may 
result in technical process benefits, higher amorphous stability of the drug in the modified matrix as well 
as drug release advantages of the polymeric matrix as well as the possibility of also interacting with the 
drug and stabilize all components in the formulation.  
 
As shown in Figure 1.3, there are various characteristics necessary for an excipient. These requirements 
can be divided into aspects like regulatory acceptance for oral use, which are more important for the 
approval of a drug product, and other properties like stability, miscibility, and molecular interactions 
regarding a given drug, which are already relevant during early pharmaceutical development. For 
information on the oral acceptance as well as regulatory implications, the legislations ICH Q6A, USP 
Chapter 3 and EudraLex Chapter 4 can be used. A practical source of information is the generally 
recognized as safe (GRAS) list by the FDA. Excipients selected from this list have shown to be safe 
among qualified experts in the field. Therefore, an additive which is mentioned in the GRAS list can be 
more easily used in a polymeric matrix even though this does not directly entail regulatory acceptance 
as pharmaceutical excipient in the different countries. There are other excipient aspects that have more 
technical relevance for the choice of the amorphization technique. Such properties are primarily about 
chemical and physical stability at elevated temperatures, which need to be considered depending on the 
manufacturing process. An excipient with insufficient stability upon heating would not be feasible for 
example for hot melt extrusion (HME). Moreover, the excipient has to be stable over the duration of a 
stability study, which means substances that chemically degrade may lead to inacceptable impurities of 
the final drug product. Closely related to the stability aspect is the hygroscopicity of an excipient. The 
inclusion of water in the formulation typically leads to physical instability of an amorphous drug because 
of a massive reduction in the glass transition temperature (Tg) [42]. Moreover, a polymer or additive 
used in an ASD should have sufficient wettability to ensure appropriate drug release. The drug release 
is majorly determined by the properties of the polymer used, especially when the drug load in the ASD 
is comparatively low [43,44]. A recent publication by the group of Lynne Taylor highlighted that the 
analytical determination of both, drug and polymer dissolution is an important advancement of in vitro 
testing and a synchronized release of drug and precipitation inhibiting polymer is beneficial for the later 
enhanced absorption.  
Such insights into the biopharmaceutical performance of amorphous systems lead to even more 
excipient aspects to be considered. It underlines the need to have sufficient choice among orally accepted 
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polymers and opens the discussion towards the modification of existing polymers with generally 
accepted additives. 
 
  
Figure 1.3. Requirements for an excipient used in an ASD 
 
 Objectives 
The objective of this scientific work was to investigate beneficial excipient combinations for HME of 
poorly water-soluble drugs by targeting molecularly designed interactions of polymer and co-formers to 
obtain modified polymeric matrices and compare those with other solid dispersion formulation 
techniques. Such an evaluation was based on amorphous stability, dissolution performance including 
supersaturation potential, and technical feasibility. An important aspect of the latter process performance 
was the improvement of extrudability with regards to properties of the polymers. Molecular interactions 
among the components have a critical impact on the before mentioned formulation characteristics. 
Therefore, the assessment was complemented with the analysis of such interactions by applying 
spectroscopic techniques reaching from heat-resolved Fourier transform infrared spectroscopy (FTIR) 
to solid-state nuclear magnetic resonance spectroscopy (SS-NMR) throughout the different studies. 
Throughout the chapters of this thesis, various polymers in combination with different interacting small 
molecular additives are studied regarding their applicability in HME. 
 
In the theoretical chapter 2, the important aspects and excipient considerations regarding amorphous 
solid dispersions are explained. The amorphous state with a focus on drug features like GFA or glass 
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transition temperature are explained. Furthermore, the manufacturing techniques as well as the analytical 
and biopharmaceutical implications of the amorphous form are outlined. 
The second part of chapter 2 particularly focuses on the manufacturing technique of HME. In this 
section, the process as well as the restrictions and excipient selection are explained. Since the 
interactions with a co-former in the formulation are a key component of this work, the last subsection is 
focused on the application of this novel approach in the field of amorphous solid dispersions regarding 
increased amorphous stability and the improvement of dissolution performance. 
 
In the third chapter, the concept of a HME formulation containing a polymer, an interacting additive, 
and a drug was evaluated in comparison to a conventional polymer-drug-extrudate. As a novel 
component, the co-former was specifically selected to interact with the polymer and therefore led to 
improved polymer properties focusing on HME. Such investigated properties were an improved 
processability, increased amorphous stability, and enhanced release behavior. Moreover, the 
pronounced interaction between the additive and the polymer was demonstrated by NMR and FTIR. 
 
The concept described in the third chapter was applied in the fourth chapter including a broader range 
of co-formers. The latter small molecules consisted of basic amino acids and three other molecules with 
proton-acceptor groups. As polymeric counterpart, the polyelectrolyte sodium carboxymethylcelluose 
(NaCMC) was selected. This is of particular interest because neat NaCMC presents beneficial release 
behavior upon aqueous dispersion, while due to its degradation at high temperatures, it is unfeasible for 
extrusion. Therefore, a preliminary solvent evaporation step was applied to produce an extrudable 
polyelectrolyte matrix. For an increase in resolution and the ability to probe extrudates at different 
points, the matrices were analyzed with a synchrotron X-ray beam. Favorable compositions as well as 
additives were identified regarding extrudability and successful amorphization. 
 
As polymeric HME has been applied in the pharmaceutical field for several years, there is a necessity 
to compare it with new, promising formulation techniques. In chapter five compounds, which are 
specifically challenging for amorphization methods were used to compare polymeric extrudates with 
mesoporous silica formulations. The study was designed to show over three months differences in the 
stabilization of an amorphous active pharmaceutical ingredient (API) under accelerated stability 
conditions. Moreover, the implications on the biopharmaceutical performance were investigated. These 
results were complemented with additional solid-state characterization like scanning electron 
microscopy (SEM) and solid-state nuclear magnetic resonance spectroscopy (SS-NMR).  
 
For the final assessment of bio-enabling capabilities, the most promising polyelectrolyte matrices were 
used in the development of amorphous formulations containing fenofibrate as model drug. Therefore, 
in chapter six, the formulations consisting of NaCMC/lysine/fenofibrate and 
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NaCMC/meglumine/fenofibrate were evaluated in vitro and in vivo. In these studies, the physical 
mixtures of the formulations were compared with the corresponding formulations in FaSSIF non-sink 
dissolution as well as a rat study. Additional solid-state characteristics were applied to confirm the 
amorphous state of the formulations and viscosity measurements should provide insights in the 
stabilization properties of the polyelectrolyte upon aqueous dispersion. 
 
 
 
 
 
 
 
 
Theoretical section 
 
2.1 Amorphous solid dispersions 
2.1.1 General consideration 
The formulation approach of amorphous solid dispersion was introduced by Chiou and Riegelmann in 
1969 because of an increasing number of poorly water-soluble compounds that required a new 
formulation perspective [32]. Since then this approach has been common practice for solubility 
enhancement [32] of poorly water-soluble drugs [31]. As mentioned in Section 1.1, drugs with limited 
bioavailability as a result of poor solubility can potentially benefit greatly from an increase in their 
apparent solubility through amorphization. 
 
In a recent review, Wyttenbach and Kuentz highlighted the thriving need of amorphous formulations. 
Currently there are 17 drugs formulated as amorphous solid dispersions and 5 drugs in their amorphous 
form available in internationally marketed products [41]. As highlighted in Table 2.1, most of the 
amorphous formulation are manufactured via HME or spray drying.  
 
Solid dispersions can be categorized according to the physical state of the given phases [33]. The first 
dispersions were often eutectic mixtures, which were miscible in the molten state. A disadvantage of the 
eutectic systems is that recrystallization occurs at the characteristic eutectic temperature, which typically 
takes place during the cooling process. Pioneer solid dispersions were prepared with a water-soluble 
carrier like citric acid, and a poorly water-soluble drug (e.g. griseofulvin) [32]. Depending on the 
individual composition it is possible to obtain an amorphous solid solution, where a compound is 
dispersed molecularly in the amorphous carrier [45]. Leuner and Dressman pointed out that solid 
solutions can be continuous versus discontinuous or substitutional versus interstitial. Systems with an 
amorphous carrier are generally called glasses where glass solutions can be differentiated from glass 
suspensions depending on the physical state of the drug and whether one or two phases are present in 
the system [45]. 
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Table 2.1. Marketed amorphous formulations (adapted from [41]) 
Compound Carrier 
Manufacturing 
technology 
Dosage form 
Etravirine HPMC Spray drying Tablet 
Everolimus HPMC Spray drying Tablet 
Fenofibrate PEG Spray melt Tablet 
Griseofulvin PEG HME Tablet 
Itraconazole PVPVA 64 HME Tablet 
Ivacaftor HPMCAS Spray drying Tablet 
Lopinavir / Ritonavir PVPVA 64 HME Tablet 
Nabilone PVP HME Capsule 
Nifedipine PVP Melt/absorb on carrier Tablet 
Nilvadipine HPMC n/a Tablet 
Nimodipine PEG Spray drying Tablet 
Posaconazole HPMCAS HME Tablet 
Ritonavir PVPVA 64 HME Tablet 
Tacrolimus HPMC Spray drying Capsule 
Telaprevir HPMCAS Spray drying Tablet 
Troglitazone PVP HME Tablet 
Vemurafenib HPMCAS Co-precipitation Tablet 
Verapamil hydrochloride HPC/HPMC HME Tablet 
Neat amorphous drugs 
Cefuroxime axetil - - Tablet 
Nefinavir mesylate - - Tablet 
Quinapril hydrochloride - - Tablet 
Rosuvastatin calcium - - Tablet 
Zafirlukast - - Tablet 
 
Since solid dispersions have a long tradition, different generations of formulation types have been in 
use. These different generations were described in detail by Vo et al. [46]. Main differences are given 
in the types of excipients selected during the pharmaceutical development of solid dispersions (Figure 
2.1.). 
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Figure 2.1. Generations of solid dispersions 
 
In the first generation of solid dispersions, crystalline carriers (i.e. mostly small molecular additives) 
were used for dispersing the drug homogeneously in the solid state, which had the disadvantage that a 
rather fast drug precipitation was often observed upon aqueous dispersion. Therefore, a second 
generation of improved formulations was proposed. These formulations were based on polymeric 
carriers, which were advantageous regarding the biopharmaceutical fate of the drug. Such solid 
dispersions typically showed a dissolution rate that was widely controlled by the hydration and 
dissolution of the polymeric matrix [47]. The third generation of solid dispersions consisted mainly of 
polymeric carriers combined either with each other or with surfactants to improve the aqueous dispersion 
following oral administration. Interesting is here a combined functionality like, for example, the BASF 
polymer Soluplus®, which represents a polymer (polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol graft copolymer) with significant amphiphilic characteristics of a surfactant. 
 
General aspects have to be considered for a successful formulation of an ASD (Table 2.2). Such 
considerations in the early development can be divided in solid state and dissolution performance 
related.  
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Table 2.2. Aspects to be considered during the development of ASDs (adapted from [48]) 
 
2.1.2 The amorphous form 
The amorphous form comes with distinctive structural properties that are different to the crystalline 
counterpart. An amorphous solid is lacking the long-range order, which leads to a rather random 
orientation of molecules more in the sense of a frozen liquid with no symmetry operators present [49]. 
This can be experimentally verified by the absence of distinct Bragg peaks in the X-ray diffraction, 
which results in a distinctive halo of an amorphous substance (Section 2.1.4). Such a solid has the 
properties of a liquid on the molecular level and the properties of a solid on the macroscopic and 
rheological level [50,51]. Current research has highlighted the fact that the amorphous form is most 
likely not completely amorphous and organized in a random manner. It is rather the case that even in an 
amorphous formulation, some order is given as smaller short-range clusters. However, in contrast to the 
crystalline material, such clusters are too small to present crystalline properties [52]. 
 
 Aspect Recommendations 
Solid state 
Polymer-drug ratio Selection of sufficient amount of polymer to ensure 
amorphous stability in the solid state over the shelf 
life 
Miscibility Assessment of miscibility to avoid phase separation, 
which could later lead to recrystallization 
Amorphization process Determination of a process with a focus on the API 
(thermal stability for HME or solubility in volatile 
solvents), but also suitable the used excipients 
Hygroscopicity Highly hygroscopic materials could lead to water 
uptake in the ASD, which decreases Tg. This could 
lead to potential recrystallization. 
Dissolution 
Dissolution apparatus 
including media selection 
Apparatus selection as well as media selection 
should simulate the physiological conditions and 
must be adequate for the given dosage form. 
Sink or non-sink 
conditions 
Both aspects have to be investigated. Sink 
dissolution may be used as quality test for batch 
release, whereas non-sink dissolution enables 
analysis of drug supersaturation/precipitation and 
can be coupled with a permeation test. 
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2.1.2.1 Thermodynamic implication of the amorphous state 
From a thermodynamic viewpoint, an amorphous state has generally higher Gibbs free energy than a 
crystal. Therefore, an amorphous state is considered metastable with a considerable risk of 
crystallization in a non-stabilized amorphous solid dispersion. 
Figure 2.2. emphasizes the differences in Gibbs Energy between an amorphous and crystalline 
material [53]. Moreover, it shows the changes in this energy with increasing temperature, going from 
the glassy to a possible rubbery state in case of the amorphous form and from the crystalline to the 
molten state in case of the crystalline form. The two temperatures in Figure 2.2. mark the transition of 
an amorphous and a crystalline state. The Tg represents the alteration between a glassy state and a 
rubbery state, whereas the other change in the solid state of crystalline material can be observed at Tm, 
when the crystals melt.  
 
 
Figure 2.2. Gibbs Free Energy of amorphous and crystalline material (Reprinted with permission of Elsevier [53]) 
 
 
Furthermore, the difference in Gibbs free energy shown in Figure 2.2. results in an enhanced apparent 
solubility compared to the crystalline form [54]. This so-called amorphous solubility advantage was 
coined by Hancock and Parks, who associated the difference in free energy to the difference in apparent 
solubility according to equation 2 [55]. 
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The different solubilities of the amorphous and the crystalline drug at a fixed temperature are represented 
by 
a
T  and 
c
T , respectively. Consequently, 
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,  is the difference in free energy at a given 
temperature. A higher difference in free energy can be associated with a larger solubility advantage of 
the amorphous form over the crystalline form [55]. Such increased apparent solubility has to be balanced 
with the general drawback of potential physical instability of an amorphous form.  
Since the crystalline form has lower chemical potential, possible drug crystallization to the original 
crystal form or any other polymorph has to be monitored by adequate solid-state analysis. Such 
recrystallization can be described by the two kinetic processes of nucleation and growth. Thus, small 
crystalline nuclei in an amorphous formulation can grow over time to manifest a macroscopic 
crystallization [56]. 
On a molecular level there can be certain kinetic factors identified that lead to recrystallization. One of 
such kinetic influences is the presence of foreign particles, which are insoluble in the undercooled melt 
and act as a site of heterogeneous nucleation [56,57]. Other sources for increased recrystallization are 
the plasticizing behavior of water, which introduces a reduced glass transition with a general increased 
molecular mobility thereby enhancing nucleation kinetics [13].  
 
2.1.2.2 The glass transition 
Amorphous materials, as discussed in the previous section, are lacking the well-defined lattice of a 
crystal. Crystallinity comes with a specific melting point for every drug and its polymorphs, whereas 
amorphous materials show a glass transition at which the material goes from metastable equilibrium to 
a frozen-in non-equilibrium state (Figure 2.2) [58]. As a result of the formation of a non-equilibrium 
state, the glass transition is not a thermodynamic phase transition like for example melting and can 
therefore not be categorized according to the Ehrenfest definition of thermodynamic phase transitions 
[58,59].  
A Tg can vary depending on the cooling rate and hence possibly the manufacturing method [60,61]. 
Based on the given variations of this critical temperature, it is more accurate to refer to a glass transition 
range rather than a clearly defined point [61,62]. 
Below the measured glass transition, the viscosity increase is limiting molecular movement in the 
formulation. Relaxations within the amorphous formulation are considered as major factors for 
instability, which lead to recrystallization. Such molecular movements can occur as α relaxations, which 
represent a global mobility and are rarely present below Tg. This is why in a recent publication, this Tg 
was referred to as Tgα [62]. In contrast, the so-called Johari-Goldstein β relaxation is associated with 
local mobility within the molecule and can still occur below Tgα. The reason for this is the lower 
activation energy of the β relaxation compared to the cooperative α relaxation [63]. Therefore, recent 
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publications investigate the temperature at which the β relaxation is massively reduced to possibly avoid 
recrystallization in ASDs [62]. For general stability consideration, it is favorable to reduce such 
relaxation in amorphous drug delivery systems [64–66] by storing the formulation at sufficiently 
reduced temperatures and low humidity. Introducing water into the system through humidity leads to an 
increase of the drug’s mobility as it acts as a strong  plasticizer decreasing the Tg [67]. Recrystallization 
certainly can occur above but might also happen below Tg [68], which means that storing the amorphous 
formulation below Tg cannot guarantee sufficient stability. A classical rule of thumb is to target a Tg that 
is at least 50 °C above the storage temperature to result in sufficient stability because of the additional 
reduction of β relaxation. 
Due to the practical importance of a glass transition, several methods have been proposed to measure 
Tg, such as: differential scanning calorimetry (DSC), atomic force microscopy, dynamic mechanical 
thermal analysis, thermally stimulated current spectroscopy, density, and inverse gas chromatography 
[69]. Most abundantly employed in the pharmaceutical industry as well as in academia is the DSC 
method. 
 
2.1.2.3 Glass forming ability 
The characteristic glass forming ability (GFA) is generally described as the ease of vitrification of a 
liquid upon cooling [70]. Before the definition of classes, it was proposed that a differentiation could be 
applied in compounds that prefer to be in a crystalline state and drugs being stable in their amorphous 
form. For such a differentiation, temperature dependencies of the nucleation rate and growth velocity 
were used [71] in a diagram which would be today applied as a time-temperature-transformation 
diagram to access the glass forming ability of drugs [72]. Based on these diagrams, fast crystallizing 
compounds exhibit nucleation and growth occurring in an overlap region, while stable glass formers do 
not cross such a crystallization region for most practically accessible cooling rates [61]. 
Baird and coworkers applied the concept of glass forming ability and proposed a more accessible 
solution of the definition in classes [36]. In their publication, the researchers defined three groups of 
drugs based on their recrystallization behavior in a heating-cooling-heating DSC experiment. Such 
experiments provided an initial assessment of GFA. However, the heating and cooling rates during the 
DSC experiments have an impact on the recrystallization of the drug. This is hardly critical for GFA 
class I and GFA class III drugs, since their differentiation is robust in a wide range of typical cooling 
rates from the undercooled melt. However, GFA class II drugs might be categorized differently because 
of variations in the given measurement protocol. Therefore, Blaabjerg and coworkers proposed the 
categorization based on critical cooling rates of the melts (Table 2.3.). Their definitions reached from 
GFA I compounds, which require heating rates higher than 750 °C/min to GFA III compounds, which 
can be cooled with 1 °C/min and still enable the vitrification of the drug [72]. However, like any 
simplified classification also this proposal includes an element of arbitrary group assignment. 
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Table 2.3. Glass forming ability definitions 
 
GFA I GFA II GFA III 
Baird et al. 
[36] 
Recrystallization after cooling 
of the melt 
Recrystallization after 
reheating the cooled 
melt 
No recrystallization 
Blaabjerg 
et al. [72] 
Cooling rate 
> 750 °C/min 
Cooling rate 
10 – 20 °C/min 
Cooling rate 
1 °C/min 
 
It has to be noted that the GFA can be used as predictor of amorphous stability in the development of 
new formulations [34,73]. However, by applying this concept, the influences of the additional 
compounds like polymers have to be taken into consideration. Unbeneficial properties such as 
insufficient miscibility with the polymer or an extensive drug load can still lead to recrystallization of 
otherwise stable glass formers (GFA III) [74]. 
 
2.1.3 Manufacturing techniques 
There are numerous formulation techniques in the field of ASDs with spray drying and HME being the 
most common. More generally, the production of amorphous formulations can be mainly divided into 
melt-based and solvent-based methods [54]. This is critical since the preparation has a substantial effect 
on the physicochemical characteristics, stability and therefore performance of solid dispersions [75]. 
Considering the marketed solid dispersions, it is interesting to see that a rather limited number of 
polymeric carriers and production techniques have been used [41]. While the choice of the formulation 
components is generally based on physical and chemical considerations and long series of experiments 
during development, the production methods are often more arbitrarily selected depending on available 
technological knowledge and equipment [76]. The selection of the manufacturing method based on the 
physicochemical drug properties could accelerate process development and should finally result in a 
robust manufacturing of drug product. 
 
Different melt and fusion techniques represent the classical methods to prepare drugs in their amorphous 
form [76,77]. For the melting of the API and a carrier, temperatures should be above the Tm of the 
API [78]. Raising the temperature above the Tg of the mixture creates adequate molecular mobility for 
the API to be incorporated in the carrier [76]. Although a variety of methods and modifications have 
been introduced throughout the years, solid dispersions containing APIs with high Tm values (e.g. 
quercetin) typically encounter issues of lacking temperature stability of the carrier. These high-melting 
APIs therefore only have a limited range of available polymers that can be used at the needed process 
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temperatures. Moreover, high shear forces in a process of HME may facilitate the removal of oxygen 
and moisture, besides the vigorous mixing and the desirable dispersion of the API in the carrier [46,79]. 
This enables the incorporation and usage of APIs that are sensitive to oxidation. However, high shear 
forces may also compromise the stability of thermo-sensitive APIs, due to possible local high 
temperatures [79]. 
 
An alternative to any melt method is to prepare a solution of drug and carrier in a solvent. The fate of 
the solution may vary, from solvent evaporation to amorphous precipitation. The solvent evaporation 
method includes first the dissolution of API and carrier in a common organic solvent (or solvent mixture) 
and the subsequent removal of the solvent by heating, spray drying or freeze-drying [80]. The choice of 
a common solvent for the API-carrier systems may prove to be limiting, as it is challenging to identify 
a solvent for combinations that vary significantly in polarity [80]. Generally, thermal degradation is not 
a common limitation in the solvent evaporation methods, as temperatures are kept low. Specifically for 
thermo-labile compounds, a freeze-drying method is of interest, where the API-carrier solution is frozen 
and the solvent or solvent mixture is sublimated at temperatures below the Tg of the mixture [76]. A 
sublimation above this critical temperature comes with increased molecular mobility that can facilitate 
recrystallization. Consequently, APIs with extremely low Tgs may not be suitable for this method. In 
addition, during the removal of the solvent by heating, molecular mobility is critical, as elevated 
temperatures (above Tg) may facilitate API diffusion from the carrier, thereby creating a phase separation 
and subsequent crystallization. This suggests that this method may be less suitable for APIs with a Tg 
below the boiling point of common organic solvents (e.g. methanol, ethanol, acetone ~60-70 °C).  
An innovative technique applied in the amorphization of a commercial product is micro precipitation. 
This technique was invented by Roche and first applied as amorphization technique of Vemurafenib 
(Zelboraf®). The high melting point as well as the insufficient solubility in volatile solvents made this 
compound impractical to be processed by either spray drying or HME. The process of micro 
precipitation starts with dissolving the polymer and drug in a solvent with high boiling point, which 
would not be feasible for spray drying. Afterwards, an anti-solvent is added to result in a solvent-
controlled precipitation of the amorphous drug in the polymer [81,82]. 
 
2.1.4 Analytics 
Due to the high relevance of identification and quantification of amorphous drug in a solid dispersion, 
there several methods are commonly applied. These methods are on one side based on solid-state 
characterization, which are mainly used for the structural characterization and stability monitoring. On 
the other side, analytical methods investigate the biopharmaceutical performance of the formulations by 
conducting dissolution experiments in different setups, which mostly simulate in vivo release and 
sometimes include also a permeation step to mimic absorption in the human GI tract. 
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Table 2.4. Solid-state analytical methods for ASDs 
 
Analytical method Measurement Considerations for ASDs 
Powder X-ray diffraction X-ray counts at various 
detection angles 
Application in the detection of 
polymorphic forms and the 
absence of crystalline structures 
Pair distribution 
function 
Derived from Fourier transform 
X-ray patterns 
Describes the probability of 
finding two atoms at a defined 
interatomic distance  
Assessment of specific 
configurations in a polymeric 
system 
Differential Scanning 
Calorimetry 
Heat flow changes of the 
sample over a defined 
temperature range 
Various thermal events can be 
detected as well as different 
heating programs applied to 
increase sensitivity or 
differentiate. 
Fourier transform infrared 
spectroscopy 
Measurement of absorption or 
transmission of a drug in the 
infrared region 
Such a measurement can be also 
combined with a microscope to 
scan in specific areas for 
predefined wavenumbers. 
Raman spectroscopy Detection of Raman scattering 
over a defined region of 
wavelengths  
Evaluation of interactions and 
amorphous content. Not well 
applicable with substances 
showing fluorescence. Same 
possible combination with a 
microscope like with IR. 
UV/Vis spectroscopy Absorption at a defined 
wavelength within the UV/Vis 
spectrum 
This method is widely applied 
as stand-alone instrument or 
integrated into an LC system for 
the quantification of UV-active 
samples 
Nuclear magnetic resonance 
spectroscopy 
Detection of nuclear spin 
energies in a high magnetic 
field with additional inductive 
magnetic fields in the range of 
radio frequencies [83,84] 
Can be applied in the solid and 
liquid state as well as 
specifically detect spins of 
various nuclei (1H, 13C, 15N, 19F, 
29Si, and 31P) 
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A widely used solid-state technique is powder X-ray diffraction (PXRD), which is based on the 
measurements of X-ray scattering over a range of scattering angles [85], where an amorphous form 
shows a halo and absence of any Bragg peaks [86] over the 2θ angles (usually between 2° and 40°). This 
is a result of the lack of long-range order in an amorphous solid [49]. The resolution of such 
measurement is highly dependent on the X-ray source used. This fact is further highlighted in the 
calculation of the Q-value, which can be used in the diffractogram, where the intensity of the scattering 
is displayed on the y-axis and the Q-value on the x-axis. 
 
Q = 4π sin θ/λ (3) 
 
Common measurement setups consist of a copper X-ray source, which provides Qmax values of 8 Å-1. In 
case a laboratory diffractometer is not sufficient for needed resolution, a measurement at a synchrotron 
facility can be performed, which has Qmax values of 20 Å-1. Such measurement comes with higher 
resolution, increased sensitivity to small amounts of crystallinity, and the possibility of probing the 
sample by focusing the beam at different areas. The X-ray measurement is of particular interest for the 
measurement of the local structure in an amorphous solid by pair distribution function (PDF). This 
function can be obtained by Fourier transformation of information from a regular X-ray diffraction 
pattern. For the information content of a PDF, it is highly beneficial to use synchrotron radiation [85]. 
Another common method is DSC, where the absence of a melting endotherm and the presence of a Tg 
indicate an amorphous state. In such a measurement, the sample is put in a crucible, in which it is 
typically first heated then cooled and heated again. During these measurements, the solid state of the 
sample is monitored by measuring the heat flow through the sample over a defined temperature range. 
As a result, thermal events like melting peaks, recrystallization peaks or glass transitions give indications 
about the initial solid state of the sample. During the first heating, the current state of the samples is 
recorded. In the subsequent cooling and the following heating, the amorphous stability as well as the 
miscibility in case of a mixture can be assessed. This was also used for the determination of the GFA 
(Section 2.1.2.2.). The Tg of mixtures can be estimated by the classical Gordon Taylor or the Kwei 
equation, which both combine the Tgs of the substances in the calculation. A major advantage of the 
Kwei equation is the introduction of an interaction parameter to predict Tgs more reliably [87]. 
 
Depending on the heating rate, the sensitivity can be adjusted, although this has to be applied with 
caution. A higher heating rate comes with higher peak intensity, but it also leads to a shift of the thermal 
events. Therefore, for the comparison of samples, the same heating rate should be selected. For the 
differentiation of thermal events, which occur at similar temperatures, modulated DSC can be applied. 
During such modulated measurements, the heating rate is modulated and a subsequent transformation 
of the thermogram leads to the differentiation in reversed and non-reversed heat flow. More details on 
modulated DSC can be inferred from the literature [88]. 
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The most widely applied spectroscopic method is FTIR which can be used for the identification of 
substances by the absorption in the infrared spectrum reaching from wavelengths of about 2.5 to 50 μm 
and wavenumbers of 4000 to 200 cm- 1. In the research field of ASDs, the spectra are more commonly 
used to identify interactions between molecules through changes, which are visible in the mixture but 
not in the spectra of pure substances. Examples for such changes can be found in the absorption range 
of 1750 cm- 1, which corresponds to the C=O functional group and can be impacted by direct hydrogen 
bonding or molecular interactions of neighboring atoms. This evaluation should always be performed 
with the physical mixture and the given formulation, because dilution effects of mixing between 
excipients and drug can result in reduction of peak intensities making such a control experiment 
necessary. Moreover, the samples should be dried because water reduces the detectability of peaks at 
higher wavelength areas. FTIR measurements are usually conducted in the attenuated total reflection 
mode, which comes with the benefit that the sample can be placed in its neat form on the sample holder 
and measured without further preparation. Another sample preparation involves the compression of the 
sample with KBr. 
 
Table 2.5. Microscopic analytical methods for ASDs 
Analytical method Measurement Considerations for ASDs 
Polarized light microscopy Microscopic Images with 
polarized light resulting in 
bright appearance of 
birefringent crystalline 
structures 
Since nucleation can randomly 
occur, the complete sample 
should be assessed to identify 
possible sites of crystallization.  
Atomic force microscopy Topographical measurements Small amounts of phase 
separation or crystallization can 
be monitored in phasing images 
or simple surface 
measurements. 
Scanning electron 
microscopy 
Monochromatic images of 
morphological features on the 
surface detected through 
backscattered electron detection  
Crystal structures and 
morphological features can be 
analyzed. However, the clear 
identification of crystals might 
not be possible. 
Energy dispersive X-ray 
detection 
Elemental information on 
electron microscopy images can 
be gathered 
The color coding of different 
elements can be used to map the 
distribution of a drug, if a 
detectable element is available 
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Closely related to FTIR for probing molecular vibrations as well is the Raman spectroscopy, in which 
Raman scattering of an incident laser light is detected following adequate filtering of Rayleigh 
scattering. Fiber optical connections enable in-line Raman probes that can be used to monitor 
recrystallization and amorphization processes during HME [89]. Another application is the analysis of 
precipitates during dissolution experiments, because Raman spectroscopy is less disturbed by water than 
FTIR and has the ability to differentiate between dissolved drug and precipitated compound [90]. In line 
with FTIR, Raman measurements can also be used to investigate interaction in an ASD in the solid state 
[91]. 
 
Optical methods can be used as well for the investigation of ASDs. Such methods reach from the simple 
visual inspection to more complex methods like atomic force microscopy (Table 2.5). The method 
commonly applied for the detection of crystals is polarized light microscopy. In contrast to DSC and 
PXRD in a normal setup, the polarized light microscopy can detect smaller amounts of crystallinity in 
transparent or slightly opaque samples. Through the polarization of the light, crystalline features can be 
detected as shining objects in the sample. However, this analysis has to be carefully applied, because 
the measurement of artifacts is also possible. 
 
Another microscopic measurement method is the imaging via scanning electron microscopy. In this 
method, monochromatic images are taken by the detection of backscattered electrons. Depending on the 
instrument, high magnifications can be reached. Of great interest for the analysis of ASDs is the 
combination with electron dispersive X-ray detection. This measurement setup allows for the detection 
of different chemical elements on surface of the sample. Therefore, the distribution of an API like 
fenofibrate, which contains a chlorine atom, can be detected. Unequal distribution of a drug, which could 
lead to stability issues, can be identified as well [92]. 
 
Table 2.6. Dissolution methods for ASDs 
Analytical method Measurement Considerations for ASDs 
Sink dissolution Measurement of complete drug 
content, which is released by the 
investigated formulation over 
time 
The conditions are defined in regulatory 
documents to assure consistent 
measurements. Measurements can be 
conducted at various conditions to 
simulate different parts of the GI tract. 
Non-sink dissolution Quantification of the drug 
concentration released over 
time at oversaturated starting 
conditions  
Precipitation and supersaturation in 
biorelevant media can be detected to 
show the solubility advantage of an 
amorphous formulation 
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Atomic force microscopy presents a method which is used for the detection of morphological sample 
features by using a cantilever, which scans the surface of the sample. With this method, phase separation 
on the surface of sample can be monitored even before recrystallization occurs [88,93]. Therefore, 
stability issues can be spotted at an early stage. However, the measurement setup should be in a 
mechanical resonance-reduced area, since minor vibrations can lead to artifacts in the measurement. 
 
The initial biopharmaceutical evaluation of a newly developed formulation is usually done in a 
dissolution apparatus. In this measurement, the release of drug is monitored over a defined period of 
time at constant conditions. Different types of dissolution equipment are described in the pharmacopeias 
and  test conditions for drug release of marketed products are defined in various regulatory documents 
for different types of drug release products to ensure comparable testing conditions [94]. The research 
on biorelevant dissolution testing procedures has further improved the conditions reaching from the 
apparatus to the release media used. This development led to such in vitro experiments becoming more 
comparable to the human GI tract. Different media were developed for a standardized biorelevant 
comparison at fasted or fed state release of drugs [95]. The generally most applied dissolution equipment 
is the paddle apparatus (USP 2) in combination with dissolution media defined in the pharmacopeia 
(Ph.Eur. or USP). This apparatus also enables the previously mentioned detection of drug precipitation 
from supersaturated formulations through the use of Raman inline probes. Other instruments are used 
as well with regards to different dosage forms. Moreover, the pH and other changes during the GI transit 
can be evaluated through media changes in the standard dissolution vessel (as described in the American 
pharmacopeia; apparatus USP 1 and 2) or the flow through cell (USP 4). Such more elaborate dissolution 
testing is typically used for the development of controlled release formulations or in a later stage of 
formulation development. 
The experimental condition in which the drug can be released completely according to its solubility is 
called sink dissolution (Table 2.6). In this experiment type, it is possible to monitor when certain 
percentages of drug release are reached. The previously mentioned USP 2 apparatus provides a typical 
vessel for sink dissolution experiments. However, phenomena like supersaturation, which occur at 
concentrations higher than the equilibrium solubility, can hardly be investigated with the described 
setup. Therefore, smaller volumes can be used, which are not sufficient to solubilize the complete 
amount of drug in the formulation. Especially for ASDs, this is essential, because important factors like 
supersaturation and precipitation can be easily detected and are expected to provide a more realistic 
simulation of the events occurring in the GI lumen. In pharmaceutical research, such experiments can 
be conducted on a small scale to get a first idea of the supersaturation potential of the formulation. 
Moreover, these experiments can be used to investigate the precipitation of drug in the presence of 
different polymers. In these experiments, a polymer is pre-dissolved in the dissolution medium and 
afterwards a drug solution in an organic miscible solvent is added [96]. For polymers with poor drug 
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stabilization properties of a supersaturated solution, recrystallization can be detected, whereas polymers 
with sufficient drug stabilization would sustain drug in a supersaturated state. 
 
2.1.5 Biopharmaceutical implications 
After the oral administration of an ASD, the amorphous drug is exposed to the digestive fluids in the GI 
tract. Upon this aqueous dispersion, different species are formed. Friesen and coworkers described 7 of 
those species: free or solvated drug, drug in bile-salt micelles (2 to 20 nm), free or solvated polymer, 
polymer colloids (10 to 20 nm), amorphous drug/polymer nanostructures (20 to 100 nm), 
nanoaggregates of amorphous drug/polymer nanostructures (70 to 300 nm), and precipitates (> 500 nm) 
[97]. The drug is kept in amorphous form in the nanostructures and their aggregates. Therefore, these 
species have the greatest impact on the amorphous solubility advantage and the related enhanced 
bioavailability [97].  
One of the reasons for the enhanced bioavailability is the formation of a supersaturated state in the 
intestinal fluids, which is exceeding the solubility of the crystalline drug (Section 2.1.2.1) [45,55]. This 
formation of the supersaturated state in aqueous media is described in the spring and parachute model 
by Guzman [98]. In this model, the drug is quickly released and stays in a state exceeding equilibrium 
solubility as result of the amorphous solubility advantage. The duration and therefore the parachute of 
such supersaturation is highly dependent on the stabilization through excipients acting as precipitation 
inhibitors (Figure 2.3). An example is the embedment of a drug in mesoporous silica without any 
precipitation inhibitor. Due to the non-crystalline state of the API, a spring (i.e. high initial 
supersaturation) is obtained. However, since mesoporous silica alone is unable to stabilize drug 
supersaturation, the drug typically precipitates quickly due to the lacking parachute effect, and the 
solubility decreases to the equilibrium solubility. If balanced carefully, the supersaturation over the 
absorption window within the human GI tract can lead to improved absorption properties of a solubility-
limited drug. As a reference, the dissolution of a crystalline material is shown in Figure 2.3, which 
slowly dissolves until it reaches the equilibrium solubility. Depending on the drug and the dissolution 
medium, slightly higher concentration that the equilibrium solubility might be reached even here, 
because of surface amorphization or solubilization by micelle containing biorelevant media [99]. 
 
During the dissolution of an ASD, the amorphous solubility, as shown in the spring and parachute 
behavior depicted in Figure 2.3, can lead to such high concentrations resulting in a liquid-liquid phase 
separation (LLPS) in a drug-rich and a drug-poor phase in solution if the drug stays in the non-crystalline 
state. LLPS is expected to have a positive implication on the bioavailability enhancement of poorly 
water-soluble drugs [44,100]. An important implication of the LLPS is, however, that drug permeation 
can only be driven by the free fraction of drug that is lower than drug of the apparent concentration since 
there is a drug reservoir in colloidal droplets. The group of Lynne Taylor showed further that there is an 
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apparent sweet spot in the dissolution of ASDs. This sweet spot is specific for each individual drug and 
formulation as it is about a synchronized release of drug and polymer from the surface and thereby 
enabling the desired sustained drug supersaturation without particular enrichment of the drug occurring 
on the surface [44]. This led to the conclusion that low drug loadings would be beneficial with regards 
to drug dissolution from ASDs, which would lead to high supersaturation and eventually the formation 
of non-crystalline liquid-liquid phase separated colloidal species upon aqueous dispersion [44]. Such 
balanced release of drug in relation to hydration of the polymeric matrix should become an important 
biopharmaceutical objective for formulators of ASDs. 
 
 
Figure 2.3. Drug release profiles of a stabilized ASD, a non-stabilized ASD, and a crystalline reference in non-
sink dissolution. The terms of spring and parachute effects are explained in the text. 
 
Moreover, it was highlighted by Neman et al. in an overview of ASDs that such a formulation approach 
increases the oral bioavailability in 82 % of the investigated solid dispersions, whereas in 8 % of the 
cases even a decrease in oral bioavailability was evidenced compared to a reference drug [48]. It is 
therefore important to study biopharmaceutical properties of ASDs early on in their development. Drug 
release is usually first evaluated using a biorelevant medium to simulate the release behavior in the GI 
tract [95,101]. In this context it might be an advantage to apply a non-sink dissolution testing, since 
events like precipitation and supersaturation, which are highly relevant for the biopharmaceutical 
performance of any supersaturating formulation such as ASDs [102], can be monitored more precisely 
[103]. Afterwards, promising formulations can be evaluated in the animal model.  
An alternative to this approach prior to an animal study is the application of an experimental setup, 
which allows the evaluation of the dissolution as well as the drug permeation. Such an experimental 
setup was recently published by Sironi and colleagues, in which a tubing loop was linked to a biomimetic 
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membrane (i.e. PermeaLoopTM) to simulate physiological dissolution coupled with an absorption step. 
The described setup has the benefits of increased area-to-volume ratio and the capability of showing 
how dissolution can be rate limiting [104]. Such dissolution testing using a biomimetic membrane with 
an absorption compartment bears much potential for the testing of ASDs. It allows to mimic an 
absorption process from supersaturation occurring in the donor compartment of the dissolution test. 
However more research is needed in the future to finally assess how predictable such an in vitro test is 
for the in vivo situation.   
 
2.2 Hot melt extrusion 
2.2.1 Process 
The process of HME was first developed in the manufacturing of plastics in the 1930s, only later in 
1971 was it initially applied in pharmaceutical formulation design [105]. The increasing need of 
formulation techniques for poorly water-soluble drugs encouraged this processing step to be applied in 
the formulation development and later in the manufacturing of drug products. A particular advantage is 
that it is free of a solvent and the footprint of the equipment in a production floor is comparatively low. 
Moreover, HME can also be applied for other purposes than the increase of apparent solubility, such as 
controlled drug release, taste masking, and to achieve particularly shaped drug delivery systems. 
Depending on the equipment and requirements used, common shapes are patches, granules, powder, 
spheres or films.  
In general extruders consist of a hopper, a mechanical motor, a control panel, a barrel, a temperature 
regulating system, one or two screws, and a die (Figure 2.5).  
 
 
Figure 2.4. Example of a twin-screw hot melt extruder for compounding on a relatively small scale 
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In a modern extrusion setup, the hopper is connected to a feeder, which ensures a constant flow of 
material. Such a feeder can be further equipped with a mixing device to prevent the powder mixture 
from separating prior to extrusion. The feeding has to be accurate to ensure adequate content uniformity, 
which goes hand in hand with a constant filling of the barrel to ensure sufficient mixing and a constant 
pressure at the die. The motor of the extruder determines the torque, which is applied on the screws. It 
drives the rotation speed as well as the direction of the rotation. The motor of a twin-screw extruder 
further determines whether the screws are co- or counter-rotating. Since counter-rotating screws are only 
beneficial when higher shear forces are necessary and show limited mixing capabilities in comparison 
co-rotating screws, the setup of co-rotating screws is mostly applied in the pharmaceutical industry 
[106]. The barrel, which is visible at the right side of Figure 2.4, primarily ensures the smooth running 
of the screws and the equal heat distribution throughout the full length the extrusion. Different sizes of 
heating segments and split barrels can be used to adapt the heat uptake and facilitate the cleaning of the 
barrel, respectively. Furthermore, it can be equipped with additional openings for the application of 
analytical in-process probes or additional feeding ports. The given software-controlled panel can be used 
for the control of the whole process. In a basic setup, the parameters of the temperature regulating system 
and the screw speed can be adjusted. More sophisticated machine setups with more complex control 
panels can inform about for example the torque generated at the end of the extruder. Such information 
can be critical, since fluctuations are an indicator of insufficient barrel filling or unpredicted changes in 
the material. For the temperature control, heating cartridges around the barrel are used and monitored 
by thermocouples.  
The screws play an essential role in the extrusion. Extruders can be either equipped with one or two 
screws, which can be either counter- or co-rotating. As mentioned above, a typical formulation 
development makes use of twin-screw extruders, which do not rely as much on shear forces as single 
screw extruders. Furthermore, they have only a minor problem with the formation of agglomerates and 
show more sufficient mixing as well as better conveying. The two screws, which are a key part of the 
extruder, can be adapted to fit different purposes or process requirements. 
 
 
Figure 2.5. Example screws of a 9 mm hot melt extruder 
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The screws can be equipped with different elements, like conveying, mixing, and kneading parts. Such 
elements can vary in their staggering angle and disk widths. These features can be adapted to intensify 
the heat impact and mixing efficiency of the extruded formulation [107]. Usually at the end of the screw, 
where the feeder is located, the flights have a deeper pitch, which makes the conveying along the barrel 
easier. At the melting and mixing zone, the pitch is reduced and kneading elements can be applied to 
increase the pressure and ensure homogeneous melting. Throughout the transition along the discharging 
zone, a constant flow of material has to be created to enable further downstream processing or collecting 
of the extrudate. Figure 2.6 depicts the typical geometry of a conveying element. Moreover, there are 
screws consisting of changeable screw elements which can be stacked on a template screw to achieve 
specific extrusion parameters. The screws are normally defined by their diameter in mm, which means 
an extruder with 9 to 12 mm can be used for first extrusion trials during early pharmaceutical 
development with later scale-up options. Extruders of that size can produce amounts of 60 to 600 g/h. 
In contrast, production scale screws in the pharmaceutical industry can have dimensions up to 50 mm 
in diameter with a flow rate of 150 kg/h. These extruders are used in continuous manufacturing and are 
able to be operated over a longer period of time, while being switched off only for cleaning purposes. 
 
 
Figure 2.6. Geometry of an extruder screw (Reprinted with permission of Elsevier from [106]) 
 
At the end of the extruder as downstream processing units, equipment like chill rolls and pelletizers are 
required to transform the extrusion strand into a powder, which can be pressed into tablets or filled into 
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capsules. Another processing option is the direct shaping after extrusion. Extruded products are available 
in a broad variety of shapes for different applications ranging from ophthalmic to vaginal [108]. 
 
With the application of continuous manufacturing in the field of HME, process analytical technology 
(PAT) tools gained a major interest. Therefore, in-process controls (IPC) to monitor the performance 
were developed and encouraged for  application of the quality by design approach by regulatory 
authorities [109,110]. Crucial parameters with a great impact on the formulation are processing 
temperature, screw configuration, screw speed, torque, transition time, and solidification properties at 
the outlet [111]. In a modern continuous manufacturing extrusion setup, parameters like feeding rate 
and barrel temperature can be adjusted during the process, whereas parameters like torque, material 
temperature, pressure at the die and other PAT parameters are monitored. Newly developed PAT tools, 
which enable in-line measurements, consist of spectroscopic measurements at the die. Such 
measurements can be performed by near infrared (NIR) probes, which monitor chemical as well as 
physical changes in the sample [79]. More specific with the inclusion of a Raman probe, properties like 
the concentration of a certain substance and the crystallinity can be determined, which is essential 
considering the fact that extrusion is widely used in the manufacturing of amorphous drug products [79]. 
Moreover, optical sensors can be used to determine mean residence time by detecting the change in 
color of a marker that was added to the formulation at the end of the barrel. 
 
Versatile applications and scale-up options of extrusion in the pharmaceutical industry range from the 
field of bio-enabling drug delivery to taste masking and controlled drug delivery, which led to a broad 
implementation of the extrusion technology within pharmaceutical development. With further 
development of continuous manufacturing and PAT tools, HME has the potential to be even more 
applied in the future within the pharmaceutical industry. 
 
2.2.2 Restrictions and benefits 
Since there is a variety of amorphization techniques applied in the field of pharmaceutical development 
and manufacturing, the adequate selection of the amorphization method is crucial for a successful 
formulation. Therefore, this section describes the applicability of HME by highlighting advantages and 
possible disadvantages, which would make the process either preferred or unfavorable. 
One of the advantage and reason why HME is broadly applied in the pharmaceutical field of enabling 
formulations is the increase in apparent solubility (Section 2.1.1 and 2.1.5.), which comes with the 
successful amorphization of the drug substance. Although this can also be achieved with other 
techniques like spray drying or micro precipitated bulk powder, a unique advantage of the before 
mentioned technique is that it is a solvent-free process and it reduces the oxygen exposure during 
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formulation compounding [112]. This is particularly relevant when a drug is not stable in contact with 
a solvent or feasible solvents for the formulation are unavailable due to safety or other restrictions. 
Moreover, an extruder can run in a continues operation, while being monitored through process 
analytical tools (Section 2.2.1.) because of the robustness of the process [113]. In addition, complex 
downstream processing like tableting can be avoided for example by direct shaping. The process is 
highly adaptable and can be used for different applications from immediate to controlled release as 
mentioned before. In addition, different routes of administration are possible with such systems. 
Extruded formulations can be used for example transdermal, oral, transmucosal or subcutaneously. 
 
The major disadvantage of extrusion is the heating of the compounds. Therefore, compounds with 
insufficient thermal stability are not available for HME. Furthermore, it presents a more complicated 
and expensive formulation technique in comparison to common techniques like tableting. With the 
formulation of the drug in its amorphous state (Section 2.1.2), this formulation approach comes with the 
risk of recrystallization, which has to be avoided over the shelf life of the drug product. Another practical 
restriction is the processing of molecules with high melting points as highlighted in Section 1.1. 
Although high melting drugs might dissolve in the molten polymer, if melting of such drug is required, 
HME might not be the most feasible formulation technique. 
 
2.2.3 Excipient selection 
Typical compounds for an extruded formulation are one or more thermoplastic polymers, which are used 
as a carrier system to embed and stabilize the drug in its amorphous form [114,115]. Another advantage 
of the polymer is the stabilization of the drug in the supersaturated state upon aqueous dispersion as 
mentioned before [116]. Therefore, the selection of the polymer in the formulation is one of the most 
important decisions to be made during the design of a formulation [117]. As a consequence, to encourage 
a rather rational decision in contrast to a trial and error approach, the screening of polymers for 
amorphous drug stabilization (SPADS) approach was introduced by Wyttenbach and colleagues [118]. 
In this approach, combinations of polymer and drug are screened in various compositions with regards 
to supersaturation potential, amorphous stability and molecular interactions of drug with the matrix. 
Other functional excipients are needed to act as plasticizers during the extrusion and therefore reduce 
the necessary processing temperature [119]. Further excipients include surfactants for an increase in 
wettability, antioxidants to increase the stability, pH and release modifiers regarding the 
pharmacokinetic needs of the drug and additional excipients to facilitate further downstream processing 
[113]. Depending on the required drug delivery system, further parameters play an important role such 
as Tg, Tm, melt viscosity, thermal stability, solubility parameters, solubility, hygroscopicity, lipophilicity, 
hydrophobicity [113]. Additionally, when a specific molecular interaction within the extrudate is 
targeted, the hydrogen donor acceptor moieties as well as ionizable groups can play an important role. 
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Such an interaction can be formed during the extrusion and result in beneficial mixing, stability and 
release properties [120–122]. 
 
2.2.3.1 Miscibility considerations 
As described in the previous sections, the miscibility of the components of an amorphous solid 
dispersion is crucial for the performance. Therefore, different concepts were developed to predict and 
assess the miscibility and maximum drug load in homogenous mixtures. Miscibility or solubility 
considerations are mostly based on the principle of “like dissolves like”. However, this concept is not 
theoretically applicable without any numerical values. Therefore, the first concept of a solubility 
parameter was introduced by Hildebrand and Scott in 1950 [123]. This model calculated the solubility 
of a specific material in another material by means of the introduced concept of the solubility parameter 
that is the square root of the cohesive energy density [124], which can be also expressed as the energy 
needed to remove solvent molecules for creating an ideal cavity for solute [125]. The described cohesive 
energy (Etotal) can be divided further into the dispersive energy from for example Van der Waals forces, 
which represent the atomic nonpolar forces (Ed); the energy based on polar forces (Ep), and the energy 
contributed by hydrogen bonding (Eh). 
 
𝐸𝑡𝑜𝑡𝑎𝑙
𝑉𝑚
=
𝐸𝑑
𝑉𝑚
+
𝐸𝑝
𝑉𝑚
+
𝐸ℎ
𝑉𝑚
 (4) 
 
The division of these energy contributions by the molar volume results in the partial solubility 
parameters, which can be added to the total Hansen solubility parameter [126]. 
 
𝛿𝑡𝑜𝑡𝑎𝑙
2 = 𝛿𝑑
2 + 𝛿𝑝
2 + 𝛿ℎ
2 (5) 
 
Such solubility parameter can be derived from various analytical methods such as solubility evaluation 
in solvents with known cohesive energy or by inverse gas chromatography [124,125]. Another common 
approach to estimate solubility parameters is their in silico calculation, for which novel methods are 
particularly encouraging [127]. The comparison of calculated solubility parameters is a common method 
for the theoretical evaluation of the miscibility between polymer and drug during the development of an 
ASD. The assessment of miscibility here is based on the difference between the solubility parameter of 
the API and the polymer. Apart from the mentioned calculation approach, classical group contribution 
methods can be applied as well [125]. The Van Krevelen method and calculation of the total solubility 
parameter by summation of the functional group contributions, which provide the partial solubility 
parameters in equation 5, is well established in the field of research [126]. To finally evaluate the 
miscibility of polymer and drug, the difference between the solubility parameters should be below 
7 mPa1/2. If the difference is below 2 mPa1/2 the compounds might form a solid solution. In contrast, if 
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the difference is more than 10 mPa1/2 the compounds are most likely not miscible [124,128,129]. 
Consequently, a different polymer in the case of an ASD should be selected. 
 
The solubility parameter derived from the methods described above can be used in the thermodynamic 
evaluation of mixing for the calculation of the interaction parameter in the Flory-Huggins theory, which 
was developed to describe the dissolution of crystalline material in a solvent [130–132]. According to 
this theory, the free energy of mixing can be calculated as shown in equation 6.  
 
∆𝐺𝑚𝑖𝑥
𝑅𝑇
= 𝑛𝑑 ln 𝜑𝑑 + 𝑛𝑝 ln 𝜑𝑝 + 𝜒𝑑𝑝𝑛𝑑𝜑𝑝  (6) 
 
The entropic contributions to the mixing are represented on the right side by the two first terms, which 
not only include the molar amount of the drug (nd) and of the polymer (np), but also the volume fractions 
of these components (φd,p). The enthalpic contribution as the third term on the right hand side of the 
equation determines whether the result is a negative free energy of mixing and therefore 
thermodynamically favorable. A major contribution to that last term is the previously mentioned Flory-
Huggins interaction parameter χdp. In case this parameter is negative, the adhesive forces between drug 
and polymer should be greater than the cohesive forces between drug-drug and polymer-polymer, 
respectively. It has to be noted that the interaction parameter depends on temperature, composition and 
chain length of the polymer [124]. A major limitation of the described theory is the inability to take 
interactions like hydrogen bonding into account. Moreover, like any consideration of mixing, it does not 
consider crystal lattice energy break and therefore assumes the mixing of the drug and the polymer in 
the amorphous form [133]. 
 
A phase diagram based on the energy of mixing derived from the Flory Huggins theory can be applied 
for the determination of stable regions at specific polymer-drug ratios [97,132,134,135]. Another 
method to predict either miscibility or the solubility of an API in a polymeric system is the perturbed-
chain statistical associating fluid theory (PC-SAFT), which is based on the perturbation theory with 
regards to chain molecules and evaluates the interactions between molecular chains by reducing them 
to spherical segments [136,137]. This comparatively more elaborate thermodynamic method is widely 
applied in pharmacutics by the group of Professor Sadowski to for example estimate the stability of 
drugs in polymeric amorphous solid dispersions [138,139]. 
The phase diagram divides the different states of an ASD based on the temperature and the composition 
of drug and polymer. The space under the phase separation curve on the right hand side describes states 
of the ASD, at which spontaneous separation in drug-poor and drug-rich phases could occur 
spontaneously above and below the Tg [140].  In the area between the solubility line and that of the phase 
separation, the ASD can be kinetically stabilized in its supersaturated state by a polymeric compound. 
Destabilization in those areas requires a certain activation energy so those systems are much more stable 
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when stored sufficiently below their Tg. Although the areas above the solubility line lead to the best 
stability, such low concentration are mostly not feasible for the formulation of a poorly water-soluble 
drug. 
 
 
Figure 2.7. Theoretical phase diagram of a polymer drug mixture constructed using the PC-SAFT theory 
with the combined glass transition temperature (dashed line) [139]. 
 
More recently molecular dynamics and docking have been used for the screening of applicable excipient 
combinations and the interaction between them [141–143]. These studies have shown that for example 
a Tg and the effect of a plasticizer on this property can be estimated by molecular dynamics. Moreover, 
such simulations have been shown to enable the simulation of HME by a simulated annealing step, 
which was further used for the evaluation of miscibility of the compounds used.  
 
2.3 Co-former in amorphous solid dispersions 
2.3.1 General considerations 
In an amorphous drug delivery system, excipient characteristics are particularly critical for the 
formulation performance like miscibility of the components, aqueous solubility, supersaturation 
behavior, and stability of the amorphous form as outlined in the previous sections. Since the need of 
viable multifunctional excipients has outgrown the number of available pharmaceutical polymers, 
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different research groups presented the concept of introducing small molecular additives, which interact 
specifically either with the drug [40,144–147] or with the polymer [122,148,149]. The important 
difference to the simple combination of two polymers in a blend and the systems described in this section 
is that a specific interaction between the components is targeted already through the selection of the 
additives. Such systems can be differentiated in either modified polymeric matrix systems [122], co-
amorphous systems [150], or co-crystals [151]. The intended molecular interaction has at least for co-
crystals not always been a characteristic aspect but it is these days common in modern crystal 
engineering [152]. The co-amorphous and modified matrix systems are more recent formulation options 
and come generally with the engineering approach of targeting the interactions. The major differences 
between these systems are described below and highlighted in Table 2.7. 
 
Table 2.7. Overview co-former systems 
 
 
The polymeric matrix systems mostly focus on altering polymer properties as described in section 3 by 
mainly targeting the interaction between the co-former and the polymer rather than the interaction with 
the drug [122,148]. Co-amorphous systems are mainly investigated with regards to the sole interaction 
between a drug and a small molecular additive and have been proposed to be feasible without the 
addition of a polymer [40,153]. The third option when combining small molecular additives with APIs 
is the formation of a co-crystal, which describes a crystalline structure of the additive and drug. The 
absence of ionic interactions makes here a difference to drug salts. Whether a drug forms a co-crystal or 
a co-amorphous system has to be determined experimentally. There are efforts to identify co-formers 
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that rather form a co-crystal than a co-amorphous complex [154]. However, this highly depends on the 
components as well as the composition of the mixture. Moreover, it is possible for co-amorphous 
systems to be used as an intermediate during the formation of a co-crystal [155].  
 
As highlighted in the previous sections, besides the stability of the amorphous form, the ability to form 
a supersaturated state upon aqueous dispersion is pivotal for an amorphous drug delivery system. This 
is particularly important when co-formers with limited water solubility are used to increase the stability, 
because the strong interaction within the formulation has to be balanced with the intended release of the 
drug. Therefore, the majority of co-formers in amorphous formulations are amino acids, which are 
ionized upon aqueous dispersion and as a consequence present a sufficient solubility in water. However, 
other compounds like dicarboxylic acids [122] or highly water-soluble substances like urea or 
meglumine [148] have also shown beneficial properties in the application as a co-former. The highly 
water-soluble co-formers come, however, with the drawback that it is difficult to find a common solvent 
with a poorly water-soluble drug. If neither a solvent-based method nor HME is an option, the only 
feasible production process is co-milling [91,154]. 
 
In review articles, several authors suggested different approaches for the selection of additives in 
amorphous drug delivery systems [140,156]. The two crucial factors for the successful selection of a co-
former in an amorphous system are miscibility and molecular interaction with a compound in the 
formulation.  
The classical approach to select additives case-by-case on a trial and error basis is still often pursued but 
should be replaced by designing formulations. Such a concept was reported by Pajula and colleagues, 
who applied computational docking to identify promising candidates for the inhibition of drug 
crystallization [157]. In their studies, they reported that molecules with a higher free energy of binding 
than the reference molecule showed experimental inhibition of crystallization. 
Several reviews were published over the last years, which highlight the selection of co-formers as well 
as the evaluation of co-formers in amorphous solid dispersions [91,140,147,150,158,159]. Moreover, an 
overview of co-formers used in amorphous formulations is provided in table 2.8. 
 
In summary, all of the three described systems can be applied for their specific pharmaceutical 
application. The co-crystals might not reach similar apparent solubility increase and drug dissolution 
when compared to the two other amorphous systems. However, a co-crystal does not come with the 
stability issues of an amorphous formulation. Co-amorphous system and polymeric matrices come with 
the difficulty of physical stabilization as mentioned above. Although they show tremendous 
improvement in drug release, the future will show how broadly they find application in industrial 
developments of drug products. 
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Table 2.8. Co-former used in amorphous solid dispersions 
  
 Co-former Side chain Physiological 
charge 
Melting point/ 
degradation  
Typical 
interactions 
Amino Acids 
Lysine [144] -NH2 +1 224.5 °C Acid/Base or H-
bonding 
Arginine [144] -NH2-NH-NH2 +1 244.0 °C Acid/Base or H-
bonding 
Histidine [148] -NH- 0 287.0 °C H-bonding 
Phenylalanine [144] Benzene ring 0 283.0 °C Hydrophobic or π-π 
Tryptophan [160] Indole ring 0 290.5 °C H-bonding or π-π 
Serine [144] -OH 0 228.0 °C H-bonding 
Aspartic acid [144] -COOH -1 270.0 °C Acid/Base or H-
bonding 
Glutamine [144] -CONH2 0 185.5 °C H-bonding 
Threonine [140] -OH 0 256.0 H-bonding or 
hydrophobic 
Other Acids     
Citric acid 3x –COOH & -OH -3 153.0 °C Acid/Base or H-
bonding 
Succinic acid [161] 2x -COOH -2 188.0 °C Acid/Base or H-
bonding 
Tartaric acid [161] 2x -COOH &  
2x -OH 
-2 206.0 °C Acid/Base or H-
bonding 
Malic acid [122] 2x –COOH & -OH -2 130.0 °C Acid/Base or H-
bonding 
Other Co-former     
Saccharine [149] -NH-SO2 & 
Benzene ring 
-1 224.0 °C Acid/Base or H-
bonding or π-π 
Meglumine [148] 5x -OH & -NH- 1 128.5 °C H-bonding 
Quercetin [162] 5x -OH &  
Benzene rings 
-1 316.5 °C H-bonding or π-π 
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2.3.2 Application of co-formers in polymeric amorphous drug formulations 
The concept of modifying existing polymers by combining them was broadly used in current research 
to result in desirable polymer properties [163,164]. While this concept also targeted the interaction 
between the polymers, it most commonly utilized only polymer-polymer combinations. The 
combination of a small molecular additive to target specific interactions with the polymer, which could 
result in comparable beneficial processing parameter and better stabilization of a drug in its amorphous 
form, was rather new to this field. 
The basis of small molecular additives interacting with a polymer in an ASD was first proposed by 
Higashi and colleagues, who milled a ternary mixture of probucol, saccharin, and Eudragit E PO in a 
cryomill. The resulting mixtures showed interactions between probucol and Eudragit E as well as 
between saccharin and Eudragit E. Moreover, these interactions led to improved release properties in 
comparison to the mixtures without saccharin and an improvement in amorphous stability of the drug. 
In contrast to the co-amorphous systems mentioned in the previous section, the system described by 
Higashi and colleagues also targeted the interaction between the polymer and the additive to stabilize 
the drug through further interactions [149]. 
On the basis of a polymer in a ternary mixture with an additive and a drug, the amorphous drug delivery 
system of modified polymeric matrices (Table 2.7) was developed. In this concept, instead of the 
interaction between additive and drug, only the interaction between the additive and the polymer is 
addressed. A new polymeric matrix is targeted in this case that could be used for different drugs. 
Therefore, this excipient interaction primarily alters the characteristics of neat polymer but further 
interactions with drug are desired regarding formulation performance. Prior to the practical formulation 
development, the molecular interactions should be targeted based on a molecular rationale. Such a 
modified polymer matrix is produced in a two-step process, which consists of the manufacturing of a 
polymer-additive matrix and the combination of such systems with a drug in a separate step. The pre-
processing of the polymer with the additive can lead to a broader range of processing options for the 
later manufacturing of a drug- containing ASD. If this approach is applied carefully, polymeric 
compounds, which would otherwise not be feasible for HME, can be easily extruded [148]. This is of 
particular interest if HME is the most promising amorphization technique for the selected API. 
The desired improvements of a modified polymeric matrix are in line with the co-amorphous systems, 
which may provide an increase in amorphous stability as well as supersaturation upon aqueous 
dispersion thereby resulting in a likely higher absorption in vivo. The advantages of a modified matrix 
would have to be assessed specifically for a given drug.  
Another aspect of such a system is the practical use for an excipient manufacturer, who is able to produce 
for example a proprietary modified polymeric matrix to sell it to the pharmaceutical industry.  
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Consequently, the modified polymeric matrices present a valuable option in the development of modern 
ASDs. This formulation approach is especially attractive if no suitable polymer is available and the 
biopharmaceutical properties require drug formulation in an amorphous form. 
 
 
 
 
 
 
 
Ditzinger, F.; Scherer, U.; Schönenberger, M.; Holm, R.; Kuentz, M. Modified Polymer Matrix in Pharmaceutical Hot Melt 
Extrusion by Molecular Interactions with a Carboxylic Coformer. Mol. Pharm. 2019, 16, 141–150, 
doi:10.1021/acs.molpharmaceut.8b00920. 
© Reprinted with permission from [114]. Copyright 2019 American Chemical Society 
Chapter 3 
 
Modified polymer matrix in pharmaceutical hot melt 
extrusion by molecular interactions with a carboxylic 
co-former 
 
 
 
 
Summary 
Hot melt extrusion (HME) has become an essential technology to cope with an increasing number of 
poorly soluble drug candidates. However, there is only a limited choice of pharmaceutical polymers to 
obtain suitable amorphous solid dispersions (ASD). Considerations of miscibility, stability, and 
biopharmaceutical performance narrow the selection of excipients, and further technical constraints 
arise from needed pharmaceutical processing. The present work introduces the concept of molecularly 
targeted interactions of a co-former with a polymer to design a new matrix for HME. Model systems of 
dimethylaminoethyl methacrylate copolymer, Eudragit E (EE), and bicarboxylic acids were studied, and 
pronounced molecular interactions were demonstrated by 1H, 13C NMR, FTIR spectroscopy, as well as 
by different techniques of microscopic imaging. A difference was shown between new formulations 
exploiting specifically the targeted molecular interactions and a common drug-polymer formulation. 
More specifically, a modified matrix with malic acid exhibited a technical extrusion advantage over 
polymer alone, and there was a benefit of improved physical stability revealed for the drug fenofibrate. 
This model compound displayed greatly enhanced dissolution kinetics from the ASD formulations. It 
can be concluded that harnessing molecularly designed polymer modifications by co-formers has much 
potential in solid dispersion technology and in particular regarding HME processing. 
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3.1 Introduction 
Poor water solubility of new drug candidates is a main pharmaceutical challenge to avoid erratic and 
highly variable absorption following oral administration. To facilitate effective and safe medications, 
bio-enabling formulations are needed and much research has centered around amorphous drug delivery 
systems [55,165–167]. There are a few methods available for drug amorphization; however, a recent 
overview of oral drug products on the market based upon amorphous drug delivery systems clearly 
demonstrated that spray drying and hot melt extrusion (HME) were the most abundant industrial 
manufacturing processes [41,165]. 
For physical stabilization of drugs in an amorphous form, there are some pharmaceutically accepted 
polymers available. However, specific process demands of spray drying or HME manufacturing define 
some limitations to this choice. This is also reflected by the use of few different polymers in the 
compositions of marketed solid dispersions [41]. Hence, new chemically engineered polymers would be 
desirable. However, the development and regulatory requirements [168] of a pharmaceutical excipient 
results in lengthy and costly processes. Another hurdle of chemical excipient modifications is the 
resulting permanent character. This permanent modification could lead to advantages regarding 
processing and physical stability, which may not always go along with the situation upon formulation 
hydration followed by a suitable drug release and supersaturation. Consequently, a non-permanent 
modification would be beneficial to overcome the previously mentioned difficulties. 
 
Therefore, another approach to broaden the excipient landscape would be the combination of already 
approved polymers with interacting pharmaceutically acceptable small molecular compounds to obtain 
specifically designed matrices by co-processing. This could generate advantages with respect to dry 
formulation as well as improving the biopharmaceutical properties. This scope differs from classical 
addition of small molecular process aids that typically interact non-specifically without a clear molecular 
rationale [169]. Previous work on additives was either rather of an exploratory nature or it was, for 
example, intended to generate a pH microclimate upon release, which is a specific approach in its own 
right [91]. Different from the present study aims are further co-amorphous systems because the targeted 
interactions are directly between additive and active pharmaceutical ingredient (API) [145,170]. 
 
It was recently identified by Higashi and co-workers [149] that the creation of molecular interactions 
between a model drug and dimethylaminoethyl methacrylate copolymer, Eudragit E (EE) together with 
saccharine, as a small molecular additive, led to an improved drug dissolution behavior. The authors 
argued that saccharine was interacting via ionic or hydrogen bonding with the polymeric amino group. 
Drug interactions were in this case rather given by the hydrophobic side chains of the polymer. This was 
in line with a recent study, which suggested that even basic drugs can exhibit great solubility 
enhancement with EE [171,172]. This may appear counter-intuitive given the same charges of drug and 
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polymer at physiological pH. However, NMR data indicated that hydrophobic interactions of the drug 
with polymer were likely involved in the observed solubility increase. While the amino group can be 
beneficial for direct interactions with acidic drugs [172], it might be in other cases better masked or 
changed by specific additives.  
 
Encouraged by finding an additive hydrophobic interaction of EE with lipophilic drugs, [171] a change 
of the amino group in EE could lead to a modified matrix that retains its ability to interact with 
hydrophobic compounds. A concern of this approach may be that masking of the hydrophilic amino 
group possibly decreases hydration and solubility of the modified polymer; hence, an optimal interacting 
component may need to have an additional hydrophilic group to compensate. 
Therefore, the aim is to use small-molecular additives to change specifically functional polymer groups. 
In this context it is possible to profit from analytical advancements and excipient screening in the science 
of co-amorphous formulations, even though the latter field is quite different from that of modified 
matrices as the scope of co-amorphous complexes is to alter drug properties directly, for example 
regarding glass forming ability [91,173].  
 
In contrast to previous co-amorphous studies [144,145,147], the idea to design a modified polymer 
matrix by small-molecular additives is a new approach and improvements regarding processing, 
stability, or biopharmaceutical performance can origin from such a co-processed system [91]. This work 
targets specific interactions of small molecular bivalent acids with the amino group of EE. In line with 
the above-mentioned considerations, bivalent acids mask the amino group of EE, while the second 
carboxyl group is meant to retain sufficient polymer swelling and solubility. The hypothesis is whether 
such an approach is technically feasible and if it is possible to obtain clear benefits for amorphous solid 
dispersions of a poorly water-soluble model drug (i.e. fenofibrate). 
3.2 Materials and Methods 
3.2.1 Materials 
EE was kindly provided by Evonik Industries (Essen, Germany); malic acid (MA) and the model drug 
fenofibrate (FE) were bought from Sigma-Aldrich (St. Louis, MO, USA). All compounds were used as 
received either in the initial co-processing of polymer and MA or for an alternative direct extrusion of 
all components by hot melt extrusion. The different compositions of the formulations as well as 
reference mixtures are outlined in Table 3.1. For a reference of the physical mixture, crystalline FE was 
used. 
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3.2.2 Methods 
3.2.2.1 Process of hot melt extrusion (HME) 
The different solid dispersions were prepared by using the co-rotating twin-screw extruder ZE9 ECO 
from Three-Tec (Birren, Switzerland). A pair of screws with a diameter of 9 mm, a length of 180 mm 
was used that consisted of conveying as well as mixing elements. Prior to extrusion, all ingredients were 
pre-mixed in a beaker to then manually fill the extruder with a spatula. The three heating zones of the 
extruder were set to 130 °C and a screw speed of 80 rpm was applied. After extrusion, the extrudates 
were cooled to room temperature and stored at ambient conditions in falcon tubes. The formulation 
called ‘matrix extrusion’ was manufactured by an initial extrusion of the polymer with additive (EE / 
MA) to obtain a co-processed matrix (‘matrix extrusion’) that was vibrational milled at 30/s for 1 min. 
A subsequent extrusion with addition of the model compound FE provided the final drug product. All 
other formulations (FE / EE / MA ‘direct extrusion’, and FE / EE) were manufactured in the process 
described by a single extrusion step. The physical mixture was obtained by mixing and consecutive 
milling (Table 3.1). All milled powders were sieved (mesh size = 150 μm) to achieve a comparable 
particle size distribution. 
 
Table 3.1. Composition of the different extrudates and of physical mixture for comparison 
  Content MA [%] Content EE [%] Content FE [%] Manufacturinga 
Matrix 32.4 67.6 - Extrusion, milling 
Direct extrusion 27.5 57.5 15 Extrusion, milling 
Matrix extrusion 27.5 57.5 15 Extrusion, milling, 
extrusion, milling 
FE / EE extrusion - 85 15 Extrusion, milling 
Physical mixture 27.5 57.5 15 Milling 
a The described processing steps were applied in the order mentioned 
 
3.2.2.2 Molecular interaction studies 
3.2.2.2.1 Attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-
FTIR) 
The FTIR spectra were measured by a Cary 680 Series FTIR spectrometer (Agilent Technologies, Santa 
Clara, USA) equipped with an attenuated total reflectance accessory. A scanning range of 4000–600 
cm- 1 was selected with 32 scans and a resolution of 4 cm-1. The spectra were evaluated using the software 
ACD/Spectrus Processor 2016.1.1 (Advanced Chemistry Development Toronto, Canada). 
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3.2.2.2.2 Nuclear magnetic resonance spectroscopy (NMR) 
The 13C-NMR spectra were recorded at ambient conditions on a Bruker Avance III 400 NMR 
spectrometer (Bruker BioSpin AG, Fällanden, Switzerland) fitted with a 5 mm i.d. BBO prodigy probe 
and operating at 100.61 MHz. The number of scans was set to 1024. The samples were dissolved in 
deuterated DMSO, and for processing the spectra, the software TopSpin 3.5pl7 from Bruker was used. 
Deuterated DMSO was selected, because it would not interfere with the investigated interaction [120]. 
The solvent peak of DMSO served as reference for comparison of the spectra. Peaks were assigned using 
2D heteronuclear single quantum coherence spectroscopy (HSQC) NMR measurements. Moreover, the 
influence of molecular interactions between additive and polymer were also simulated by the software 
ACD/C+H NMR Predictors 2016.1.1 (Advanced Chemistry Development Toronto, Canada) to support 
interpretation of the NMR spectra. 
 
3.2.2.3 Stability assessment and drug dissolution 
3.2.2.3.1 Powder X-ray diffraction (PXRD) 
The analysis of an amorphous form by PXRD was performed on a D2 Phaser diffractometer (Bruker 
AXS GmbH, Karlsruhe, Germany) with a 1-D Lynxeye detector. The instrument was equipped with a 
1.8 kW Co KFL tube providing X-ray radiation at a wavelength of 1.79 Å. During the measurements, a 
voltage of 30 kV and a current of 10 mA were used. The increment and time per step were set to 0.02 ° 
and 2 s, respectively. The measurements were performed over a range of 5 ° to 39 ° (2θ). To avoid the 
recrystallization of the drug because of processing steps, the extrudates were cut in 2 cm long pieces and 
arranged to cover the complete sample holder of the instrument. 
 
3.2.2.3.2 Differential scanning calorimetry (DSC) 
Further solid-state assessment of an amorphous form was based on thermal analysis by using a 
differential scanning calorimeter DSC 3 (Mettler Toledo, Greifensee, Switzerland). The measurements 
were conducted at a heating rate of 10 °C/min from -20 to 140 °C. The surrounding of the sample cell 
was purged with nitrogen at 200 mL/min. To evaluate the thermal history of the sample, the first heating 
was used. The samples were cut into small pieces and 5 - 9 mg was placed in an aluminum pan with a 
pierced lid. The thermal events were analyzed with the STARe Evaluation-Software Version 16 (Mettler 
Toledo, Greifensee, Switzerland). 
 
3.2.2.3.3 Polarized light microscopy (PLM) 
An assessment of crystallinity was based on polarized light imaging using a microscope Olympus BX60 
(Volketswil, Switzerland) equipped with a polarization filter. Extrudates that were transparent were 
placed in the sample holder and analyzed by taking pictures with full polarized light to detect crystals 
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as birefringent spots. The images were compared with pictures in unpolarized light. All of these pictures 
were acquired with a digital camera XC30 from Olympus attached to the microscope. The magnification 
remained constant throughout the whole measurement (scale bars are displayed in every image). 
 
3.2.2.3.4 Scanning electron microscopy (SEM) with energy dispersive X-ray spectroscopy 
(EDX) 
Cross sections of the extrudates were analyzed with a SEM TM3030 Plus (Hitachi, Tokyo, Japan). 
Elemental constitution was evaluated using EDX with an acceleration voltage of 15 kV. The Quantax 
70 system was employed, which consisted of an X Flash Min SVE signal processing unit, Megalink 
interface, a scan generator, and an X Flash silicon drift detector 410/30H (Bruker Nano GmbH, Berlin, 
Germany). Images were processed for detection of the halogen chloride to analyze the spatial 
distribution of FE on the sample. 
3.2.2.3.5 Confocal laser scanning microscopy (CLSM) 
The 3D CLSM (Keyence VK-X200) images were acquired on a Keyence VK-X200 confocal laser 
microscope with a wavelength of 408 nm to measure even larger areas of the samples. Image 
magnifications are shown in the pictures. Cross sections of the extrudates were evaluated after cutting 
the extrudates with a razor blade. 
3.2.2.3.6 Atomic force microscopy (AFM) 
Measurements were performed on a NanoWizard 4 from JPK (maximum XY scan range: 100 x 100 
mm, Z-height maximum: 15 mm) at ambient conditions of 25 °C. The cantilever Tap190 was used in 
the so called tapping or AC (amplitude control) mode. In this mode, the probe is oscillated near its 
mechanical resonance frequency. During each cycle of the oscillation, the probe lightly taps the surface 
and the amplitude of oscillation is reduced due to damping or dissipation of energy already in close 
proximity of the interacting surface. The AFM system uses this change in amplitude to track the surface 
topography. If the phase imaging mode is carried out, the phase shift relative to the driving oscillator is 
monitored in addition to the amplitude. Typically, the phase signal is sensitive to variations in 
composition, adhesion, friction, viscoelasticity as well as other factors. Therefore, material differences 
manifest in brighter and darker regions in the phase images, comparable to the way topography changes 
are recorded in height images. The cantilever had a force constant of 48 N/m and a resonant frequency 
of 190 kHz. All pictures are given in 512 x 512 pixel and adjusted coloring for comparison. Samples 
were cut to investigate the cross sections and placed into the sample holder of the instrument. 
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3.2.2.3.7 Dynamic flow properties 
A rotating drum system (Revolution®, Mercury Scientific Inc., USA) was employed to measure powder 
flow properties. The powder movement in the barrel with a diameter of 55 mm and a width of 35 mm 
was scanned by a camera (resolution of 648 × 488 pixel). The acquired pictures at 10 frames per second 
were analyzed by the Revolution® V3.00 software (Mercury Scientific Inc., USA). Prior to the 
measurement, the drum was filled with a constant sample volume of 14.5 mL, and the initial rotation 
time was set to 45 s. After that time, 150 avalanches were monitored at a rotation speed of 1 rpm. All 
measurements were performed in triplicates. The measured properties were avalanche angle [°] and 
absolute break energy [mJ/kg]. The avalanche angle was recorded as the angle between the center point 
of the powder edge and the highest position before the occurrence of an avalanche. The absolute break 
energy was defined to be the maximum energy in the powder sample before the beginning of an 
avalanche. This value is considered as the required energy for the start of an avalanche [174,175]. 
3.2.2.3.8 Comparison of dissolution behavior 
Drug dissolution was studied for comparison of the extruded formulations and the physical mixture. 
Prior to dissolution, all samples including the physical mixture were milled in a vibrational mill for 1 
min at a speed of 20/s. A USP II dissolution apparatus filled with phosphate buffer solution at pH 6.4, 
as described by PhEur. 2.9.3, in combination with 0.5 % sodium dodecyl sulfate was used. The paddle 
speed and temperature were set to 100 rpm and 37.0 °C, respectively. This experimental procedure was 
in accordance with quality control dissolution setups [94]. Upon withdrawal from the dissolution media, 
the samples were filtered through a 0.4 µm filter directly. The withdrawn media was replaced 
immediately with temperature-controlled dissolution media. Samples were analyzed by a high pressure 
liquid chromatography system from Agilent (Agilent Technologies, Santa Clara, USA) equipped with a 
UV detector, which was set to 287 nm. The flow rate was set to 0.25 mL/min with a run time of 10 min 
and an injection volume of 20 µL. As separation reverse phase column a ZORBAX Elipse Plus C18 
(Agilent Technologies, Santa Clara, USA) was used. 
3.3 Results and discussion 
3.3.1 Molecular considerations for polymer and co-former selection 
The polymer selection is critical for any solid dispersion and should particularly consider the type of 
intended release as well as miscibility with a given drug [176]. It has been attempted previously to 
choose polymers based on ab initio considerations of molecular drug interactions[177], which should 
not only help to achieve a good kinetic stability of the solid dispersion, but also facilitate sustained 
supersaturation upon formulation dispersion [118]. Further selection criteria are linked to the intended 
processing (i.e., HME), why the glass transition temperature (Tg), the melting point (Tm), degradation 
temperature (Tdeg), as well as the resulting melt viscosity at extrusion temperature should be considered. 
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Optimal is of course when formulators could choose from a broad variety of alternative polymers to 
meet the technical needs of manufacturing; however, such a selection is rather limited with 
pharmaceutically acceptable polymers. To generate more potential variations and thereby options, the 
current work hypothesized that co-processing of a polymer with small molecular additive could provide 
a specifically modified polymer matrix with advantages for solid dispersions produced by HME. The 
model polymer EE was selected for this purpose, as the aminoalkyl group can interact with acidic small 
molecular additives in line with the scope of the current study. Moreover, the polymeric side chains of 
EE seem attractive regarding possible hydrophobic interactions with a drug [171,172,178]. Strong 
hydrogen bonding of a weak carboxylic acid with EE’s tertiary amines have been reported, and direct 
drug-polymer interactions were shown not to lead to any salt-formation [121]. Unlike this previous 
study, such polymer interactions were in the current work harnessed by bicarboxylic additives. Those 
additives have proven to be beneficial for HME processing by Parikh and Serajuddin, although in their 
work, the interaction was formed between an API and the acid [179]. Compared to monocarboxylic 
acids, the additional carboxy group should reduce the risk to make the EE polymer matrix too 
hydrophobic upon aqueous dispersion in gastrointestinal fluids. Thus, promising bicarboxylic acid 
candidates included succinic acid, maleic acid, fumaric acid, tartaric acid, malonic acid, and MA, which 
were studied during initial extrusion trials with EE. For the assessment of amorphous stability, FE was 
chosen as a model drug due to its well-described amorphous instability [38]. Initial extrusion trials with 
bicarboxylic acids could not result in completely amorphous FE formulations as demonstrated by PXRD 
measurements or showed poor processing ability. Different mechanisms possibly contributed to less 
favorable extrusion results such as decomposition, differences in melt viscosity or melting point, or lack 
of miscibility. On the basis of the initial bicarboxylic acid screening, a focus was made on the most 
promising compound, MA as co-former for EE. 
 
3.3.2 Modified polymeric matrix 
3.3.2.1 Molecular interaction 
In line with the targeted molecular assembly of EE and MA, a first objective of this work was to verify 
the molecular interaction as well as the potential benefits for the HME of EE and MA experimentally. 
Technical extrudability was indeed improved in the presence of MA. Compared to pure EE, the ease of 
resolidification and strand formation from the orifice of the extruder was improved in the modified 
matrix. The final product was a transparent and homogeneous extrudate. FTIR measured on the 
extrudate (Figure 3.1) showed the broadening of the O-H peak in the region of 3400 cm-1, which led to 
a flatter, hardly detectable peak. This could be associated with MA, since it is the only molecule in the 
mixture with a free hydroxyl group [144]. It also has to be taken into account that the amorphous nature 
of the extrudate caused a rather general peak broadening. Moreover, a specifically broad peak holding 
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for an asymmetrical stretching vibration at 1580 cm-1 was identified, which can be associated with 
hydrogen bonding interaction of the carboxylic group of MA [146,180]. 
 
 
Figure 3.1. (A,B) FTIR spectra of the different formulations between 3200−3600 cm-1 and 1500 −1650 cm-1, respectively. 
The curves represent powders of FE (black), EE (gray), MA (green), extrudates of MA /EE (red), FE/MA/EE (light blue), 
and the physical mixture of FE/MA/EE (dark blue). 
 
The vibrational FTIR spectroscopy was complemented by NMR analysis. While in the 1H-NMR, a 
differentiation between the different hydroxyl groups of MA and therefore their specific interaction with 
the polymer was hardly detectable, 13C-NMR was applied for a more detailed analysis. An interesting 
region for the two carboxylic groups of MA was shown between 172 and 176 ppm, which in the 
13C spectrum corresponds to a shift of the two carbons in the two carboxylic groups (Figure 3.2). In 
comparison to the pure MA, the spectrum of the extruded polymeric matrix showed a peak shift, which 
was more intense for the carboxylic group with an alpha hydroxyl group (Figure 3.2). Therefore, this 
group is likely to show an interaction with the polymer, which was formed during the extrusion [178]. 
Neither FE nor EE showed interfering peaks in the investigated region, because the ester peak of FE 
could be clearly distinguished from the carboxylic peaks of MA. 
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Figure 3.2. 13C NMR spectra region between 176 and 172 ppm of MA (green), MA / EE (red), and FE /MA /EE (blue). 
 
The observed shift was in line with a simulation of the spectrum as calculated by the ACD/C+H NMR 
Predictor. Moreover, the same shift could be observed in the formulation with FE (Figure 3.2). 
Consequently, the interaction was not interrupted by the addition of the model API, which showed a 
peak between the two carboxylic peaks of MA. 
 
3.3.2.2 Amorphous form and phase behavior 
An initial physical characterization of the modified matrix was based on DSC and PXRD analysis. The 
thermograms of the modified matrix displayed a single glass transition and no melting endotherm, which 
supported the transparent aspect of the extrudates and hence miscibility of polymer and co-former 
(Figure 3.3).  
 
Figure 3.3. DSC thermograms of MA (green), FE (black), EE (gray), and MA/EE (red). Insert shows the Tg of EE and 
MA/EE 
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These findings were in accordance with the observations provided by the PXRD experiments, where the 
distinct peaks of crystallinity of MA were no longer visible in the modified matrix (Figure 3.4).  
 
 
Figure 3.4. PXRD of MA (green), FE (black), EE (gray), and MA/EE (red) 
 
The diffraction pattern and thermograms were complemented with imaging methods. The extrudates of 
the novel matrix exhibited a smooth surface and absence of noticeable features inside the matrix as 
evidenced by CLSM (data not shown). For a homogeneity analysis on a nanometer scale, extrudates 
were studied further by AFM phase analysis [181]. Figure 3.5 shows that only one phase was present in 
the cross section of the modified polymer matrix. Different sampling areas were scanned, and no signs 
of separating domains that could suggest the beginning of a phase separation were observed. Imaging 
by AFM is a meaningful complementary analysis to other previously mentioned bulk methods. 
Especially phase separations of non-crystalline components are not detected by a classical PXRD 
analysis, and it can be challenging for DSC, in which a single Tg is not always a reliable marker of 
homogeneity in a nanometer domain [182]. However, since the AFM imaging also suggested 
homogeneity across the analyzed length scales, the modified polymeric matrix was considered a glassy 
solution. The results therefore experimentally confirmed that a single-phase modified matrix could be 
obtained as hypothesized. 
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Figure 3.5. AFM phase images of the modified polymeric matrix (MA /EE) 
 
3.3.3 Formulation of a model drug in the modified polymer matrix 
An important study objective was to demonstrate the utility of the modified polymer matrix with a poorly 
water-soluble model drug. FE was used for this purpose, and it was hypothesized that mainly the 
hydrophobic side chains of EE would lead to interactions with the drug, while the tertiary amine of the 
polymer would mostly be interacting with MA. The assumption of hydrophobic side chain interactions 
was encouraged by recent studies that successfully used EE in combination with non-acidic drugs 
[171,183]. Based on such dispersive interactions with the lipophilic drug FE and the targeted molecular 
interactions with MA, Figure 3.6 shows an image of the assumed molecular architecture. The amine 
moieties of the polymer are in close proximity with carboxyl groups of the MA (shown in magenta), as 
it was also experimentally confirmed by the spectroscopic results of the previous section. This polymer 
and co-former matrix can host FE mostly between the acyl chain residues, which offers various 
hydrophobic interactions. The multitude of interaction options entails a favorable enthalpy of mixing 
with the polymer matrix, while at the same time various configurations of drug inclusion are also 
beneficial with respect to the entropic contribution when mixing with the drug. FE may further profit 
from the modified matrix because the polymeric amine is mostly masked by MA. Nitrogen-containing 
functional groups are known in the field of glycerides to often reduce drug solubilization of lipophilic 
drugs [184]. However, to verify these theoretical considerations experimentally, a proof-of-concept 
study was conducted. The modified matrix was first manufactured as a co-extruded material of EE and 
MA. The milled extrudate served as a novel polymeric matrix for HME together with FE. A comparison 
to this modified matrix approach was to directly compound EE, MA, and drug in a single HME step. 
Apart from such "direct extrusion" samples, there was also a comparison made with extruded drug with 
EE alone (i.e., without the co-former MA). 
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Figure 3.6. Visualization of the polymer matrix (EE displayed as tubes with standard color codes) together with FE (bronze tubes) and 
the co-former MA (magenta tubes). Only a part of the matrix is shown together with molecular surfaces for clarity of presentation. Graphic 
is based on YASARA version 16.12.6 using an AMBER14 force field. 
 
3.3.3.1 Drug formulation processability, homogeneity and stability 
A first advantage of the FE formulation with the modified matrix was observed during HME. The 
polymer EE was barely extruded in other studies with drugs like FE that exhibit a low melting point 
[185,186]. Thus, pure EE with FE produced soft strands with slow resolidification kinetics when exiting 
the extrusion orifice. This processing behavior was similar to what was obtained with polymer alone 
and in our experience; it could be barely improved by any optimization of process parameters. Moreover, 
even after longer cooling a certain stickiness remained. In contrast to these results, drug formulated with 
the modified matrix resulted in a fast resolidification upon extrusion, and the extrudates were 
comparatively harder and therefore more suitable for any down-stream processing. The drug formulation 
with MA appeared to have similar properties to the modified matrix alone and clearly different to 
polymer without MA, which exhibited marked particle aggregates after milling. These qualitative 
observations were compared with quantitative flow properties of the milled materials in the Revolution 
analyzer (Table 3.2) [187–189].  
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Table 3.2. Flowability and process assessment parameters for all formulations 
  Absolut Break 
energy [mJ/kg] 
Avalanche  
Angle [deg] 
Feeding 
properties 
Cleaning 
(i.e. lack of 
stickiness)a 
Manufacturing 
MA / EE 119.38 ± 0.27 44.33 ± 0.21 + ++ Extrusion, milling 
FE / MA / EE  
(direct 
extrusion) 
127.11 ± 0.12 43.67 ± 0.25 + + Extrusion, milling 
FE / MA / EE  
(matrix 
extrusion) 
124.31 ± 0.25 45.63 ± 0.12 + + + Extrusion, milling, 
extrusion, milling 
FE / EE 212.74 ± 5.14 87.4 ± 6.51 - - Extrusion, milling 
EE powder 228.76 ± 2.19 74.80 ± 3.27 - - - n/a b 
a For all formulations and the pure powder EE, processing parameters for feeding and cleaning are evaluated qualitatively in 
comparison to PVP VA 64, which is known to have good flowability properties. 
b The pure EE was analyzed as received from the supplier. 
 
The strong cohesion forces within the bulk of EE or FE / EE formulation resulted in an increased 
absolute break energy, which correlated with an increase of the avalanche angle. The comparison 
between pure EE and MA / EE revealed the improvement of particle flowability by the formation of the 
modified matrix, and such improvement was also observed when drug was included as in the direct 
extrusion and matrix extrusion.  
 
The drug-containing formulation of the modified matrix as well as the reference manufactured by direct 
extrusion and pure drug with EE displayed no crystallinity of FE when investigated by DSC and PXRD 
immediately after the manufacturing. However, these classical analytical methods have limited 
sensitivity for small traces of initial crystallinity, and moreover, the beginning of an amorphous phase 
separation is often better detected by AFM.  
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Figure 3.7. (A-C) AFM phasing images of samples from the modified polymeric systems with FE represented in the 
matrix extrusion (A) and direct extrusion (B), both in comparison to the FE /EE extrudate (C). 
 
Figure 3.7 depicts AFM images of the different extrudate products with drug. Extrudates with MA 
displayed some micro pores (Figure 3.7A and 3.7B) but the submicron structure was very homogeneous 
in the case of matrix extrusion (Figure 3.7A) and slightly less homogeneous for direct extrusion (Figure 
3.7B) because of the formation of small domains that were only visible at a high magnification [93]. 
However, there was no clear indication of a phase separation in both formulations containing MA. On 
the other side the FE / EE extrudate (Figure 3.7C) showed a spreading phase separation, which is often 
accompanied by drug crystallization [190]. 
 
Figure 3.8. (A-C) CLSM images of the samples of drug products as modified matrix extrusion (A), direct extrusion (B), 
and FE /EE (C). 
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When a larger length scale was considered in images of CLSM, there was some crystalline material 
observed (Figure 3.8C), probably as a result of the previously described phase separation in the FE / EE 
formulation (Figure 3.7C). By contrast, in the products with MA no crystals were observed (Figure 3.8A 
and 8B), where only some surface effects were seen because of the sample preparation. In summary, the 
physical imaging methods performed pointed towards the observation of a phase separation (Figure 
3.7C) and some drug crystallinity (Figure 3.8C) of FE / EE extrudate, which made a clear difference to 
the formulations with MA. 
 
 
Figure 3.9. (A-C) SEM EDX images of the matrix extrusion (A), direct extrusion (B), and control (C). The green area 
represents the distribution of carbon, whereas the blue areas are correlated with the distribution of chlorine atoms 
 
In addition to the physical imaging techniques, the extrudates were further investigated by the chemical 
imaging of SEM EDX to identify domains of FE, as detected by the distribution of chloride that is given 
as blue clusters in Figure 3.9. For the FE / EE formulation, an accumulation of mesoscopic drug clusters 
was evidenced. This was in agreement with findings of the inhomogeneous drug distribution in the 
polymer alone. As expected, there were no pronounced large drug clusters evidenced in the matrix 
extrusion and direct extrusion (Figure 3.9A and 3.9B). It may be that the matrix extrusion was most 
homogeneous with respect to drug distribution but a clear differentiation to direct extrusion was hard to 
make by a qualitative comparison. 
 
Finally, polarized light microscopy (PLM) was used to compare the different samples. This imaging 
technique is different from AFM, CLSM, or SEM-EDX as a lower spatial resolution is given in this 
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optical microscopy. However, once nuclei grow to relatively bigger crystals; PLM has the advantage 
that the crystals are well detected as shining birefringent structures (data not shown). This was only 
detected in samples of FE with EE after two weeks storage at room temperature, whereas the samples 
of melt extrusion and direct extrusion did not show any crystals in line with the aforementioned results 
from AFM, CLSM and SEM-EDX. 
 
3.3.3.2 Amorphous dissolution benefits 
Dissolution of the formulations was conducted, using the method described for quality control [94], to 
identify any potential difference in the formulations with respect to their dissolution behavior. The scope 
was to reveal potential differences, which should be differentiated from the rationale to mimic in vivo 
conditions, since this would otherwise require biorelevant dissolution testing [94,95,191]. 
For a comparison, all samples were milled in a vibration mill for 1 minute. Although all samples were 
treated equally, the FE / EE formulation showed very poor milling processability, which resulted in 
agglomeration under different milling conditions. This was likely a consequence of the earlier described 
technical issues of FE / EE with especially the pronounced cohesion of the material. Probably as a result 
of this difference, the comparison between the two extruded formulations and the physical mixture 
showed a clear improvement in drug release for the extruded formulations. Since the FE / EE 
formulation did not result in a comparable processed formulation, which was also visible in the 
dissolution behavior, it can be concluded that the direct extrusion and the matrix extrusion were a clear 
advancement in terms of drug release compared to the physical mixture (Figure 3.10). In accordance 
with the previous analytical results, which showed phase separation and recrystallization of FE / EE, 
repeated dissolution experiments over time may further reveal differences in dissolution performance 
during storage. 
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Figure 3.10. Dissolution curves of the matrix extrusion (black squares), direct extrusion (gray triangles), FE /EE 
extrudate (black dots), and physical mixture FE /EE /MA (gray diamonds). 
 
3.4 Conclusions 
Various aspects in HME processing of amorphous solid dispersions limit the selection of pharmaceutical 
polymers for a given drug. This work started from a molecular rationale to modify a polymer matrix of 
EE physically by co-extruding it with a bivalent acid. The molecular rationale differs greatly from classic 
formulation approaches, where plasticizer or antiplasticizer are screened empirically without a clear 
molecular rationale. Therefore, the described approach offers new opportunities based on molecular 
pharmaceutics to modify a polymeric matrix by means of selected small molecular additives. Such a 
theoretically designed modified matrix was experimentally verified as a glassy solution that was 
homogenous at the different length scales studied. Moreover, spectroscopic methods confirmed the 
assumed molecular interactions. An explicit objective was to show benefits of the new polymeric matrix 
with a model drug FE. This drug was selected to interact primarily with the acyl side chains of the 
polymer via hydrophobic interactions, while the masked tertiary amine of EE would primarily interact 
with the co-former MA. Benefits of the modified matrix compared to amorphous dispersions of FE in 
EE without co-former were demonstrated for technical feasibility but also with respect to drug 
distribution and lack of crystalline material. Moreover, drug dissolution was enhanced for the direct 
extrusion and matrix extrusion formulations, when compared to the reference formulations of pure drug 
and polymer. 
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Interesting findings were the slight differences in technical feasibility as well as drug distribution 
between direct extrusion and matrix extrusion with the additive MA. This could be used potentially by 
excipient suppliers, which would be able to offer directly a modified matrix to the pharmaceutical 
industry to widen the selection of suitable polymeric vehicles for HME. This approach to modify the 
polymeric matrix based on a molecular rationale is highly interesting and more research could target 
specific solubility parameters that are currently not available with existing pharmaceutical polymers for 
HME. The idea to modify polymers non-chemically can be harnessed in the future to target a specific 
increase or decrease of the glass transition or, for example, to tailor polymer swelling in water for a 
desired drug release. Finally, research in the future could emphasize the effects of modified matrices on 
long-term physical stability of amorphous solid dispersions.
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Summary 
Solid dispersions are important supersaturating formulations to orally deliver poorly water-soluble 
drugs. A most important process technique is hot melt extrusion but process requirements limit the 
choice of suitable polymers. One way around this limitation is to synthesize new polymers. However, 
their disadvantage is that they require toxicological qualification and present regulatory hurdles for their 
market authorization. Therefore, this study follows an alternative approach, where new polymeric 
matrices are created by combining a known polymer, small molecular additives, and an initial solvent-
based process step. The polyelectrolyte, carboxymethylcellulose sodium (NaCMC), was tested in 
combination with different additives such as amino acids, meglumine, trometamol, and urea. It was 
possible to obtain a new polyelectrolyte matrix that was viable for manufacturing by hot melt extrusion. 
The amount of additives had to be carefully tuned to obtain an amorphous polymer matrix. This was 
achieved by probing the matrix using several analytical techniques, such as Fourier transform infrared 
spectroscopy, differential scanning calorimetry, hot stage microscopy, and X-ray powder diffraction. 
Next, the obtained matrices had to be examined to ensure the homogeneous distribution of the 
components and the possible residual crystallinity. As this analysis requires probing a sample on several 
points and relies on high quality data, X-ray diffraction and starring techniques at a synchrotron source 
had to be used. Particularly promising with NaCMC was the addition of lysine as well as meglumine. 
Further research is needed to harness the novel matrix with drugs in amorphous formulations. 
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4.1 Introduction 
The rising number of poorly water-soluble drugs in the development pipelines as well as on the market 
encouraged the pharmaceutical industry to develop new formulation techniques. One strategy is the 
formulation of a drug in an amorphous form as a solid dispersion, which normally leads to drug 
supersaturation upon oral administration to promote absorption [45,55,165–167]. Among the different 
process techniques for the manufacturing of amorphous solid dispersions, hot melt extrusion (HME) and 
spray drying are the most common methods [41,45]. These two process techniques mostly use a 
combination of drug and polymeric compound. However, HME formulations currently available on the 
market utilize only about six of the pharmaceutically accepted polymers or a combination of these [41]. 
Contemporary research is primarily focused on finding new combinations of well-established polymers 
with plasticizers and surfactants [192], or even on designing new monomers for novel synthetic 
polymers that come with the aforementioned multiple development hurdles to reach the pharmaceutical 
market [107]. Another approach is the fine tuning of the extrusion process by changing screw 
configuration, temperature profiles or by employing different downstream processing steps [106,193]. 
Recently, we introduced the approach to molecularly modify a polymeric matrix by interacting 
excipients [122]. The difference to a classical mixture approach with excipients is that molecular 
interactions are specifically targeted by design and cannot be facilitated in an extrusion of the physical 
mixture. In line with this idea, the current study explores the possibility to use selected additives that 
can interact ionically or via hydrogen bonding to enable HME of a matrix based on the polyelectrolyte 
carboxymethylcellulose sodium (NaCMC) for the first time. 
 
NaCMC was recently extruded with polydimethylsiloxane as a polymeric mixture to form material for 
3D printing [194] or it is occasionally used in spray drying [195]. The polymer shows good water 
solubility and extensive swelling behavior, which are both interesting properties for a new modified 
matrix produced by HME.  
The concept of formulating ionic substances to produce a semi-solid or even liquid with a lower melting 
point is a well-known technique of “ionic liquids” and an important pharmaceutical application in the 
field of lipid-based formulations [196,197]. Recent publications highlighted the positive implications of 
salt formation on HME [120,179], but primarily for keeping the drug in amorphous form through the 
formation of ionic interactions [91,146]. Such an approach is of particular interest, since the direct 
extrusion of neat unprocessed NaCMC is not applicable, because it decomposes at 252 °C instead of 
having a melting point [198]. 
Therefore, this paper studies polymeric films of NaCMC in combination with six interacting small 
molecular additives that were first transformed into a solid excipient dispersion through solvent 
evaporation. In a second processing step, HME was performed. The solvent evaporation step (involving 
a medium with a high dielectric constant) enabled targeted ionic interactions between polyelectrolyte 
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NaCMC and the ionizable additive [91]. The main reason, why a solvent evaporation step was conducted 
prior to extrusion was that the compounds used would not be feasible for extrusion as otherwise neat 
powders because of their high melting points. 
As the first group of co-formers to be studied with NaCMC, the basic amino acids, histidine, lysine, and 
arginine, were chosen, as they have been proven to interact with acidic groups of mostly drugs in various 
studies and consequently improved formulation properties such as amorphous stability, miscibility and 
plasticizing effects [124,140,145,147,153,158,173,199,200]. The second group of substances consisted 
of water-soluble inactive substances, which were also hypothesized to likely form an interaction with 
NaCMC after solvent evaporation and extrusion. The chosen co-formers were urea, meglumine and 
trometamol (TRIS). 
 
Powder X-ray diffraction (PXRD) was applied to determine the maximum amount of additive that is 
still feasible for successful miscibility and an extrusion process to form an amorphous product. Two 
limiting factors had to be considered during the described processing: on the one hand, the unfavorable 
extrusion properties of NaCMC, which required a high amount of additive to enable the extrusion and 
on the other hand, the crystalline structure of the additives, which would lead to a crystalline product in 
high concentrations because of insufficient miscibility. While the preliminary measurements could be 
carried out using the laboratory diffractometer, conclusive results could only be obtained by using the 
data collected at a synchrotron source. Namely, to ensure the amorphous formulation, it was necessary 
to collect high quality PXRD data that is sensitive to extremely low amounts of crystalline phases in the 
sample. Secondly, to examine the distribution of the additive in the sample, the sample had to be probed 
on several points, which again required a specific sample stage at a synchrotron source. 
Further assessment included thermal analysis by differential scanning calorimetry, which was 
complemented by hot stage microscopy and hot stage attenuated total reflectance Fourier transform 
infrared spectroscopy (ATR-FTIR) to show crystallinity and form changes upon heating [91]. The hot 
stage microscopy images were used as a complimentary analysis of the thermal miscibility and melting 
behavior of the evaporates during the extrusion [193,201]. 
 
This paper highlights the capability of different small molecular additives to enable the formulation of 
a polymeric compound, which would otherwise not be suitable for extrusion. Such a combination 
resulted in the development of a new modified excipient matrix for HME that formulators will find 
helpful to cope with challenging pharmaceutical compounds. 
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4.2  Materials and Methods 
4.2.1 Materials 
Carboxymethylcellulose sodium salt (low viscosity), urea, meglumine, TRIS, L-lysine, L-aspartic acid, 
and L-histidine were bought from Sigma Aldrich (St. Louis, MO, USA). Purified water, which was used 
for the solvent evaporation, was taken from a MilliQ Millipore filter system (Millipore Co., Bedford, 
MA, USA). 
4.2.2 Methods 
4.2.2.1 Preparation of Hot Melt Extrudates 
Binary mixtures of NaCMC and the additive (according to the composition given in Section 3.1.1 and 
Section 3.2.1) were mixed in a mortar and dissolved in MilliQ water in a round bottom flask. Afterwards, 
the water was removed by a rotary evaporator (Rotavapor Büchi, Flawil, Switzerland), which resulted 
in a transparent film. This film was cut into smaller pieces and extruded on co-rotating screws with a 9-
mm diameter and 180 mm in length in a ZE9 ECO twin-screw extruder by ThreeTec (Birren, 
Switzerland). A screw speed of 80 rpm was applied at a temperature of 130 °C through all three heating 
zones. The final extrudates were cooled to room temperature and stored in falcon tubes. 
 
4.2.2.2 Laboratory Powder X-Ray Diffraction (PXRD) 
Mixtures were studied for their potential amorphous form by PXRD on a D2 Phaser diffractometer 
(Bruker AXS GmbH, Karlsruhe, Germany) with a 1-D Lynxeye detector. The instrument was equipped 
with a Ge-monochromator (Cu Kα radiation) providing X-ray radiation at a wavelength of 1.541 Å. 
During the measurements, a voltage of 30 kV and a current of 10 mA were used. The increment and 
time per step were set to 0.020 ° and 1 s, respectively. The measurements were scanning a range of 5° 
to 40° (2θ). 
 
4.2.2.3 Differential Scanning Calorimetry (DSC) 
Samples were further assessed by a differential scanning calorimeter on a DSC 3 (Mettler Toledo, 
Greifensee, Switzerland). The samples were cut in small pieces and 5 to 9 mg was placed in a 40 μL 
aluminum pan with a pierced lid. A heating rate of 10 °C/min from −10 °C to 140 °C was applied, while 
the surrounding sample cell was purged with nitrogen 200 mL/min. Moreover, the combination of 
heating, cooling and heating cycles was used to fully evaluate the samples. For the assessment of the 
initial form, the first heating was used. The thermograms and glass transition temperatures (Tgs) were 
analyzed with the STARe Evaluation-Software Version 16 (Mettler Toledo, Greifensee, Switzerland). 
All thermograms show exothermic events as upward peaks. 
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4.2.2.4 Hot Stage Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) 
A Cary 680 Series FTIR spectrometer (Agilent Technologies, Santa Clara, CA, USA) was used, which 
was equipped with a heatable attenuated total reflectance accessory (Specac Limited, Orprington, UK) 
and the control panel 6100+ by WEST (West Control Solutions, Gurnee, IL, USA). The scanning range 
of 4000–600 cm−1 was selected with 1500 scans over a period of 30 min and a resolution of 4 cm−1. The 
heating rate was set to 5 °C/min going from 30 °C to 130 °C. For the evaluation, a spectrum was 
extracted and evaluated by the software ACD/Spectrus Processor 2016.1.1 (Advanced Chemistry 
Development, Canada) every minute (i.e., every 5 °C). Every spectrum shows a 5 °C temperature 
increase going from the front to the back of the figures. The increase of peaks towards higher 
temperatures in the area of 2000 cm−1 is related to the heat implications on the ATR crystal. For the hot 
stage FTIR analysis, the solvent evaporated films were used, whereas the FTIR spectra at room 
temperature were recorded from the physical mixture, solvent evaporates, and extrudates. 
 
4.2.2.5 Synchrotron Powder X-ray Diffraction 
X-ray powder diffraction data were recorded at the ID22 beamline at the European Synchrotron 
Radiation Facility (ESRF, France) using a two-dimensional detector (PerkinElmer XRD 1611CP3) and 
an incident X-ray energy of 60 keV (λ = 0.20678 Å, Qmax = 24 Å−1). A beam size of about 0.5 mm x 0.5 
mm was used. Reference samples were packed in 0.7-mm diameter borosilicate capillaries. Extrudate 
samples were mounted directly on capillary supports and measured as is. In order to minimize any 
possible radiation damage, samples were cooled down to 100 K using an Oxford Cryosystem 
Cryostream. To improve the overall statistics, 200 two-dimensional images were recorded (2 s per 
frame) and averaged. The one-dimensional diffraction patterns were retrieved after integration using the 
PyFAI software [202]. Five diffraction patterns on five different locations were recorded on each 
extrudate sample in order to check for heterogeneity. 
 
4.2.2.6 Hot Stage Microscopy (HSM) 
The HSM analysis employed a Leica DMRM at magnifications of 100×, which is also displayed as a 
scale bar in the images. The microscope was equipped with a temperature-controlled microscope stage 
from Linkram. This analysis was used for the evaluation of the behavior of the formulation upon heating 
in the extruder and to complement the DSC analysis [106,129,179]. For a close relation to the extrusion 
process, the temperature ramp was set from room temperature (RT) to 130 °C. During this ramp, the 
temperature was kept steady and images were taken at RT, 90 °C, and 130 °C. The obtained images 
were converted into black and white to highlight the melting process. 
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4.3 Results and Discussion 
4.3.1 Amino Acids as Additives 
4.3.1.1 Characterization of the Formulations 
Formulations containing the additives arginine and lysine were found to be amorphous after evaporation 
as well as extrusion. In contrary, it was not possible to convert histidine to an amorphous form neither 
with evaporation nor with extrusion. Table 4.1 highlights the different aspects, which were essential 
during processing of the formulation such as a qualitative evaluation of technical feasibility during 
HME. The extrusion was evaluated compared to a standard extrusion of the polymer, PVPVA 64, which 
is considered arbitrarily as ideal for extrusion. Such extrusion behavior is influenced by melt viscosity, 
thermoplasticity, and degradation [193]. 
 
Table 4.1. Properties of amino acid / polyelectrolyte matrices 
Additive Maximum 
Amorphous 
Amount  
Molar Fraction 
(Monomeric) * 
Tg After 
Evaporation 
Tg After 
Extrusion 
Extrudability 
** 
Amino Acid + NaCMC 
Lysine 50% (w/w) 0.64 30.27 °C 30.62 °C ++ 
Arginine 33% (w/w) 0.43 35.36 °C 33.15 °C + 
Histidine 20% (w/w) 0.30 36.59 °C - - - 
* For the calculation, the molar weight of the NaCMC monomer was used.  
** Technical feasibility was qualitatively assessed and details are given in the text. 
 
The optimal amounts of additives necessary to produce an amorphous polymer matrix are presented in 
Table 4.1, expressed as loadings in weight/weight as well as the calculated molar fractions of the 
formulation components. Lysine resulted in the highest amount of additive, which was formulated in an 
amorphous form in combination with NaCMC, whereas histidine being less feasible for the evaporation 
and the later extrusion could only be incorporated in the lowest molar ratio used in this study. This is 
also reflected by very poor extrusion behavior as well as the disappearance of the Tg in the DSC 
measurements of the corresponding extrudates, which may be explained by recrystallization from 
amorphous state as crystallinity was found in the extruded histidine formulation (Figure 4.1). For the 
above-mentioned table, it has to be mentioned that lower amounts of additive during a previous 
formulation development were leading to worse extrusion performances, which underlines the 
insufficient extrusion performance of neat NaCMC. 
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Figure 4.1. The solid lines represent the differential scanning calorimetry (DSC) thermograms of the extrudates and 
the dotted lines represent the evaporates which were used for the later extrusion. The amino acids added to sodium 
carboxymethylcellulose (NaCMC) are arginine (cyan), lysine (orange), and histidine (green). 
In detail, the dotted lines in Figure 4.1, representing the solvent evaporates, show only slight indications 
of a Tg in all samples. Whereas only the thermograms of extrudates containing lysine and arginine show 
the presence of a clear Tg in the extrudates (see Table 4.1). This can be associated with an amorphous 
form of the additive in the formulation [203] and gives a first indication of formed molecular 
interactions  [153,199]. These two additives also formed more prominent Tgs during the extrusion, which 
entails a higher amount of amorphous additive in the formulation. Consequently, such a processing was 
beneficial for the formation of an amorphous modified matrix of NaCMC. However, this still needed 
further measurements for confirmation. 
As mentioned before, the Tg in the histidine extrudates disappeared after extrusion, which suggested that 
the amorphous form changed during extrusion, leading to a crystalline fraction as indicated by the 
diffraction peaks in the corresponding PXRD analysis (Figure 4.S3). Although a Tg was detectable for 
lysine and arginine after the extrusion in the DSC, it has to be kept in mind that the substances used 
show rather high individual melting points, which would have led to degradation during the thermal 
measurement. 
Therefore, to obtain high quality data that is sensitive to extremely low amounts of crystalline phase in 
the sample, it was necessary to perform the diffraction and scattering experiments at a synchrotron 
source. 
Thus, synchrotron X-ray diffraction offered a more thorough assessment of the amorphous form to 
complement the DSC and benchtop PXRD data, which indicated that the raw substances were crystalline 
except for the polyelectrolyte NaCMC (Figure 4.S1). PXRD data collected at the synchrotron source 
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featured Bragg peaks that could be related directly to the crystallinity of the respective additive. 
Pronounced crystallinity evidenced in the histidine evaporate was in accordance with the initial X-ray 
and DSC assessment and was still detectable after extrusion, which is pointed out by the peaks at 
1.07 A−1, 1.71 A−1, 2.11 A−1, 2.60 A−1, 2.81 A−1, 3.06 A−1, 3.61 A−1 (Figure 4.2). Moreover, the 
measurement at five different locations throughout the extrudate showed the inhomogeneous 
distribution of the crystalline additive in the extrudate (Figure 4.2), which can potentially lead to more 
recrystallization. The diffraction pattern of the arginine extrudate indicated a more homogeneous 
distribution of the additive compared to histidine, although peaks at 3.05 A−1 still underline some partial 
crystallinity of the extrudate, which was detectable neither in the initial benchtop PXRD assessment nor 
by DSC. 
Figure 4.2. X-ray synchrotron results (i.e., arbitrary counts versus Q vector, Q = 4πsin(θ)/λ) are displayed from the 
extrudates with amino acid co-formers. The amino acids added to NaCMC are from left to right: arginine (cyan), lysine 
(orange), and histidine (green). Each diffraction pattern corresponds to a measured area in the extrudate. 
The FTIR spectra of arginine/NaCMC in Figure 4.3B exhibit reduced guanidyl vibrations of arginine at 
1675 cm−1 and 1614 cm−1, which can be associated with the interaction between the ionized arginine 
side chain and the negatively charged NaCMC [199]. 
For the co-former lysine, only smaller shifts in the FTIR spectrum are present in the evaporate and the 
extrudate including the shoulder of the COO− bond at 1607 cm−1, which is less pronounced in the 
extrudate than in the physical mixture [194,204]. In addition, a slight shift and a pronounced broadening 
of the peaks at 1570 cm−1 and 1540 cm−1 [205] both highlight the interaction of the carboxylic group of 
NaCMC (Figure 4.3C). The analysis of histidine/NaCMC in Figure 4.3A shows pronounced similarities 
of the physical mixture and extrudate. This supported the previous findings of the extrusion leading to 
a change in the solvent evaporate with recrystallization of histidine [158]. 
As mentioned in the previous section, the NaCMC was completely amorphous prior to processing. 
Therefore, the observed peak broadening and shifts are related to the amorphization of the additive. 
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Figure 4.3. Fourier transform infrared spectroscopy (FTIR) spectrograms of NaCMC and histidine (A, green), 
arginine (B, cyan) and lysine (C, orange). Dotted lines represent the physical mixture, dashed lines represent the 
solvent evaporates and the extrudates are shown in solid lines. 
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4.3.1.2 Heat Assisted Characterization 
The hot stage microscopy was applied to better understand the processes occurring during the extrusion 
of the evaporated films and to complement the results of extrusion performance using the different 
additives. It should be noted that bright structures in the HSM images are not necessarily related to 
crystallinity as they can also highlight an increase in capillarity of the samples. 
Thus, Figure 4.4 top shows an increasing number of capillaries building up in the polyelectrolyte film 
containing arginine, which can be directly associated with the positive extrusion performance. In this 
case, even though the HSM suggests a successful extrusion, as highlighted in the previous section, the 
arginine extrudate still contained crystallinity. This could be explained by the insufficient mixing 
behavior of the two excipients, which is underlined by the minimal changes visible in the heat-resolved 
FTIR. In Figure 4.4 bottom, only minor changes in the FTIR are visible during the heating. 
 
 
Figure 4.4. Hot stage microscopy (HSM) images at the top and temperature-resolved FTIR of 33% arginine in 
NaCMC at the bottom. The images show HSM images taken at RT, 90 °C and 130 °C (from left to right). The 
displayed scale bar refers to 500 μm. Each spectrum was measured at temperatures from 30 °C (measured first in 
the front) to 130 °C (in the back) by increasing steps of 5 °C. 
The evaporated film containing lysine showed no crystals in the microscopic images and small 
indications of melting in the images taken at 130 °C in comparison to RT (Figure 4.S4). Even in case of 
minor melting events, the torque in the extruder facilitates the plasticizing and melting of the evaporate 
during the extrusion. Therefore, the analysis of films represents a kind of “worst case scenario” 
regarding shear forces. It is still possible to successfully obtain an extrudable amorphous formulation as 
in the given case of lysine. The heat-resolved FTIR spectra in Figure 4.S4 at the bottom show an increase 
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in the peak at 1560 cm−1 and 1516 cm−1, which are related to the carboxylic groups of NaCMC [205]. 
Such an observation can be interpreted as an increase of the interaction between NaCMC and lysine. 
The HSM images of the histidine evaporate at RT showed pronounced crystallinity, which was in 
accordance with the PXRD diffraction patterns (Figure 4.S2). Moreover, the images taken at the 
operating temperature of the extruder (130 °C) did not show any reduction in crystallinity or a phase 
transition, which could be associated with a glass transition. This is supported by the measurable 
crystallinity and immiscibility in the extrudate (Figure 4.5 in green) [91]. 
 
 
Figure 4.5. The images at the top show HSM images of histidine/NaCMC evaporated films taken at RT, 90 °C and 
130 °C (from left to right). At the bottom, a temperature-resolved FTIR spectrum is shown. The displayed scale bar 
refers to 500 μm. Each spectrum was measured at temperatures from 30 °C (measured first in the front) to 130 °C 
(in the back) by increasing steps of 5 °C. 
The thermal evaluation of the evaporated films aligned the prior solid-state characterization as well as 
the actual behavior in the extruder, meaning the formulations containing arginine and lysine, which were 
successfully incorporated in a concentration of 33% and 50%, respectively, performed well in the 
extruder and could only be differentiated by a synchrotron X-ray measurement showing slight 
crystallinity in the arginine formulation. By contrast, the histidine formulations demonstrated poor 
melting behavior as well as pronounced crystallinity after extrusion. Moreover, the distribution of 
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histidine was insufficient throughout the extrudate, which leads to differences in the diffraction pattern 
evidenced by the synchrotron X-ray measurement. 
 
4.3.2 Additives other than Amino Acids 
4.3.2.1 Characterization of the Formulations 
Analogous to previous results, it was necessary to combine solvent evaporation and HME in the mixtures 
of NaCMC and the further tested co-formers. This was suggested by the X-ray diffraction patterns of 
the formulations following solvent evaporation. The X-ray diffraction pattern of the TRIS/NaCMC 
solvent evaporates showed Bragg peaks that indicated the presence of TRIS in a crystalline form (Figure 
4.S2). However, TRIS was completely transferred into an amorphous form following a subsequent HME 
step (Figure 4.S3). The urea and meglumine formulations were amorphous after the solvent evaporation 
and did not recrystallize to a detectable extent based on the benchtop PXRD results (Figure 4.S3). 
 
Table 4.2 presents a comparison of the maximal amount of additives for which the polymer matrix was 
kept in an amorphous state. The differences in molar weight have to be taken into account for such an 
evaluation, leading to a comparable molar fraction of meglumine and urea and a lower loading as well 
as molar fraction of TRIS (Table 4.2). This observation was a first indicator of the different technical 
feasibility of the various additives to obtain suitable modified matrices of NaCMC. A higher loading of 
TRIS led to crystallinity after evaporation as well as extrusion. Therefore, a lower loading had to be 
chosen, which resulted in non-ideal extrusion performance as described in the introduction. The 
additives meglumine and urea could be incorporated at much higher molar ratios and positively 
influenced the extrusion process. 
Table 4.2. Properties of the other additive polyelectrolyte matrices. 
Additive Maximum 
Amorphous 
Amount  
Molar Fraction 
(Monomeric) * 
Tg After 
Evaporation 
Tg After 
Extrusion 
Extrudability 
** 
Other Additive + NaCMC 
Meglumine 50% (w/w) 0.57 5.58 °C 9.18 °C + 
Urea 20% (w/w) 0.52 37.99 °C 40.36 °C 0 
TRIS 25% (w/w) 0.42 - 39.18 °C - 
* For the calculation, the molar weight of the NaCMC monomer was used. ** Technical feasibility was qualitatively assessed 
and details are given in the text. 
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The thermograms in Figure 4.6 indicate the presence of remaining water after the solvent evaporation, 
given as a broad peak around 100 °C. The Tg of urea can be hardly detected because of small difference 
in heat capacity at the glass transition and for the TRIS formulation, no Tg could be detected. On the 
other hand, the extrudate of meglumine shows a rather pronounced Tg and also a shift towards a lower 
temperature in comparison to all other extrudates, which can be associated with the good miscibility of 
meglumine and NaCMC [206,207]. 
 
 
Figure 4.6. The solid lines represent the thermograms of the extrudate and the dotted lines represent the evaporates, 
which were used for the later extrusion. The additives used in addition to NaCMC are meglumine (black), TRIS 
(red) and urea (blue). 
All samples were measured at five different areas. However, differences in the patterns can be seen only 
for the case where TRIS was used as the additive, particularly for differences in scattered intensity and 
the emergence of Bragg peaks at Q values of 3.03 A−1, 3.50 A−1, 4.95 A−1 and 5.81 A−1. By contrast, the 
patterns of the extrudates containing meglumine and urea present no observable differences in their X-
ray synchrotron results (Figure 4.7). The absence of Bragg peaks in the patterns collected on samples 
containing meglumine and urea prove that the obtained polymer matrices were fully amorphous at the 
molar fractions of 0.57 and 0.52, respectively. The PXRD patterns, collected on the sample containing 
TRIS at the synchrotron source, showed indications of crystallinity, which were not detectable in the 
patterns of the laboratory diffractometer. Such crystallinity could be a sign of recrystallization after the 
extrusion as well as residual crystallinity. Both sources of crystallinity are related to the instability of an 
amorphous form [208]. 
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Figure 4.7. X-ray synchrotron results (i.e., arbitrary counts versus Q vector) of co-formers other than amino acids. 
The additives in addition to NaCMC are: urea (blue), meglumine (black), and TRIS (red). Each diffraction pattern 
corresponds to a measured area in the extrudate. 
In the FTIR spectra, the combination of NaCMC and meglumine shows the previously discussed 
broadening due to the amorphization [209,210]. It can be seen how following solvent evaporation, 
distinct peaks are observed, which are broadened in one peak at 1000 cm−1 and 1400 cm−1. Moreover, 
the previous discussed carboxylic peak at 1570 cm−1 of NaCMC is more pronounced and broader, which 
indicates a change in the intermolecular binding of the polyelectrolyte [204,205]. 
 
The FTIR spectrum of urea in line with the spectrum of NaCMC/meglumine shows an increase of the 
peak at 1580 cm−1, which indicates the same interaction with the carboxylic group as meglumine [205].  
The spectrum of TRIS showed specific peak broadening as a result of the amorphous formulation 
(Figure 4.8). However, this broadening is overlapping a lot with the peaks formed because of a potential 
interaction. The increase of broader peak between 1400 cm−1 and 1600 cm−1 can be interpreted as an 
indication of an interaction [120,194,211]. However, a further, more sensitive analysis is required for a 
precise statement about the interaction. 
Polyelectrolytes in Hot Melt Extrusion: A Combined Solvent-Based and Interacting Additive Technique for Solid 
Dispersions 71 
 
 
 
 
 
Figure 4.8. FTIR spectrograms of NaCMC and TRIS (A, red), meglumine (B, black), and urea (C, blue). Dotted 
lines represent the physical mixture, dashed lines represent the solvent evaporates and the extrudates are shown in 
solid lines. 
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Interestingly, the observed changes in the FTIR spectra indicate a likely change in the hydrogen bonding 
structure because of the processing rather than the formation of a distinct salt. 
 
4.3.2.2 Heat Assisted Characterization 
The microscopic images at the top of Figure 4.9 present the melting process of the meglumine 
formulation, which can be connected to the thermoplastic behavior in the extruder. The prominent peak 
broadening around 90 °C in the area above 3000 cm−1 is an indicator of a successful amorphization 
because of differences in the molecular arrangement as well as the near range order [199,210]. This 
finding is in line with the start of a melting process in the HSM image at 90 °C. Moreover, these findings 
are in accordance with the performance observed during extrusion of the meglumine formulation. 
 
 
Figure 4.9. The images at the top show HSM images of 50% meglumine/NaCMC solvent evaporates taken at RT, 
90 °C and 130 °C (from left to right). At the bottom, a temperature-resolved FTIR spectrum is shown. The displayed 
scale bar refers to 500 μm. Each spectrum was measured at temperatures from 30 °C (measured first in the front) 
to 130 °C (in the back) by increasing steps of 5 °C. 
HSM images of the TRIS formulation show only minor changes. Although, an indication of minor 
“bubble-shaped” features was recorded that may be associated with small melting events taken place in 
the formulation (Figure 4.10). The FTIR spectrum supports the observation of a change with higher 
temperatures. The broadening of the peaks above 3000 cm−1 can not only be associated with the 
successful amorphization in the TRIS sample [210], as discussed before (Table 4.1), it furthermore 
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shows the decrease of hydrogen bonding throughout the heating process [205,212], leading to a lack of 
intramolecular interaction in the NaCMC, thereby resulting in more available interaction sites for TRIS. 
 
 
Figure 4.10. The images at the top show HSM images of 25% TRIS/NaCMC evaporated films taken at RT, 90 °C 
and 130 °C (from left to right). At the bottom, a temperature-resolved FTIR spectrum is shown. The displayed scale 
bar refers to 500 μm. Each spectrum was measured at temperatures from 30 °C (measured first in the front) to 130 
°C (in the back) by increasing steps of 5 °C. 
As described before, the urea formulation formed an amorphous stable formulation after evaporation 
and extrusion (Figure 4.S5). The HSM images show a melting process over the temperature range 
recorded. However, in the heat-resolved FTIR, only minor changes in peak intensity can be observed. 
In line with Figure 4.9, this suggests that urea has a plasticizing effect without showing a pronounced 
interaction with NaCMC. A possible reason for that is the lack of ionizable groups in the urea molecule. 
4.4 Conclusion 
The application of additives and targeted molecular interactions together with an initial solvent step 
enabled the extrusion of the polyelectrolyte, NaCMC. Differences in melting behavior and loading 
highlighted the suitability of the investigated additives to form as a fully amorphous polyelectrolyte 
matrix after extrusion. The additives, lysine and meglumine, in a concentration of 50% (w/w), have 
proven to be beneficial for extrusion and formation of a fully amorphous polymer matrix. Moreover, the 
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application of synchrotron X-ray diffraction helped to further differentiate between the formulations by 
examining the distribution of the additive throughout the matrix and residual crystallinity in the sample. 
PXRD data collected at the synchrotron source proved the amorphous state of the lysine, meglumine, 
and urea formulations compared to arginine and TRIS, for which crystallinity was not detectable by 
means of benchtop PXRD or DSC. 
 
While recent work has shown that the formulation of an amorphous ionic interaction is possible by hot 
melt extrusion [179], the current concept presented a not extrudable polymer, which was altered by 
interacting additives in a modified matrix feasible for HME. We refrained from naming the obtained 
systems as ionic liquids because this would suggest exclusively ionic co-former interactions with the 
polymer. Moreover, ionic liquids have an arbitrary defined melting characteristic of <100 °C, which is 
not required for pharmaceutical application as solid dispersions. However, it is expected that the 
modified matrices share much of the molecular attractiveness of ionic liquids. Further studies may 
harness the potential benefits of the solvent evaporates for pharmaceutical HME, reaching from new 
systems for amorphous drug stabilization over the generation of drug supersaturation to the precipitation 
inhibition of poorly water-soluble compounds. 
 
4.5 Supporting information 
4.5.1 Powder X-ray diffraction patterns 
 
The following graphs were used for the final formulation evaluation of the polyelectrolyte matrices. The 
following powder X-ray diffraction (PXRD) analyses were based on the benchtop X-ray diffractometer 
that is described in the methods section. 
 
 
Figure 4.S1. PXRD patterns of the physical mixtures. Colors and labels are in line with Figure 4.2 and 4.8, which 
can be inferred from the main article. The diffraction pattern of pure NaCMC in shown in bordeaux with an offset. 
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Figure 4.S2. PXRD diffraction patterns of the solvent evaporates. Colors and labels are in line with Figure 4.2 and 
4.8, which can be inferred from the main article. 
 
 
Figure 4.S3. PXRD patterns of the extrudates. Colors and labels are in line with Figure 4.2 and 4.8, which can be 
inferred from the main article. 
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4.5.2 Hot stage microscopy and hot state FTIR 
 
Figure 4.S4. Heat resolved FTIR and HSM images of 50 % lysine / NaCMC solvent evaporates. The images at the 
top show HSM images taken at RT, 90 °C and 130 °C (from left to right). Each spectrum was measured at 
temperatures from 30°C (measured first in the front) to 130°C (in the back) by increasing steps of 5°C. 
 
 
Figure 4.S5. The images at the top show HSM images of 20 % urea / NaCMC solvent evaporated films taken at 
RT, 90 °C and 130 °C (from left to right). At the bottom, a temperature resolved FTIR spectrum is shown. Each 
spectrum was measured at temperatures from 30 °C (measured first in the front) to 130°C (in the back) by increasing 
steps of 5 °C. 
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Opportunities for successful stabilization of poor glass-
forming drugs: A stability-based comparison of 
mesoporous silica versus hot melt extrusion technologies 
 
 
 
 
Summary 
Amorphous formulation technologies to improve oral absorption of poorly soluble active 
pharmaceutical ingredients (APIs) have become increasingly prevalent. Currently, polymer-based 
amorphous formulations manufactured by spray drying, hot melt extrusion (HME) or co-precipitation 
are most common. However, these technologies have challenges in terms of successful stabilization of 
poor glass former compounds in the amorphous form. An alternative approach is mesoporous silica, 
which stabilizes APIs in non-crystalline form via molecular adsorption to inside nano-scale pores. In 
line with these considerations, two poor glass formers, haloperidol and carbamazepine, were formulated 
as polymer-based solid dispersion via HME and with mesoporous silica, and their stability was 
compared under accelerated conditions. Changes were monitored over three months with respect to 
solid-state form and dissolution. The results were supported by solid-state nuclear magnetic resonance 
spectroscopy (SS-NMR) and scanning electron microscopy (SEM). It was demonstrated that 
mesoporous silica was more successful than HME in the stabilization of the selected poor glass formers. 
While both drugs remained non-crystalline during the study using mesoporous silica, polymer-based 
HME formulations showed recrystallization after one week. Thus, mesoporous silica represents an 
attractive technology to extend the formulation toolbox to poorly soluble poor glass formers. 
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5.1 Introduction 
The increasing prevalence of poorly water-soluble drugs has driven the field of pharmaceutical 
technology to develop modern approaches for formulation development. A well-established technique 
is to formulate the drug in an amorphous form, which results in an increase in apparent solubility, 
dissolution performance, and subsequent oral bioavailability [45,55]. However, such an approach comes 
with difficulties related to thermodynamic instability of the amorphous state, which can lead to 
recrystallization and thus negation of the aforementioned formulation advantages [213]. 
To give guidance on the recrystallization tendency of drugs, Baird et al. developed a classification 
system based on a molecule’s “glass forming ability” (GFA). The GFA is related to recrystallization 
behavior from super cooled melts [36–38]. Three classes of substances were defined: class one (GFA-
I) drugs recrystallizing upon cooling from the molten state; class two (GFA-II) drugs recrystallizing 
after a heating-cooling-heating procedure, and class three (GFA-III) drugs that remain amorphous 
throughout the entire experiment. Although the classification was developed for undercooled melts, 
which can be directly related to hot melt extrusion (HME), it has proven to be accurate for solvent 
evaporation processes as well [214]. This is a particularly relevant consideration for mesoporous silica 
systems, given that drug loading is driven by solvent penetration into pores and subsequent evaporation 
[35]. 
 
GFA-I compounds, poor glass formers, are particularly prone to recrystallization in amorphous 
formulations [39]. One strategy to tackle this instability is to combine the drug with a polymer in an 
amorphous solid dispersion. A very common technique to manufacture amorphous solid dispersions is 
HME [41,79]. In this process, polymer and API are mixed in the molten state to form an extrusion strand, 
which is further processed into a solid dosage form, e.g. tablet or a capsule. 
 
Another approach is to formulate GFA-I drugs with mesoporous silica. This is of particular interest due 
to the high stability of the amorphous API once it has been loaded into the porous network of the silica. 
This enhanced stability is related to nano-confinement in the meso-scale pores, which by definition 
range from 2-50 nm [215,216]. Stability is further improved with complementary pore-API interactions 
that lower the free energy of the system [217]. Muller and co-workers demonstrated amorphous stability 
at ambient and accelerated conditions for 30 different mesoporous silica formulations [218]. One key 
consideration for mesoporous silica formulations is the location of the API within the sample. For GFA-
I compounds, it is essential that the loading process is carried out carefully, avoiding oversaturation of 
the silica, to ensure the drug is loaded within the pores and not on the outer surface. GFA-I compounds 
adsorbed on the outer surface are prone to rapid crystallization, which can be observed with techniques 
such as differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). However, upon 
successful loading of the drug in the internal porous network, silica formulations can provide a viable 
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alternative for drugs that fail to form a stable amorphous formulation in classical solid dispersions [219–
221]. Although amorphous stability in mesoporous silica has been well described, there has been no 
comparison on stability of poor glass formers in HME and mesoporous silica technology published to 
date.  
 
Certainly, solid-state stability is not the only important formulation consideration for poorly soluble 
drugs that are also poor glass formers. It is also essential to consider stability of the supersaturation 
generated upon dissolution. Indeed, recent work has demonstrated that, due to their high propensity for 
recrystallization,  poor glass formers may also have issues with rapid onset of precipitation upon release, 
thus limiting their therapeutic potential [222]. This is in line with the well-established “Spring and 
Parachute” model [98], which identifies the need for additional excipients to sustain supersaturation of 
APIs in solution [116]. For polymer-based solid dispersions, the polymer may be able to meet both 
requirements: suspending the drug in an amorphous form, and inhibiting precipitation from the 
supersaturated state. An example of such a polymer is polyvinyl alcohol that is interesting due to its low 
hygroscopicity and for which a special grade has been introduced recently for HME [223]. Unlike 
polymer-based solid dispersions, the ability of mesoporous silica to inhibit precipitation of the 
supersaturated API is limited. Therefore it is often necessary to incorporate precipitation inhibitors into 
mesoporous silica formulations [224].  
 
In this study, the amorphous stability of two model poor glass formers, haloperidol and carbamazepine, 
formulated as HME and with mesoporous silica, was investigated in line with ICH Q1 [225] accelerated 
stability conditions over three months. The stability was monitored by means of PXRD and underscored 
with DSC measurements of the samples before and at the end of the study. To the best of our knowledge, 
such a comparative study has not been reported previously. This stability comparison was complemented 
by non-sink release testing in biorelevant media [191,226] to monitor potential supersaturation and 
recrystallization during drug release [224,227]. Non-sink dissolution was not used as a direct 
comparison between the two formulations, as the mesoporous formulations do not inhibit precipitation 
upon release. Rather, the release curves are demonstrative of the decrease in dissolution performance 
that can be observed upon solid-state transformation. Finally, solid-state nuclear magnetic resonance 
(SS-NMR) spectroscopy was applied to investigate any qualitative changes drug-polymer spectra in 
HME formulations over the duration of the stability study [228]. 
 
From a practical perspective, both drugs have no thermal instability, which avoids the risk of heat-
induced degradation during the HME process [229,230]. The drug load selected for the technology 
comparison was the highest amount that enabled initial amorphous loading for both HME and 
mesoporous silica formulations, so that a direct comparison between techniques could be attained.  
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It was hypothesized that mesoporous silica formulations of haloperidol and carbamazepine would show 
enhanced solid-state stability over time compared to solid dispersion obtained from HME.  
 
5.2 Materials and Methods 
5.2.1 Materials 
Haloperidol, carbamazepine, HPLC grade acetonitrile and HPLC grade methanol were purchased from 
MilliporeSigma (Darmstadt, Germany). Parteck MXP® and Parteck SLC® were kindly provided by 
Merck KGaA (Darmstadt, Germany). FaSSGF/FaSSIF/FeSSIF powder to make biorelevant dissolution 
medium, Fasted Simulated Intestinal Fluid (FaSSIF), was obtained from Biorelevant.com (London, 
UK). 
5.2.2 Methods 
5.2.2.1 Thermodynamic Solubility Determination 
FaSSIF was prepared by weighing 45 mg of FaSSGF/FaSSIF/FeSSIF powder into 45 mL of phosphate 
buffer (pH 6.5) [95]. API (2-3mg) was accurately weighed into a Uniprep® syringeless filter (5mL; 
0.45µm). 2 mL of FaSSIF was added and the samples were agitated at 450 rpm for 24 hours at 37 °C. 
The pH was checked at 7 hours and adjusted with 0.1 N NaOH or 0.1 N HCl, if a deviation greater than 
+/- 0.05 pH units was observed. The final pH was also recorded after 24 hours.  
Samples were filtered into the inner chamber of the Uniprep through the built-in PTFE 0.45 µm 
Whatman filter after 24 hours. Filtrates were immediately diluted with acetonitrile and water (1:4 V:V) 
to avoid precipitation from the saturated solution. Samples were analyzed with UHPLC (Thermo Dionex 
Ultimate 3000, Thermo Fisher, MA, USA) to determine the API concentration. API concentration was 
determined based on a standard calibration curve of nine standard concentrations (50, 30, 10, 5, 3, 1, 
0.5, 0.3, 0.1 µg/mL). Three control samples of known concentrations (30, 3, 0.3 µg/mL) were prepared 
and used to check the robustness of the calibration curve. The determination was carried out in duplicate.  
 
5.2.2.2 Ultra-High Performance Liquid Chromatography (UHPLC)  
UHPLC analysis was performed using a Thermo Dionex Ultimate 3000 (Thermo Fisher, MA, USA) 
equipped with a diode array detector at 282 nm for carbamazepine and 247 nm for haloperidol (Thermo 
Fisher, MA, USA). The separation was achieved on an Acquity UPLC BEH column C8 (2.1 x 50 mm, 
1.7 µm, Waters, MA, USA). The mobile phases A and B consisted of water: formic acid 999:1 (V:V) 
and acetonitrile : formic acid 999:1 (V:V), respectively. Gradient and flow rate is shown in Table 5.1. 
System management, data acquisition and processing were based on the Chromeleon™ software 
package, version 7.2 (Thermo Fisher, MA, USA).  
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Table 5.1. UHPLC gradient and flow rates 
Time 
(min) 
Flow rate (mL/min) % (V:V) Mobile phase A % (V:V) Mobile phase B 
0.00 0.83 90 10 
0.83 0.83 10 90 
1.20 1.50 90 10 
2.00 1.50 90 10 
2.01 0.83 90 10 
 
5.2.2.3 Preparation of Hot Melt Extrudates 
PVA was selected as an optimal polymer for hot-melt extrusion. This was based on three factors: 1) 
grade of PVA is specifically designed for optimal hot melt extrusion due to particle size distribution and 
viscosity 2) partial solubility parameters 3) low hygroscopicity of PVA reduces water uptake in the 
extrudates. 
Binary mixtures of polyvinyl alcohol (PVA, Parteck MXP®) and drug at various drug loadings were 
mixed in a mortar and extruded on a ZE9 ECO twin-screw extruder by ThreeTec (Birren, Switzerland) 
with 9 mm diameter and 180 mm length co-rotating screws. A screw speed of 80 rpm was applied at a 
temperature of 190 °C through all three heating zones, which is in accordance with recommendation by 
the polymer manufacturer [231]. After extrusion, the extrudates were ground in a mortar, and the fraction 
retained between mesh sizes 150 and 425 µm was retained for use in the study. The final extruded 
mixtures were cooled to room temperature and stored in falcon tubes. Mixing feasibility of the selected 
polymer for both drugs was verified by the Hansen solubility parameters [124,129], which were 
calculated using the quantitative structure property relationship (QSPR) method of the COSMOquick 
software (COSMOlogic, Germany, Version 1.6) [127,232]. For the investigation of the formulations, a 
7.5 % (w/w) drug loading of haloperidol and 20 % (w/w) was used for carbamazepine. This was selected 
on the basis of the highest drug load that was initially successful for both formulation technologies, and 
was the result of a formulation screening. 
 
5.2.2.4 Preparation of API-Loaded Silica Formulations 
Mesoporous silica formulations were prepared using the incipient wetness method [216]. API (3 g) was 
dissolved in acetone (300 mL; 10 mg/mL), which was added drop-wise at a rate of 0.5 mL/minute to 
Parteck SLC® mesoporous silica (7 g), under constant stirring and heating at 60 °C. After complete 
addition of the concentrated API solution, the samples were dried overnight in a vacuum oven at 60 °C 
to ensure complete removal of the solvent. For the investigation of both formulations a drug loading of 
7.5 % for haloperidol and 20 % for carbamazepine was used. 
Opportunities for successful stabilization of poor glass-forming drugs: A stability-based comparison of 
mesoporous silica versus hot melt extrusion technologies 82 
 
 
 
5.2.2.5 Storage of Samples for Stability Studies 
For storage of the samples in the stability study, each of the formulations was placed in a separate glass 
jar with a secure lid. A separate beaker containing saturated sodium chloride solution, also placed in the 
beaker, ensured a constant relative humidity of 75% in the surrounding environment [233]. This 
enclosed system was then placed in a stability cabinet set to 40 °C to obtain storage conditions in 
accordance with ICH Q1. 
 
5.2.2.6 Powder X-Ray Diffraction 
Samples were prepared between X-ray amorphous films and measured in transmission mode using Cu-
Kα1-radiation and a Stoe StadiP 611 KL diffractometer (STOE & Cie GmbH, Darmstadt, Germany) in 
transmission mode equipped with Dectris Mythen1K PSD (DECTRIS Ltd., Baden-Daettwil, 
Switzerland). The measurements were evaluated with the software WinXPow 3.03 by Stoe (STOE & 
Cie GmbH, Darmstadt, Germany), the ICDD PDF-4+ 2014 Database (ICDD, PA, USA), and Igor Pro 
Version 6.34 (Wavemetrics Inc., OR, USA) Angular range: 1-65 °2θ; PSD-step width: 2 ° 2 θ; angular 
resolution: 0.015 °2 θ measurement time: 15 s/step, 0.25 h overall. 
 
5.2.2.7 Non-Sink Mini-dissolution in FaSSIF 
The equivalent of 5 mg API of extrudate or API-loaded silica was weighed into a glass vial. 5 mL of 
FaSSIF was added. The vials were agitated at 37 °C and 450 rpm in a shaker (IKA -Werke GmbH & 
CO. KG, Staufen, Germany) for 2 hours. Samples of 0.3 mL were taken at 2, 15, 60, 90 and 120 minutes, 
filtered (0.45 PTFE Whatman filters), diluted with acetonitrile and water, and analyzed by UHPLC. The 
mini-dissolution trials were conducted in duplicate for all samples. 
 
5.2.2.8 Scanning Electron Microscopy 
Samples were prepared on carbon tape and imaged using a TM3000 Tabletop Scanning Electron 
Microscope (Hitachi, Tokyo, Japan), tungsten source, using low vacuum and accelerating voltage of 5 
kV and 15 kV. A 4-Quadrant BSE detector was used, and imaging was at a magnification between 15x 
– 30,000x.  
 
5.2.2.9 Differential Scanning Calorimetry 
Samples were assessed by differential scanning calorimetry on a DSC 3 (Mettler Toledo, Greifensee, 
Switzerland). An amount of 5 to 9 mg sample was placed in a 40 μL aluminum pan with a pierced lid. 
A heating rate of 10 °C/min from 20 °C to 200 °C was applied under nitrogen purging at 200 mL/min. 
The thermograms were analyzed with the STARe Evaluation-Software Version 16 (Mettler Toledo, 
Greifensee, Switzerland). 
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5.2.2.10 Solid-State Nuclear Magentic Resonance (SS-NMR) Spectroscopy 
SS-NMR experiments were conducted with magic-angle-sample (MAS) spinning using a Bruker 4 mm 
MAS HXY probe in double resonance mode with a Bruker Avance I 600 MHz wide bore NMR 
spectrometer (Bruker, Rheinstetten, Germany) with a 4 mm rotor. The readout on the probe 
thermocouple was set to 290 K. The sample spinning frequency was set to 10 kHz. All spectra were 
recorded with 1H-13C-cross polarization (CP) using a contact time of 1 ms. 100 kHz high power proton 
decoupling following the SPINAL64 scheme was applied during acquisition. The recycle delay was 3 s. 
The spectra were indirectly referenced to 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) via the CH2 
signal of Adamantane at 40.49 ppm. 
5.3 Results 
5.3.1 Macro- and Microscopic Changes 
Qualitative macroscopic differences were observed between the fresh and one-week stressed samples of 
the hot-melt extrudates (Figure 5.1). Extrudates of carbamazepine and haloperidol were transparent 
immediately after manufacturing. This indicates the presence of  molecularly dispersed API throughout 
the polymer in the amorphous form [79]. However, after only 7 days exposure to 40 °C and 75% RH, 
both extrudates became opaque, indicating phase separation in the formulations [107]. This was in 
contrast to mesoporous silica formulations, in which no macroscopic differences were observed between 
the fresh and one-week stressed samples. Indeed, the appearance of mesoporous silica formulations 
remained consistent over the duration of the 3-month study. 
 
 
Figure 5.1. Haloperidol (top) and carbamazepine (bottom) HME before (left) and after (right) 7 days accelerated 
stability conditions as specified in the materials and methods section.  
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Changes in the extrudate samples over time were also observed on a microscopic level in the SEM 
images. In freshly prepared formulations, the extrudates showed no heterogeneity but at the end of the 
stability study, after 90 days, phase separation and recrystallization were observed. API-loaded silica 
formulations, however, did not exhibit qualitative changes under either visual inspection or by SEM 
(Figure 5.2 and 5.3). 
 
 
Figure 5.2. SEM images for carbamazepine loaded silica (a) and HME (b) showing particle size and morphology 
at 0 days (top) and 90 days stability (bottom) as specified in the materials and methods section. 
 
 
Figure 5.3. SEM images for haloperidol loaded silica (a) and HME (b) showing particle size and morphology at 0 
days (top) and 90 days stability (bottom) as specified in the materials and methods section. 
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5.3.2 Solid-State Stability of the Amorphous Form 
Both haloperidol and carbamazepine were crystalline before formulation with either HME or 
mesoporous silica. The outcome of the empirical loading approach is shown in Table 5.2. For 
mesoporous silica, both APIs were successfully stabilized in the amorphous form at an initial 
concentration of 30% (w/w). However, HME was only successful in stabilizing amorphous API for 
carbamazepine at 20% (w/w) and haloperidol at 7.5% (w/w) (data not shown). At higher concentrations, 
the extrudates were crystalline upon cooling. Therefore, for the comparative accelerated stability study 
of the formulations a drug load of 20% (w/w) carbamazepine and 7.5% (w/w) haloperidol was selected 
for both the mesoporous silica and HME based solid dispersions. PXRD indicated that the initial form 
in both formulations was amorphous (Figure 5.4 and 5.5). 
 
Table 5.2. Loading capacities for both formulation techniques  
Formulation Loading Content (%, w/w) 
 30 20 15 7.5 
Haloperidol HME Crystalline Crystalline Crystalline Amorphous 
Haloperidol loaded silica Amorphous Amorphous Amorphous Amorphous 
Carbamazepine HME Crystalline Amorphous Amorphous Amorphous 
Carbamazepine loaded 
silica 
Amorphous Amorphous Amorphous Amorphous 
 
 
Differences between silica-based formulations and PVA extrudates were apparent after one month of 
storage at elevated temperatures, with both HME formulations showing development of crystallinity. 
The crystalline percentage increased month by month over the duration of the study (Figure 5.4 and 5.5). 
Conversely, both API-loaded mesoporous silica formulations remained amorphous for the duration of 
the three-month stability study, with no evidence of crystallinity in the PXRD patterns (Figure 5.4 and 
5.5).  
 
These findings were underscored by the absence of melting endotherms in the DSC thermograms of the 
silica-based formulations after 90 days [234]. By contrast, melting peaks were observed in both samples 
of the extruded formulations after 90 days, indicating the presence of drug crystallinity (data not shown). 
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Figure 5.4. PXRD patterns for carbamazepine loaded silica (top) and carbamazepine HME (bottom) showing 
crystalline carbamazepine (a), unstressed carbamazepine formulation (b) and stressed carbamazepine formulations 
at 30 (c), 60 (d) and 90 (e) days. The arrows indicate crystalline peaks in the diffractograms. 
 
Although drug-polymer interactions were not detectable in the SS-NMR spectroscopy for 
carbamazepine and haloperidol HME, it was possible to observe qualitative differences before and after 
storage of the samples at 45 °C/70% RH. Specifically, the freshly prepared samples had broad peaks in 
the spectra, related to the amorphous state of the sample. By contrast, an increased fine structure 
observed in the NMR-spectra at the end of the study indicated an increase in crystallinity. This was 
especially pronounced for haloperidol, with the stressed sample exhibiting peaks corresponding to the 
crystalline pure drug at 118 ppm, 153 ppm and 200 ppm in Figure 5.6 top correspond to peaks of the 
crystalline drug (Figure 5.6 bottom). 
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Figure 5.5. PXRD patterns for haloperidol loaded silica (top) and haloperidol HME (bottom) showing crystalline 
haloperidol (a), unstressed haloperidol formulation (b) and stressed haloperidol formulations at 30 (c), 60 (d) and 
90 (e) days. The arrows indicate crystalline peaks in the diffractograms. 
 
 
For carbamazepine, the change was more subtle, because of overlapping peaks. However, it was obvious 
that the stressed sample exhibited crystalline peaks that were not observed in the freshly prepared 
samples e.g. at 131 ppm, as shown in Figure 5.7. The presence of sharper peaks in the stressed samples 
underscores the recrystallization in the formulations suggested by the X-ray diffraction data. 
 
Opportunities for successful stabilization of poor glass-forming drugs: A stability-based comparison of 
mesoporous silica versus hot melt extrusion technologies 88 
 
 
 
Figure 5.6. 13C SS-NMR spectra for crystalline haloperidol (bottom), HME formulation at 0 days (middle) 
90 days (top). 
 
 
Figure 5.7. 13C SS-NMR spectra for crystalline carbamazepine (bottom) and carbamazepine HME formulation at 
0 days (middle) 90 days (top). 
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5.3.3 Stability of the Supersaturated State in FaSSIF 
The thermodynamic solubility of haloperidol and carbamazepine in FaSSIF was measured to be 
259 (± 1) µg/mL and 203 (± 2) µg/mL. Accordingly, the crystalline APIs showed a dissolution profile 
approaching these values over the course of the FaSSIF dissolution experiment.  
Although both drugs have some solubility in FaSSIF, the dissolution was enhanced by both the 
mesoporous silica and HME formulations. For carbamazepine, a maximum supersaturation of 1.8 and 
1.5-fold was generated for the silica and HME formulations, respectively. For haloperidol, a maximum 
supersaturation of about 2.0-fold was generated for both silica and HME.  
 
The PVA in the HME formulation was able to sustain supersaturated concentrations for both APIs by 
inhibiting precipitation from aqueous medium. Mesoporous silica, on the other hand, was barely able to 
inhibit drug precipitation from the supersaturated state and therefore, precipitation was observed for 
both APIs, with concentrations returning to the thermodynamic solubility. 
For mesoporous silica formulations, further development of the formulation would include a screening 
and a selection of a precipitation inhibitor to include in the formulation. The precipitation inhibitor 
would prevent the precipitation of the supersaturated API and could subsequently enhance oral 
absorption. However, although important, the precipitation inhibitor in a mesoporous silica formulation 
is not expected to impact on the solid-state stabilization of the API in the amorphous form. This is due 
to the fact that precipitation inhibitors are simply blended with the drug-loaded silica when the drug is 
already loaded onto the porous silica and stabilized in the solid state. Therefore, as the focus of this 
study was on the innate stabilization potential of mesoporous silica using poor glass formers, 
incorporation of a precipitation inhibitor was out of scope.  
For both APIs, the dissolution profiles from mesoporous silica formulations were comparable 
throughout the duration of the entire accelerated stability study. Particularly notable was that the degree 
of supersaturation, or ‘spring’, remained consistent over the whole stability study (Figure 5.9). For HME 
formulations, the curves showed a decrease in supersaturation in each successive month of the stability 
study. After 30 days, the HME formulation containing carbamazepine was still able to generate 
supersaturation, but the profile was no longer stable:  the carbamazepine concentration returned to the 
thermodynamic solubility within 60 minutes. This difference between fresh and 30-day carbamazepine 
samples was indicative of the presence of seed crystals in the formulations. Such seeds foster 
crystallization in the formulation as well as in solution to most likely override the inhibition of 
precipitation by the polymer [235]. Furthermore, the release performance of carbamazepine HME 
declined even further at 60 days and 90 days. By 90 days, no supersaturation was observed at any 
measured time point during the experiment, and the dissolution curve resembled that of crystalline 
carbamazepine more closely (Figure 5.8).  
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Figure 5.8. FaSSIF mini-dissolution curves for carbamazepine loaded silica (left) and carbamazepine HME 
formulation (right) showing crystalline carbamazepine ( ), unstressed carbamazepine formulation (●) and stressed 
carbamazepine formulations at 30 (▪), 60 (X) and 90 ( ) days. 
 
Similar reductions in dissolution performance with storage were observed for the HME formulation of 
haloperidol. Although the dissolution performance of the haloperidol HME did not decline as quickly 
as that of the carbamazepine HME, its dissolution profile also resembled that of the crystalline API after 
90 days (Figure 5.9). 
 
 
Figure 5.9. FaSSIF mini-dissolution curves for haloperidol loaded silica (left) and haloperidol HME formulation 
(right) showing crystalline haloperidol ( ), unstressed haloperidol formulation (●) and stressed haloperidol 
formulations at 30 (▪), 60 (X) and 90 ( ) days. 
 
5.4 Discussion 
Development of amorphous solid dispersions requires a thorough understanding of the factors that 
influence stability in the amorphous form. One such factor is the GFA. According to the classification 
system proposed by Baird et al [36], GFA-I drugs are especially challenging when developing 
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amorphous formulations, due to the high propensity for re-crystallization of such compounds. It is 
essential to demonstrate good physical stability in amorphous formulations to ensure that 
recrystallization does not occur over time, as this would reduce the shelf-life of the product [236]. As 
crystallization is based on the stochastic nucleation process, a lack of physical stability could lead to 
variable product quality among batches. Any initial crystallization in the batch, or differences in the rate 
of crystallization, could lead to out-of-specification results based on insufficient drug product 
performance, for example in dissolution testing. Variability among batches would thus be problematic 
in terms of meeting regulatory and commercial requirements. Herein, it has been demonstrated that 
mesoporous silica can be used to successfully stabilize compounds of poor amorphous stability that are 
unsuitable for formulation in standard polymer-based amorphous solid dispersions. 
 
Initial formulation development demonstrated the potential impact that such a poor amorphous stability 
could have on the viability of a formulation. For both HME formulations, significantly lower percentage 
drug loads were attainable in the initial formulation development. This is a crucial topic for the 
development of amorphous formulations. Taking the example of haloperidol, it was only possible to 
stabilize 7.5% (w/w) of the API in the amorphous form in the HME. Assuming a theoretical dose of 200 
mg, one would require a tablet of approximately 2.6 g in weight to incorporate the entire dose in a single 
dosage form. Furthermore, this represents a very conservative estimation, as the actual API content 
would likely be reduced further to 3.25% when one considers that 50% of the tablet may consist of 
fillers, binders, glidants and disintegrants. Ultimately, a low drug loading would be a substantial risk to 
the viability of the formulation, and could result in failure of the project. Mesoporous silica, however, 
was successful in stabilizing more reasonable drug loads in non-crystalline form. 
Furthermore, the successful low drug loading HME formulations developed for carbamazepine and 
haloperidol were observed to be unstable during the ICH Q1 stability study (Figure 5.4 and 5.5). 
Instability in polymeric amorphous solid dispersions can be linked with increasing temperature and 
humidity. As temperature or water content in amorphous formulations increases, mobility of the drug 
within the polymer dispersion increases. Mehta and co-workers demonstrated this effect on model 
amorphous solid dispersions (ASDs). In their study, an increase in molecular mobility of all APIs in the 
polymer ASDs led to a decrease in recrystallization time [65,236]. As both studies by Mehta and 
colleagues investigated the physical stability of good to moderate glass formers (GFA-II/III), it is likely 
that the effect of moisture and temperature on increasing molecular mobility and subsequent physical 
instability would be even greater for GFA-I compounds. 
 
The observed instability of these poor glass formers is even more remarkable when one considers that, 
of the available polymers for hot melt extrusion, PVA has an extremely low hygroscopicity [231]. This 
low hygroscopicity would have a stabilizing effect on the formulation due to a reduction in the uptake 
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of water in the stressed conditions. However, this effect is not enough to prevent the poor glass formers 
from re-crystallizing in the extrudates. 
 
For mesoporous silica, however, molecular mobility is greatly reduced regardless of moisture or 
temperature. Brás and colleagues demonstrated that adsorption and nano-confinement of ibuprofen onto 
mesoporous silica resulted in a significant reduction of all known types of molecular mobility [64]. Most 
interestingly, the Johari-Goldstein β relaxation, a type of molecular mobility associated with re-
crystallization, was reduced. This was a crucial observation, as it has been shown that increased Johari-
Goldstein relaxation is related to physical instability of the amorphous form [64,65]. Similar to the work 
by Mehta and colleagues, Bras et al. focused on good glass formers (GFA-III). Additional work 
demonstrated  that a reduction in molecular mobility leads to successful stabilization of the very poor 
glass former menthol (GFA-I), which has a glass transition temperature of -54.3 °C [237]. In a further 
study, Cordeiro and colleagues successfully stabilized amorphous menthol due to nano-confinement 
within mesoporous silica. This stabilization was related to a decrease in molecular mobility of both α 
(free transitional mobility in space) and the aforementioned Johari-Goldstein β relaxations. Furthermore, 
a new type of molecular mobility, the S-type, was observed. S-type refers to mobility of a hindered 
molecule that is nano-confined within a single pore, and is much slower than standard molecular 
mobility events [237]. Based on these findings as well as those of our study (Figure 5.4 and 5.5), 
mesoporous silica may be a suitable way forward to stabilizing GFA-I glass formers under accelerated 
conditions. 
 
There are only a handful of known GFA-I compounds that are also BCS II compounds and which would 
thus benefit from the apparent solubility increase of the amorphous form. In a recent review, Kawakami 
provided an overview of pharmaceutical compounds according to GFA classes [60]. Of the GFA-I 
compounds in the database only 29% were determined to be BCS II/IV, which is far lower than the 
commonly reported percentage of commercial compounds that fall into the poor solubility category 
(60%) [35]. Hence, there appears to be a disconnect between the prevalence of compounds with poor 
solubility and the occurrence of poor glass formers on the market. This could be related to the difficulty 
in formulating such compounds, and the reduction in formulation performance related to physical 
instability.  
 
For the two model BCS II drugs selected in this study, clear differences were observed in the non-sink 
release profiles of loaded silica and HME formulations. As expected from the literature, silica alone was 
not able to sustain supersaturated concentrations of API in solution resulting in precipitation [224]. 
Conversely, in the HME formulations, the API is sustained in solution by the polymer itself, which can 
function not only as a matrix polymer but also as a precipitation inhibitor during drug release. However, 
Opportunities for successful stabilization of poor glass-forming drugs: A stability-based comparison of 
mesoporous silica versus hot melt extrusion technologies 93 
 
 
it was observed that dissolution of API loaded silica formulations remained consistent throughout the 3-
month study (Figure 5.8 and 5.9), whereas the kinetic release of HME formulations tended towards 
crystalline drug solubility (Figure 5.8 and 5.9). Here, we see the effect of phase separation and 
recrystallization on the dissolution performance of amorphous solid dispersions, with the presence of a 
crystalline phase reducing the achievable supersaturation and decreasing the dissolution performance of 
the compound [60]. Interestingly, both HME formulations retained some supersaturation after the first 
month of the stability study, indicating that full conversion from amorphous to crystalline had not yet 
occurred (Figure 5.8 and 5.9). However, the supersaturated solutions generated by the carbamazepine 
HME were less stable than those generated by the haloperidol HME and precipitation occurred (Figure 
5.8). This was related to the presence of seed crystals in the formulation, which sped up the rate of 
nucleation and reduced the ability of the polymer to prevent precipitation. Patel and co-workers 
demonstrated that a small amount of crystalline indomethacin significantly increased its recrystallization 
from the supersaturated state, even in the presence of precipitation inhibitors [235]. The present results 
support the view that GFA-I compounds may not be good candidates for formulation in polymeric 
amorphous solid dispersions, such as hot-melt extrudates, which have been investigated here. However, 
this is also expected by other formulations based on polymeric amorphous dispersions, e.g. spray dried 
dispersions or co-precipitates. Mesoporous silica, on the other hand, is an attractive formulation option 
for poorly soluble glass formers, generating consistent and supersaturated dissolution profiles.  
 
5.5 Conclusion 
The increasing prevalence of poorly soluble BCS II drug candidates in pharmaceutical development 
remains a challenging issue. Although polymer-based stabilization of the API in an amorphous form has 
been a common approach to their formulation for several decades. Such an approach may not be suitable 
for poorly soluble compounds that also show poor GFA. These compounds, which demonstrate both 
poor solubility and poor amorphous stability, are challenging for formulation with typical polymer-
based technologies due to possible phase separation and recrystallization. Ultimately, these compounds 
may have an increased risk of failure during pharmaceutical development, as they constitute a risk from 
both a bioavailability and amorphous stability perspective. In this study we demonstrated that poor glass 
forming (GFA-I) APIs have increased risk of recrystallization in polymer-based amorphous solid 
dispersions. By contrast, mesoporous silica was shown to provide optimal stabilization for such APIs. 
Therefore, mesoporous silica could be an attractive formulation technology to expand the formulation 
toolbox for APIs that are poor glass formers. More research in the future will clarify whether 
mesoporous silica should become a method of choice for oral delivery of poorly soluble GFA-I 
compounds. 
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Chapter 6 
 
In vivo performance of innovative polyelectrolyte matrices for 
hot melt extrusion of amorphous drug systems 
 
 
 
 
Summary 
Hot melt extrusion of amorphous systems has become a pivotal technology to cope with challenges of 
poorly water-soluble drugs. Previous research showed that small-molecular additives with targeted 
molecular interactions enabled introduction of a polyelectrolyte matrix to hot melt extrusion that would 
be otherwise not possible to process due to the unfavorable melting properties of the pure polymer. 
Carboxymethyl cellulose (NaCMC) with lysine or alternatively meglumine was leading to modified 
polymeric matrices that showed adequate processability by hot melt extrusion and yielded stable 
amorphous formations. The investigated formulations, including fenofibrate as a model drug, were 
characterized by attenuated total reflectance Fourier transform infrared spectroscopy, differential 
scanning calorimetry, as well as viscosity measurements after aqueous dispersion. Further 
biopharmaceutical assessment started with biorelevant non-sink dissolution testing followed by a 
pharmacokinetic in vivo study in rats. The in vitro assessment showed superiority of the lysine 
containing formulation in the extent of in vitro supersaturation and overall drug release. In accordance 
with this, the in vivo study also demonstrated increased exposure of the amorphous formulations and in 
particular for the system containing lysine. In summary, the combination of polyelectrolytes with 
interacting additives presents a promising opportunity for the formulation of poorly water-soluble drugs. 
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6.1. Introduction 
The challenge of improving the bioavailability of poorly water-soluble drugs is a crucial aspect that 
pharmaceutical experts have to cope with throughout modern pharmaceutical development. An 
approach, which has gained popularity in the recent decade, is the formulation of drug in an amorphous 
form. Such a formulation approach typically leads to an apparent solubility increase and hence drug 
supersaturation upon dispersion after oral administration [54]. A high level of stabilized supersaturation 
in the small intestine results in enhanced bioavailability of orally delivered drugs [96,238]. Especially 
enabling formulations like amorphous systems processed by hot melt extrusion (HME) are capable of 
enhancing the supersaturation of BCS (i.e. biopharmaceutics classification system) class II drugs like 
fenofibrate (FE) to an extent that the absorption upon oral administration can become comparable to 
that of a BCS class I drug [239]. The assessment of such drug supersaturation is ideally performed under 
non-sink conditions using biorelevant media [95,191,226]. Since the supersaturation potential is 
dependent on the amorphous stability of the drug in the solid state [55,60], a combination of this assay 
with a stability-based comparison of supersaturation capabilities is applied in the so-called screening of 
polymers for amorphous drug stabilization (SPADS) approach, which is a screening method applied in 
the pharmaceutical industry for polymer selection during the development of amorphous solid 
dispersions (ASDs) [118]. 
Polymers with high molecular weight often affect drug precipitation following dispersion by a decrease 
of molecular mobility [116]. Such polymers can inhibit nucleation and/or growth as it was for example 
shown for the active pharmaceutical ingredient (API) indomethacin [235] and a variety of commonly 
used pharmaceutical polymers [240]. The functionality of polymers to act as precipitation inhibitors in 
solution is crucial in a supersaturating formulation [116,224,241]. An example of such a stabilizing 
polymer is the polyelectrolyte sodium carboxymethyl cellulose (NaCMC). Polyelectrolytes are 
commonly used as superdisintegrants in conventional solid dosage forms or they can find application as 
ionic liquids, where the combination of ionically interacting substances may lead to benefits in a 
pharmaceutical dosage form [197]. For the latter application, the intense swelling of superdisintegrants 
leads to faster disintegration of the solid dosage form, which would also be beneficial in a polymeric 
ASD but should be balanced with a risk of precipitation because of a too fast drug release [116,242]. 
In particular, NaCMC showed attractive stabilization of supersaturated drug [243] and an increase in 
overall oral bioavailability [48]. One factor might be the viscosity increase as stabilization of a 
supersaturated drug [117,244]. Even before drug gets entirely into solution, a polymer such as NaCMC 
could exert stabilizing effects in contact with aqueous media. Most recently, Edueng and colleagues 
identified the need for understanding the influence of the viscous interface between amorphous material 
and water on nucleation kinetics [13]. 
Unfortunately, the polyelectrolyte NaCMC is not applicable for HME in the neat form due to its high 
melting point and thermal degradation at the required processing temperature [198]. Therefore, the 
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principle of molecularly interacting conformers [91] was investigated with a new focus of changing 
polymer properties rather than targeting direct drug-additive interactions [122,148]. In case of 
polyelectrolyte NaCMC, it was possible to obtain an extrudable polymeric matrix of the polyelectrolyte 
and a stable glass formation was demonstrated by means of synchrotron powder X-ray diffraction [148]. 
Although this recent work identified meglumine (Meg) and lysine (Lys) as most suitable co-formers in 
the applied dataset, a biopharmaceutical assessment with an in vivo study have not yet been conducted 
to support the potential of the new approach. The present study therefore used the identified 
polyelectrolyte matrices to incorporate FE as a poorly water-soluble model drug, because it is known to 
precipitate rapidly from supersaturated solution and its stabilization by excipients was found to be 
difficult [245]. 
In this study, the solid dispersions were developed with regards to a drug load that provided completely 
amorphous formulations. The amorphous form of FE in both formulations was evaluated by differential 
scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). Regarding drug release testing, the 
two formulations were compared with their corresponding physical mixtures in a non-sink Level II [246] 
fasted simulated intestinal fluid (FaSSIF) dissolution experiment [191,226]. To gain further insights in 
the stabilization properties of NaCMC, viscosity measurements were performed. For a better correlation 
with the performed dissolution experiments, the viscosity was measured in Level II FaSSIF after the 
duration of the dissolution experiments. Moreover, the formulations and their physical mixtures were 
investigated in a pharmacokinetic (PK) study in rats to investigate the viability of the approach using 
NaCMC amorphous formulations produced by HME and FE as a model compound. 
 
6.2 Materials and Methods 
6.2.1 Materials 
FE, NaCMC (low viscosity), Lys and Meg were bought from Sigma-Aldrich (Bruchs, Switzerland). 
FaSSGF/FaSSIF/FeSSIF powder media was bought from biorelevant.com (Biorelevant.com Ltd, 
London, UK). Purified water for the viscosity measurements as well as the dissolution media was taken 
from a MilliQ Millipore filter system (Millipore Co., Bedford, MA, USA). All solvents for the UPLC 
analysis were of LC-MS quality and bought from Sigma Aldrich (Bruchs, Switzerland). Filters and other 
consumables were bought from Sigma-Aldrich (Bruchs, Switzerland). 
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6.2.2 Methods 
6.2.2.1 Preparation of hot melt extrudates 
Binary mixtures of NaCMC and Meg or Lys in a ratio of 50/50 % (w/w) were mixed in a mortar and 
dissolved in MilliQ water in a round bottom flask. Afterwards, the water was removed by a rotary 
evaporator (Rotavapor Büchi, Flawil, Switzerland). The resulting film was cut into smaller pieces and 
ground in a mortar. This powder was mixed with FE in a ratio of 92.5/7.5 % (w/w) and extruded on a 
ZE9 ECO twin-screw extruder (co-rotating screws with a 9-mm diameter and 180 mm in length) by 
ThreeTec (Birren, Switzerland). A screw speed of 80 rpm was applied at a temperature of 130 °C 
through all three heating zones. The final extrudates were cooled to room temperature and stored in 
falcon tubes. This experimental procedure is in line with the previous work in which the polyelectrolyte 
matrices were developed [148]. 
 
6.2.2.2 Powder X-ray diffraction 
The extrudates were analysed by PXRD on a D2 Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, 
Germany) with a 1-D Lynxeye detector. The instrument was equipped with a Ge-monochromator (Cu 
Kα radiation) providing X-ray radiation at a wavelength of 1.541 Å. During the measurements, a voltage 
of 30 kV and a current of 10 mA were used. The increment and time per step were set to 0.020 ° and 1 
s, respectively. The measurement 2θ angles were stretching over a range of 5° to 40°. 
 
6.2.2.3 Differential scanning calorimetry 
Samples were further assessed by a differential scanning calorimeter on a DSC 3 (Mettler Toledo, 
Greifensee, Switzerland). The samples were cut in small pieces and 5 to 9 mg were placed in a 40 μL 
aluminum pan with a pierced lid. A heating rate of 10 °C/min from −10 °C to 140 °C was applied, while 
the surrounding sample cell was purged with nitrogen at 200 mL/min. Moreover, a combination of 
heating, cooling and heating cycles was used to fully evaluate the samples. For the assessment of the 
initial form, the first heating was used. The thermograms and glass transition temperatures (Tgs) were 
analyzed with the STARe Evaluation-Software Version 16 (Mettler Toledo, Greifensee, Switzerland). 
All thermograms show exothermic events as upward peaks. 
 
6.2.2.4 Determination of thermodynamic solubility 
Level II FaSSIF was prepared according to the instructions of biorelevant.com by weighing 45 mg of 
FaSSGF/FaSSIF/FeSSIF powder into 45 mL of phosphate buffer (pH 6.5) [95]. Fenofibrate (2-3mg) 
was transferred into a glass vial, 2 mL of FaSSIF were added and the samples were agitated at 450 rpm 
for 24 hours at 37 °C. The pH was checked at 7 h and adjusted with 0.1 N NaOH or 0.1 N HCl. 
Samples were filtered into a quartz glass cuvette through a 0.45 µm PTFE Whatman filter after 24 hours. 
Filtrates were immediately diluted with acetonitrile and water (1:4, v/v) to avoid precipitation from the 
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saturated solution. Samples were analyzed by a UV/VIS spectrometer (Jasco, Easton, MD, USA) at 
287 nm. The experiment was carried out in triplicates. 
 
6.2.2.5 Non-sink dissolution 
The equivalent of 10 mg API of extrudate was transferred into a glass vial. After adding 10 mL FaSSIF, 
the vials were agitated at 37 °C and 450 rpm in a shaker for 2 hours [224]. Samples were taken at 2, 5, 
10, 15, 30, 60, 90 and 120 minutes, filtered (0.45 µm PTFE Whatman filters), diluted, and analyzed by 
a UV/VIS spectrometer (Jasco, Easton, MD, USA) at 287 nm. The mini-dissolution trials were 
conducted in duplicate for all samples. 
 
6.2.2.6 In vivo bioavailability study 
For the in vivo pharmacokinetic study a protocol was used, which was approved by the institutional 
animal ethics committee in accordance with Belgian law regulating experiments on animals and in 
compliance with EC directive 2010/63/EU and the NIH guidelines on animal welfare. Male Sprague-
Dawley rats (6 for each formulation) weighing 280–320 g on the day of the experiments were purchased 
from Charles River Laboratories Deutschland (Sulzfeld, Germany). The animals were acclimated for a 
minimum of 5 days. The animals had free access to a standard rodent diet and water ad libitum during 
the study. The animals were fasted 16-20 hours before the administration and throughout the study with 
free access to water. The extrudates were each delivered as ground powders for their corresponding 
study arm. Prior to administration, the powders were suspended in Level II FaSSIF and delivered to the 
animal by oral gavage at a volume of 6.25 mL/kg with a FE dose of 20 mg/kg. By individual tail vein 
puncture, 100 μL blood samples were collected into tubes containing dipotassium EDTA, plasma was 
harvested by centrifugation for 10 min at 1000× g, followed by separation into polypropylene tubes and 
immediate freezing and storage at -20 °C. Samples were taken at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 
24 h, and 28 h following oral dosing. The animals were euthanized after the experiment. 
 
6.2.2.7 Bioanalytical Procedure 
The analysis of the plasma samples was performed according to a validated method proposed and 
applied by Berthelsen et al. [247] In short, 50 µL of the plasma were precipitated with acetonitrile 
1:4 (v/v) in an Eppendorf® tube and the mixture was placed in an ultra-sonic bath for 10 min. 
Subsequently, the samples were transferred and frozen for 10 min at -20 °C, followed by centrifugation 
at 5 °C and 17,500 rpm for 16 min. The resulting clear supernatant was transferred into a UPLC vials 
for further analysis. 
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6.2.2.8 Ultra-High Performance Liquid Chromatography (UHPLC)  
UPLC analysis was performed using a Waters ACQUITY UPLC System (Waters Corporation, MA, 
USA) equipped with a photodiode array detector. The separation was achieved on an Acquity UPLC 
BEH column C18 (2.1 x 50 mm, 1.7 µm, Waters, MA, USA) and a guard column ACQUITY UPLC 
BEH column C18 VanGuard Pre-column (2.1 mm x 5 mm 130 Å, 1.7 µm) with an injection volume of 
4 µL. The column oven temperature was maintained at 55 °C. The mobile phases A and B consisted of 
water: trifluoroacetic acid 999:1 (v/v) and acetonitrile, respectively. The gradient method employed 
began by an isocratic elution at 80:20 A:B for 0.8 min, followed by a linear increase to 0:100 A:B until 
3.1 min and return to 80:20 A:B at 3.2 minutes and equilibration over a runtime of 4 min at a constant 
flow rate of 0.6 mL/min. Chromatograms were extracted at 287 nm for FE determination. System 
management, data acquisition and processing were based on the Empower software package, version 
7.2 (Waters, MA, USA). 
 
6.2.2.9 Viscosity measurement of the dissolution samples 
Prior to the measurement, the samples were filtered through a 0.8 µm mixed cellulose ester filter to 
eliminate all non-dissolved particles. The measurement setup was reported in previous work [248]. 
In brief, the micro-electro-mechanical system capillary rheometer, m-VROC™ (RheoSence, San 
Ramon, CA), was employed to measure the viscosity of the dissolution samples. This instrument is a 
microfluidic slit rheometer, which enables viscosity measurements of various sample amounts. It 
measures the viscosity from the pressure drop of a sample as it flows through the rectangular slit. The 
glass syringe (Hamilton 81260 SYR 1000 mL) was loaded with sample and placed inside of the thermal 
block (37 °C ± 0.2) of the instrument. After the stabilization of the measurement temperature, the sample 
was pumped through the flow channel of the chip at shear rate 4000 s-1. The pressure drop was detected 
by a sensor (cell VROC-mA10; 10K Pa full scale, 100-µm flow channel). On the basis of these 
measurements the viscosity was calculated using m-VROC Control Software (RheoSence, San Ramon, 
CA). The measurements were performed in triplicates. 
 
6.2.2.10 Attenuated total reflectance Fourier transform infrared spectroscopy 
The FTIR spectrometer Cary 680 (Agilent Technologies, Santa Clara, CA, USA) was used for the 
determination of interactions. The scanning range of 4000 – 600 cm−1 was selected at a resolution of 
4 cm−1. For the evaluation, a spectrum was extracted and evaluated by the software ACD/Spectrus 
Processor 2016.1.1 (Advanced Chemistry Development, Canada). 
 
6.2.2.11 Molecular modeling and statistical analysis 
Graphical representation of molecular interactions was based on a molecular dynamics simulation in 
vacuum using the tube model in the program suite YASARA v. 18.11.10 (YASARA Biosciences GmbH, 
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Vienna Austria). An AMBER14 force field was employed and each molecule was first energy 
minimized. Sodium carboxymethylcellulose was represented as oligomer (n=10) and was in contact 
with one FE molecule to roughly approximate average relative amounts in line with the investigated 
formulations. Moreover, 10 molecules of either Lys or Meg were added and the simulation was running 
for about 1 ns at 300 K. 
 
Data from the in vivo study in rats were analyzed using non-compartmental PK analysis. Maximum drug 
plasma concentration (Cmax) values after oral dosing were extracted directly from the observed data, 
while area under the plasma concentration-time curve (AUC) value were calculated using the linear 
trapezoidal rule using Excel 2013 (Microsoft). The software StatGraphics Version 16 (Statgraphics 
Technologies Inc., The Plains, VA, USA) was used for all statistical calculations. For each formulation, 
an Analysis of the Variance (ANOVA) with a Fisher LSD post hoc test at a 95 % confidence interval 
was performed. A value of p < 0.05 comparing the formulations with the corresponding physical 
mixtures with respect to the previously mentioned pharmacokinetic responses was considered 
statistically significant. 
6.3 Results 
6.3.1 Molecular dynamics simulation 
Before preparation of the formulations, the different systems were simulated on an atomistic level for 
visualization and to gain some qualitative structural insights. Assuming a simplified local composition, 
a small-scale molecular dynamics simulation was run for 1 ns (300 K) using an AMBER14 force field. 
The Figures 6.1 and 6.2 show a possible configuration of how the model drug FE may qualitatively 
interact with the modified matrix. Figure 6.1 suggests that the drug is embedded in a pocket-like 
structure for the formulation containing Lys. Pronounced hydrogen bonding of lysine side chains with 
fenofibrate is possible while meglumine is expected to mostly interact with polar interactions and 
possible weaker hydrogen bonds of hydroxyl groups that are present in the polymer. Consequently, the 
situation of FE appeared to be different with the system including Meg as co-former in which the drug 
appears to be rather attached to the surface of the modeled polymeric matrix (Figure 6.2). Moreover, 
interaction of fenofibrate with the lysine side chain are expected in the dry state as well as upon aqueous 
dispersion, which makes a difference to the before mentioned hydroxyl interactions by meglumine. 
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Figure 6.1. Visualization of a simplified molecular structure of the formulation Lys/NaCMC/FE based on an AMBER14 
force field and 1 ns molecular dynamics simulation at 300 K (using the software YASARA [249]). Fenofibrate is in green, 
sodium ions are shown as yellow (tube model) and hydrogens are represented by dashed red lines. 
 
 
Figure 6.2. Visualization of a simplified molecular structure of the formulation Meg/NaCMC/FE based on an AMBER14 
force field and 1 ns molecular dynamics simulation at 300 K (using the software YASARA [249]). Fenofibrate is in green, 
sodium ions are shown as yellow (tube model) and hydrogens are represented by dashed red lines. 
6.3.2 Solid-state analytics 
The successful amorphization of the model drug was investigated by PXRD (Figure 6.3) as well as DSC 
(Figure 6.4.). An amorphous halo diffraction pattern was indeed obtained for the two developed 
formulations in comparison with the crystalline reference drug that displayed distinct Bragg peaks of 
the API [86]. 
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Figure 6.3. PXRD patterns of pure FE (gray, bottom), Lys/NaCMC/FE (light gray, top), Meg/NaCMC/FE (black, 
middle) 
 
  
 
 
Figure 6.4. Thermograms of Lys/NaCMC/Fe (light gray,middle), Meg/NaCMC/Fe (black,bottom) and pure FE 
(gray,top). Insert shows Tg of Lys/NaCMC/Fe (light gray,top), Meg/NaCMC/Fe (black,bottom) in the area between 
0 and 60 °C. 
 
In the DSC thermograms, no melting peak could be detected in the formulations (Figure 6.4 black and 
light gray) in contrast to the pure model drug, which had a clear melting peak. The detected glass 
transitions at 29.70 (± 0.20) °C for the Lys formulation and 10.02 (± 0.82) °C for the Meg formulation 
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(Figure 6.4 insert) were in line with previously performed measurements the polyelectrolyte matrices 
[148]. 
 
 
Figure 6.5. FTIR Spectrum of FE (A), Meg/NaCMC/FE physical mixture (B), Meg/NaCMC/FE extrudate (C) 
 
The comparison of the spectra corresponding to the physical mixture, the formulation and the pure API 
(Figure 6.5) showed a significant peak broadening between the physical mixture and the formulation 
because of the amorphization, which is also visible in Figure 6.3 and 6.4. This broadening is even more 
pronounced around 3400 cm-1 in the area of the O-H and N-H stretching vibration of the Meg 
formulation. 
 
 
Figure 6.6. FTIR Spectrum of FE (A), Lys/NaCMC/FE physical mixture (B), Lys/NaCMC/FE extrudate (C) 
 
In the formulation of Lys/NaCMC/FE, the amide bands at 1572 and 1509 cm−1 were significantly 
broadened, which almost led to the formation of a combined peak (Figure 6.6). Moreover, the extrusion 
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resulted in a broadening of the amine-stretching band at 3340 cm-1. In general, the peaks of FE were less 
visible in the extruded formulation. 
6.3.3 Biorelevant in vitro dissolution study 
Figure 6.7. Non-sink dissolution profiles of Lys/NaCMC/FE: physical mixture (gray diamonds), extruded 
formulation (black triangles). The dotted line represents the solubility of FE. 
 
The measured solubility of FE in Level II FaSSIF was 0.0154 (± 0.0005) mg/mL in agreement with 
current literature (Figure 6.7) [250,251]. For the physical mixture a short concentration increase can be 
observed at the beginning of the dissolution experiment, which was followed by a rapid decline to the 
thermodynamic solubility. The formulation containing Lys had a dissolution profile with a delayed 
release. After 30 min, the profile showed supersaturated concentrations, which were stable and 
increasing until 120 min. A rough estimation of the supersaturation shows about 12-fold increase, which 
is in line with other studies on extruded FE formulations in Level II FaSSIF [252].  
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Figure 6.8. Non-sink dissolution profiles of Meg/NaCMC/FE: physical mixture (gray squares), extruded 
formulation (black spheres). The dotted line represents the solubility of FE. 
 
The release profile of the Meg/NaCMC/FE formulation showed the identical delay in release as with the 
Lys formulation. Release profiles of both formulations indicated polymer swelling causing a delayed 
release. In contrast to the dissolution profile of Lys/NaCMC/FE, the supersaturation of Meg/NaCMC/FE 
is less pronounced. The overall dissolution performance was still improved in comparison to the physical 
mixture. 
Although, the Lys/CMC/FE extrudate presented the slowest release it was the formulation, showing 
the highest supersaturation and was able stabilize this state over the time of the experiment. 
 
Table 6.1. Viscosity of the formulations and physical mixtures in Level II FaSSIF 
Composition  Viscosity 2h (mPa s) 
Lys, NaCMC, and FE 
Formulation 3.08 ± 0.01 
Physical mixture 3.25 ± 0.07 
Meg, NaCMC, and FE 
Formulation 3.18 ± 0.01 
Physical mixture 2.81 ± 0.03 
 
The dissolution study was complemented by viscosity measurements in Level II FaSSIF at the end of 
the experiments. These measurements showed an increase of viscosity in all formulations and physical 
mixtures at the end of the study compared to the pure Leve II FaSSIF with a viscosity of 
1.11 (± 0.04) mPa s (Table 6.1). The values among the samples did not vary greatly and highest 
differences were noted between the physical mixtures of the different systems. 
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6.3.4 In vivo rat study 
Drug dissolution and subsequent absorption in the gastrointestinal tract of the rat resulted in high plasma 
levels for both formulations. The amorphous formulations generally showed faster absorption and higher 
concentrations than the physical mixtures. A comparison between these reference physical mixtures 
showed a tendency of the Lys system to provide higher exposure though not statistical significant. There 
was a pronounced difference between the physical mixture containing Meg and the corresponding 
amorphous formulation, whereas the comparison between the Lys amorphous formulation and the 
physical mixture was less distinct (Figure 6.9). 
 
Figure 6.9. Plasma concentration (fenofibric acid) – time profile after oral administration of Lys/NaCMC/FE: 
physical mixture (black spheres), extruded formulation (black triangles) and Meg/NaCMC/FE: physical mixture 
(gray crosses), extruded formulation (gray diamonds). 
 
For both formulations, the Cmax values showed a statistical significant difference between the 
formulation and the corresponding physical mixture. Even though the AUC0-28h tended to differ, only 
the Meg formulation showed a significant difference between the formulation and the physical mixture. 
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Table 6.2. Pharmacokinetic parameters of the rat study for physical mixtures and formulations of FE 
at 20mg/kg. 
Composition  Cmax (µg/mL)a) AUC0-28h (µg*h/mL)a) 
Lys, NaCMC, and FE 
Formulation 18.24 ± 3.4 b) 144.09 ± 36 
Physical mixture 13.25 ± 3.9 129.91 ± 28 
Meg, NaCMC, and FE 
Formulation b) 16.30 ± 2.3 140.09 ± 38b) 
Physical mixture 7.09 ± 2.5 76.61 ± 13 
a) Concentrations as fenofibric acid 
b) Statistically different ( p < 0.05) compared to the corresponding physical mixture 
 
6.4 Discussion 
The polymer selection in the development of a solid dispersion is a key factor for amorphous stability 
and beneficial drug supersaturation kinetics upon release. Such multiple functionality of an ideal 
polymer would call for selecting from a broad range of pharmaceutical polymers but there is 
unfortunately only a limited amount polymers available that are orally acceptable. Consequently, the 
development of new polymer matrices is needed but as new chemical entities, it would mean substantial 
work effort with regard to toxicological qualification and regulatory approval [168]. An interesting 
alternative approach is to target specific molecular interactions of small molecular additives that are 
already regulatory approved for the administration route with pharmaceutical polymers to obtain 
modified polymeric matrices [122]. Such an approach bears the potential to customize polymeric 
matrices, for example regarding stability, a manufacturing process or a release profile. 
 
A recently published article from our research group highlighted the beneficial properties of the two 
additives, Meg and Lys, on the processability of the polyelectrolyte NaCMC. These additives enabled 
HME processing of the otherwise high melting/degrading polyelectrolyte, NaCMC, resulting in a 
homogenous glass [148]. The present research used the drug FE as a model compound to investigate 
these polyelectrolyte matrices in vitro as well as in vivo to assess their biopharmaceutical performance. 
 
FE could be incorporated at a concentration of 7.5 % (w/w), which was determined as the stable 
amorphous drug load in the formulation. At such low drug loadings, the polymer plays an important role 
in the release in a way that liquid-liquid phase separation and drug enrichment on the polymeric surface 
would have a low relevance, which otherwise may have a negative impact on the dissolution 
performance [44]. Therefore, the effects of the modified matrix with its hydration kinetics and molecular 
interaction with drug were expected to dominate biopharmaceutical performance. 
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The dissolution curves in the current study highlighted, how different polymeric matrices impact the 
release and supersaturation behavior of FE. The delayed release in the dissolution curve of the Lys as 
well as the Meg extrudate may be explained by an increase in viscosity by NaCMC as expected for this 
polyelectrolyte [252]. 
 
Moreover, Lys as a highly water-soluble amino acid with protonated amines in water can form both 
ionic interactions with NaCMC as well as exhibit a likely pronounced hydrogen bonding with the drug. 
Meg as co-former would interact via hydrogen bonding with NaCMC and although there is no charge 
upon aqueous dispersion, there is still the possibility to exhibit some weak hydrogen bonding with FE. 
 
The highly soluble amino acid as co-former led to a modified polyelectrolyte matrix that greatly 
enhanced the maximum drug supersaturation and could sustain it over a sufficiently long time to alter 
the effective drug absorption. While the present research had a focus on modification of the polymer 
matrix, the use of highly soluble amino acids has been suggested before in other co-amorphous systems 
where the primarily goal was the interaction of drug and co-former to target increased amorphous 
stability [146]. 
 
The existence of different relevant molecular interactions was in agreement with FTIR spectroscopic 
results of both systems. In particular, the O-H and N-H stretching vibration of Meg were broadened in 
the extrudate, which could be interpreted as a less defined structure as a result of hydrogen bonding 
between Meg and the other molecules (Figure 6.5). Meg was proven to be able to form such hydrogen 
bonds with polymers [209,253]. These findings were in line with the molecular dynamics simulation, 
which indicated a dense network of hydrogen bonds between the additive and NaCMC. The simplified 
view obtained from the molecular dynamics simulation also suggested that FE had the possibility to 
more strongly interact via hydrogen bonding with lysine side chains. It was also visualized that further 
polar and dispersive interactions may occur in a kind of pocket the polymer matrix was forming around 
FE (Figure 6.1). Such drug integration in the modified matrix was not observed in the same way in case 
of the Meg as additive where FE was rather located on the surface (Figure 6.2). Due to the simplified 
nature of the model, some care is needed to draw firm conclusions but the obtained molecular 
visualization provides insights into the likely drug interactions occurring in the different polymeric 
matrices. The qualitative differences may also have translated into different stabilization of 
supersaturated drug upon aqueous dispersion. 
 
The FTIR pattern of the Lys formulation highlighted the interaction between the additive and NaCMC, 
in accordance with what was reported for the amino acid and a comparable substance in a previous study 
[144]. Such a pronounced matrix interaction with a drug (Figure 6.1) may thus result in superior 
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stabilization in the solid as well as in the solubilized form of the drug (Figure 6.7) [208]. The utility of 
molecular dynamics simulations and docking has previously been shown to be helpful in the evaluation 
of solid dispersion formulations and depending on the simulation details, qualitative or even quantitative 
predictions may be obtained [141]. While the ionic moieties of a polymer are especially important for 
its swelling in aqueous media, the interactions with a poorly soluble drug are often complex. An example 
is that even though ionic and polar interactions are more energetic than weaker Van der Waals 
interactions, the latter can in their summation result in a substantial contribution to how drug attaches to 
a polymer upon aqueous dispersion [171,183].  
 
The dissolution profile of the Lys/NaCMC/FE formulation in contrast to the physical mixture underlined 
the stabilization properties of the polyelectrolyte matrix for the supersaturated state of FE. An initial 
high concentration of the physical mixture may have been caused by some surface amorphization during 
drug mixing or a direct excipient effect on solubilization. However, concentrations decreased rapidly to 
the saturation level, which was in contrast to the extruded formulation that was able to stabilize the 
supersaturated FE concentration over the time of the experiment. As such stabilization of supersaturated 
drug, another mechanism than the direct interaction within the polyelectrolyte matrix for the stabilization 
of the supersaturation is the increase in viscosity through NaCMC [254]. This could be a more general 
effect of a fast swelling polyelectrolyte and the viscosity measurements between the different samples 
showed barely differences except for slightly lower values for the physical mixture of the system with 
Meg (Table 6.1). The in vitro and the in vivo experiments were compatible with the NaCMC viscosity 
increase that may have led to some lag-time in release as well as it may have affected drug 
supersaturation. This would be in line with previous experiments investigating the influence of 
polymeric mixtures on the release [252] and the viscosity increase during aqueous dispersion through 
NaCMC [255]. 
In comparison, the amorphous formulations showed higher exposure in the rat study than their 
corresponding physical mixtures (Figure 6.9). Although the Lys formulation did show an increasing 
trend in AUC0-28h compared to the physical mixture, this increase was not statistically significant. 
However, the Cmax was statistically significantly increased in comparison to the physical mixture (Table 
6.2). The comparatively good performance of the crystalline FE in combination with lysine and NaCMC 
was likely due to specific effects of the polyelectrolyte matrix combined with more general drug 
solubilization through phospholipids and bile salts [99]. Given these interesting result of the lysine 
physical mixture, more research should in the future also investigate the biopharmaceutical potential of 
crystalline formulations with polyelectrolytes and co-formers to enhance oral absorption. 
The Meg formulation showed a faster release with a lower degree drug of supersaturation in vitro and 
was able to yield a significantly higher AUC and Cmax when compared to its physical mixture. As for 
the in vivo comparison, the highest AUC and Cmax were reported for the Lys formulation, which was in 
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line with the in vitro dissolution experiments. Therefore, the obtained results were encouraging to use a 
modified polyelectrolyte matrix for the solubility and bioavailability enhancement of poorly water-
soluble drugs. 
 
 
6.5 Conclusion 
Amorphous formulations have become a key method to increase absorption of poorly water-soluble 
drugs. A limitation is here the selection of polymer because it has to fulfill different functionalities in 
the manufacturing of the formulation, for stability on the shelf as well regarding biopharmaceutical 
performance. This was addressed by the concept of modified polymeric matrices and the present study 
showed that addition of Lys and Meg enabled the amorphous formulation of FE in a new NaCMC 
polyelectrolyte matrix. The in vitro and in vivo results suggested advantages of the amorphous 
formulations compared to the physical mixture references. The amorphous formulations had 
significantly higher Cmax values than their corresponding physical mixtures, which was in line with the 
dissolution experiments. This study presents the first animal study of the previously developed 
polyelectrolyte matrices [148]. The promising results show the potential of polyelectrolytes to enable 
supersaturating oral drug delivery. Future research on ASDs containing polyelectrolytes as a modified 
matrix for HME is needed to further investigate the specific advantages for a broad range of poorly 
water-soluble drugs.  
 
 
 
 
 
 
 
Final remarks and outlook 
 
In modern pharmaceutical development, poor aqueous solubility poses a major problem for numerous 
compounds in the pipeline as well as those on the market. Amorphous systems are an important part of 
overcoming such limitations. With an increasing number of newly developed drug candidates which 
exhibit low solubility and therefore present a problem for oral administration, approaches to increase 
the before mentioned solubility are of great interest. As discussed in this work, the formulation of a drug 
in its amorphous form does not present a “one-size-fits-all” solution to the problem since preparation 
and stabilization come with great difficulties. For an application of a newly developed drug product, 
pharmaceutical companies have to guarantee stability of the amorphous form at various stability settings 
defined by the regulatory agencies. In case the drug recrystallizes during the stability study, the 
biopharmaceutical performance would be affected, which may lead to insufficient drug exposure upon 
oral drug delivery and consequently insufficient therapeutic efficacy. As a result of the previously 
described risks, such a formulation approach is only applied if conventional formulation techniques fail 
to yield sufficient drug release and a bio-enabling formulation is needed. 
 
At the start of the formulation development of an ASD, a combination of different excipients has to be 
assessed with regards to stabilization of the amorphous form. The most important compound in the 
formulation besides the drug is the polymer, which should not only stabilize the amorphous form of the 
API in the solid but also has a role in facilitating the manufacturing and should further enable and 
stabilize supersaturated drug following oral administration. Different concepts reaching from 
miniaturized assays to theoretical thermodynamic calculations can be applied in an excipient screening 
setup. As highlighted in the sections above, such concepts in combination with the careful selection of 
the manufacturing technique play an important role. Based on the multifunctional requirements of 
polymers in ASDs, this thesis presented the concept of modified polymer matrices for amorphous 
systems to broaden capabilities of formulators to formulate poorly water-soluble drugs. This work had 
a focus on HME even though it was not exclusive in that also solvent-based processes were part of the 
research. 
The present work investigated the potential of small molecular interacting additives to specifically 
interact with the polymer and to improve formulation characteristics such as processability, amorphous 
stability, and drug release. 
 
The studies described in Section 3, 4, and 6 supported the view that a molecularly oriented selection of 
an additive was crucial for successful formulation. During such a selection, certain properties of the 
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additive have to be considered starting with thermal properties like Tm and Tg, going on with functional 
groups for a possible molecular interaction, and ending with aqueous solubility. While these properties 
as well as miscibility and other structural consideration can be done during the theoretical assessment 
of the formulation design, this work has shown that practical trials with a preselected set of additives 
are still necessary, because even slight differences in structure between the molecules can have great 
influence on the interaction and therefore on the feasibility and performance of the formulation. In case 
differences cannot be detected between the selected additives, a more discriminative method has to be 
chosen. Such methods could be more demanding stability settings or more sensitive analytical methods 
like a synchrotron measurement as described in Section 4. Approaches like the SPADS screening 
(Section 2.2.3) are important improvements towards a more rational selection of excipients rather than 
an approach based on trial and error or restriction to commonly used compounds. It would also be 
possible to apply such a structured technique for the selection of an additive with a targeted molecular 
interaction. Theoretically, such an approach could start with the selection of a set of additives based on 
possible interactions and physico-chemical properties, which need to be tailored to the selected 
manufacturing technique. After the selection of specific additives, they have to be evaluated with the 
polymer selected in a miniaturized amorphization process, which should be closely related to the final 
manufacturing technique. In this experimental step, the type and amount of necessary additive should 
be identified. 
 
Afterwards, small-scale manufacturing trials can be conducted, which include a drug-free formulation 
of the additive and the polymer. As seen in Section 4, the feasible amount of an additive might have to 
be balanced between suitability for the manufacturing process and with respect to the formation of a 
homogenous and stable glass. If the drug-free trials show sufficient manufacturability and glass 
formation of the polymeric matrix, it can be combined with the drug in a next step. The vision of the 
current research is that a broad range of such modified matrices should become available to formulators 
so that a broader choice is available to incorporate a drug candidate with its specific properties. 
 
The trials in formulation development with the drug in the polymeric matrix have to be evaluated again 
with regards to amorphous stability. This evaluation should be done under controlled stability settings 
for example as described in ICH Q1 and if necessary with the most discriminative method to spot even 
minor differences between the formulations. When a stable formulation is found, the interactions within 
the formulation can be determined. As the most important factor at the end of the technical evaluation, 
biorelevant dissolution experiments have to be performed to prepare for possible in vivo studies. 
 
After the successful development of a modified polymeric matrix, another aspect of such systems in the 
formulation development is the superiority over not only common formulation approaches but also over 
other conventional ASDs. For such a comparison the aspects described in Section 3,4,5, and 6 have to 
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be combined, which means a comparable ICH Q1 stability (Section 3,4 and 5), screening for interaction 
in the formulation (Section 3 and 4), and complete biopharmaceutical evaluation including first in vivo 
animal trials (Section 6). 
 
As first step, an ASD comparison was made of HME with the modern and heavily investigated 
formulation technique of drug incorporation in mesoporous silica. This work highlighted that even after 
optimization of amorphous formulations for a given process technique, the individual drug properties 
may favor one particular approach. This work highlighted that a combination of mesoporous silica with 
a precipitation inhibiting polymer would be especially suited for drugs that are difficult to stabilize in 
amorphous form. 
 
In light of the early stage research on modified matrices, one has to admit that currently, a fully 
structured development is still missing. Since even small changes in the additive selection may have a 
great impact on the formulation performance, the selection pool of new matrices should be as big as 
possible and should include a thorough evaluation of oral acceptability and regulatory restrictions.  
 
These development considerations are not just exclusively true for modified polymeric matrices so also 
conventional ASDs have to present clear benefits in comparison to normal solid dosage forms like for 
example tablets obtain from direct compression. This is the reason why the formulation of a drug as 
ASD is currently only considered when other formulation approaches fail because of insufficient release 
behavior and in vivo performance. 
 
The research presented in this work demonstrated clear benefits of focusing on targeted molecular 
interactions within the formulation between the polymer and an additive for ASDs. . In this way, 
different modified polymeric matrices were developed to investigate the improvement of polymer matrix 
properties and later on the stabilization of the drug in its amorphous and/or supersaturated state. On a 
small-scale amorphization technique, the polymeric matrices demonstrated promising results regarding 
amorphous stability, in vitro release and in vivo exposure of selected model systems. Future research 
would have to show how broadly the novel approach can be applied in formulation development and it 
will be interesting to see how the research findings are transferred to industrial pharmaceutical practice. 
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